## PREGNANCY WITH MEDICAL DISORDERS: A PROSPECTIVE CLINICAL STUDY AT A TERTIARY CARE HOSPITAL

By

Dr. MONIKA. KANNI

Dissertation submitted to

BLDE (Deemed to be University) Vijayapura, Karnataka



In partial fulfillment of the requirements for the degree of

MASTER OF SURGERY

In

#### **OBSTETRICS AND GYNAECOLOGY**

Under the guidance of

#### Dr.ARUNA.BIRADAR

PROFESSOR

#### DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY

**BLDE** (Deemed to be University)

SHRI B.M.PATIL MEDICAL COLLEGE

HOSPITAL & RESEARCH CENTRE, VIJAYAPUR

KARNATAKA

# "PREGNANCY WITH MEDICAL DISORDERS: A PROSPECTIVE CLINICAL STUDY AT A TERTIARY CARE HOSPITAL"

## MASTER OF SURGERY OBSTETRICS AND GYNAECOLOGY

#### **CONTENTS**

SL NO.	CONTENT	. PAGE No.
1.	INTRODUCTION	20
2.	AIMS AND OBJECTIVES	70
3.	METHODOLOGY	70
4.	REVIEW OF LITERATURE	74
5.	RESULTS	95
6.	DISCUSSION	110
7.	SUMMARY	117
7.	CONCLUSION	118
8.	BIBLIOGRAPHY	120
9.	ANNEXURES	130

#### **LIST OF FIGURES**

- Figure 1- Hemodynamic changes during pregnancy
- Figure 2- NYHA functional classification of cardiac disease
- Figure 3- Risk score from CARPREG Study
- Figure 4- Modified WHO Classification of Maternal Cardiovascular Risk
- Figure 5- Physiological hormone changes in pregnancy
- Figure 6- Mechanism of conjugation of bilirubin in liver
- Figure 7- Comparison of different causes of jaundice in pregnancy
- Figure 8- Important features of different types of viral hepatitis
- Figure 9- Distribution of medical conditions
- Figure 10- Distribution of medical conditions among preconceptionally vs diagnosed in antenatal period
- Figure 11- Distribution of cardiac diseases
- Figure 12- Indications for lscs
- Figure 13- Foetal outcome

#### **TABLES**

- Table 1- Socio-demographic data
- Table 2- Distribution of Medical Conditions
- Table 3-Distribution of Medical Conditions among preconceptionally diagnosed vs Diagnosed in Antenatal period
- Table 3A- Distribution of Cardiac Diseases
- Table 4- Distribution of the mode of delivery
- Table 5-Distribution of the Medical Conditions and the Maternal Outcome
- Table 5A- Medical Conditions and mother ICU Admissions
- Table 5B- Maternal mortality
- Table 6- Distribution of Medical Conditions and Neonatal outcomes
- Table 7A- Distibution of the Foetal Outcome
- Table 7B- Perinatal mortality
- Table 8- Medical condition complicating pregnancy
- Table 9- Pregnancy complicating Medical Disorders
- Table 10- Feto-maternal outcome in women with hypothyroidism
- Table 11- Seroprevalence of HBsAg positivity among antenatal female in different studies
- Table 12- Incidences of cardiac disorders in pregnancy in various in comparison our study
- Table 13- Foetal outcome in cardiac diseases in comparison with other studies
- Table 14- Feto-maternal complications in bronchial asthmatics in comparison with other studies

#### **INTRODUCTION**

Pregnancy is a physiological situation in which practically every organ and system, including the genital tract, vascular, metabolic, respiratory, cardiac, haematological, and cutaneous tissue, undergoes numerous alterations in order to make room for the foetus. A physiological stress test called pregnancy might uncover hidden chronic conditions such diabetes mellitus, high blood pressure, chronic renal failure, heart disease, and hypercoagulability<sup>1</sup>. Prior to pregnancy, some of these chronic illnesses are undetected or asymptomatic.

Modern medicine and its several branches, such as obstetrics, neonatology, and medicine, have improved the prognosis for both mother and foetus with medical conditions3. Most women tolerate pregnancy's physiological changes well, and they are reversible. Physiological changes may make medical disease diagnosis difficult and cause changes in medical disease treatment while pregnant. Medical issues can affect the physiologic adaptation of pregnancy, resulting in a poor pregnancy outcome, and vice versa<sup>2</sup>.

In this modern era, the incidence of pregnant women with acquired medical disorders has increased due to advanced maternal age and changing lifestyle.

Hence, this study is taken upon to see the incidence of medical disorders in pregnant women and the impact of disease on pregnancy and visa versa.

More than 40% of the more than 200 million pregnancies in the world each year are accidental. Unwanted does not imply unintended. Each couple should be able to prepare for parenthood and decide when they are ready. Early prenatal care is critical in preventing poor perinatal outcomes and consequences in the 40% of unintended pregnancies. During routine checkups, sports exams, well-woman exams, emergencies, and acute visits, there are opportunities to diagnose pregnancy and prevent unwanted and unplanned pregnancies. Taking advantage of these pregnancy test opportunities can help women get into initial prenatal

care . To prevent neural tube defects, all women of reproductive age should take 400 mcg to 800 mcg of folate daily. The United States Preventive Task Force (USPTF) and The American College of Obstetrics and Gynecology (ACOG) recommend it because most women present after the critical period of organogenesis. Preventing, identifying, and addressing preconception health issues, pregnancy readiness, early prenatal care, and minimising risks during the perinatal and interconception period are the key determinants of a healthy pregnancy and reproductive life. 2,3

Organic and hormonal changes alter women's physical and mental health during pregnancy. These differences may also affect women's perceptions of their quality of life <sup>2</sup>. Pregnancy causes distinct physiological responses. It causes stress in women's bodies, leading to metabolic, hormonal, cardiovascular, respiratory, and musculoskeletal adaptations<sup>3</sup>. During pregnancy, the anatomical, physiological, and biochemical accommodations are significant, beginning shortly after fertilisation and continuing throughout the pregnancy. 4 During pregnancy, the majority of women experience nausea and vomiting, heartburn, backache, round ligament pain, frequent urination, varicose veins, constipation, leg cramps, and haemorrhoids, which can lead to decreased comfort and well-being. In contrast to general physical changes, health beliefs, values, and expectations of families during pregnancy are culturally specific. During pregnancy, the mother's psychological response shifts from uncertainty and hesitation to vulnerability and preparation for the baby's birth. The changes in the mother's body during pregnancy may create a negative image of the body in her mind, influencing her sexual response. These changes may be concerning to some couples who do not communicate their feelings to one another.<sup>5</sup> Although prenatal care is intended to improve maternal and neonatal outcomes, it should be noted that changes in this period can have an impact on a woman's life during pregnancy.<sup>6</sup> Predelivery and postdelivery (postpartum) care in women in developed countries include more comprehensive purposes in addition to prevention, diagnosis, and

management of pregnancy complications and problems. It encourages women's psychological adaptation to pregnancy, implying that the quality of life and psychological status of pregnant women are the focal points.<sup>7</sup> Although the importance of the pregnancy period has been recognised in recent years, conducting research on the fields that affect women's quality of life during pregnancy can be useful in developing appropriate maternal health strategies. There is little information available about the changes experienced by pregnant women in physical, psychological, and social areas, indicating that pregnant women's quality of life and changeable areas require more attention.<sup>8</sup> Because access to qualitative information on cultural areas is critical for effective therapeutic interventions<sup>9</sup>, and because there are few qualitative studies in this field, this study was conducted to identify the factors influencing pregnancy quality of life..

Various medical diseases affect a significant proportion of pregnancies worldwide. In the past, the majority of them were contraindications to pregnancy. Most women tolerate the medical condition well, and it is reversible.<sup>2</sup> Medical issues may also interfere with pregnancy's physiologic adaptations, resulting in a poor pregnancy outcome, and vice versa. The treatment of medical disorders in pregnancy is based on four key clinical principles.:

- Medical disorders affected by pregnancy
- Medical disorders that affect pregnancy
- Physiological changes may make diagnose of medical disease difficult
- Treatment of medical conditions may be totally different in pregnant state and nonpregnant state

In developed countries, the maternal mortality ratio is 8 per 100,000 live births; in developing countries, it is 450 for the same number of live births. <sup>3</sup> The goal of this study is to learn about the various medical disorders that can occur during pregnancy and their impact on maternal

health and foetal well-being, as well as pregnancy-related medical disorders and their consequences.

Furthermore, research indicates that stillbirth in general and intrapartum stillbirth in particular are primarily caused by attributable underlying causes such as maternal medical and obstetric conditions, access to quality obstetric care services during pregnancy, and the types, timing, and quality of intrapartum care. Ethiopia is still one of the ten high-burden countries, with a birth rate of more than 25 per 1000.<sup>4</sup> The Ethiopian Demographic and Health Survey (2011) reported 46 perinatal deaths per 1000 total births per year, while Addis Abeba experienced around 30 per 1000 births during the same period. The medical conditions of the mother during each pregnancy can influence pregnancy outcomes. Marshall and Raynor (2014:224) identify hypertensive, metabolic, endocrine, respiratory, haematological disorders, infections, and nutritional deficiencies that can emerge or worsen during pregnancy as critical factors that can lead to adverse pregnancy outcomes, including stillbirth.<sup>8</sup> For instance, of the 20,000 pregnancies that resulted in stillbirth (39% intrapartum stillbirth) in South Africa between 2008-2009, 20% were associated with hypertensive disease that could have been managed to avert the adverse outcomes. Similarly, it is widely assumed that HIV and syphilis infections have statistically significant associations with stillbirth. For example, a Namibian study found that approximately 26% of stillbirths in the study population had a history of HIV infection during their index pregnancies. 10 According to a study from North-Eastern Ethiopia, pregnant women with syphilis were three times more likely to have a stillbirth Many of these risk factors could be screened for and managed as part of standard<sup>11</sup> antenatal care, making it an essential public health practise. As a result, this study collected data from a public health facility in Addis Abeba on key maternal medical conditions such as hypertension, diabetes, infections, Antenatal Care (ANC) attendance, and foetal condition during the pregnancy to see if any of these had statistically significant associations with intrapartum stillbirth compared to livebirth outcomes.

In recent years, there have been significant changes in the management of medical disorders in pregnancy. Disease patterns have shifted as socioeconomic conditions have improved. For example, the prevalence of antenatal anaemia has steadily declined over the last few decades.<sup>1,2</sup> and pulmonary tuberculosis, which was once common, is now only seen infrequently. Chronic rheumatic heart disease has also declined in prevalence. Gestational diabetes, on the other hand, has become more common. This could be attributed in part to the establishment of screening services for gestational diabetes in many hospitals. According to the Hong Kong College of Obstetricians and Gynecologists' territory-wide audit report on obstetrics and gynaecology, the four most common medical disorders complicating pregnancy are anaemia, diabetes mellitus, cardiac disease, and uterine fibroids. Furthermore, because of advancements in pregnancy medical, obstetric, and anaesthetic management, many women with medical disorders can have a healthy pregnancy. Maternal mortality in Hong Kong has decreased from 45 per 100,000 total births in 1961 to 4 in 1990. 4 An amniotic fluid embolism is the most common cause of maternal death.<sup>3</sup> Maternal mortality is now uncommon due to medical problems, and there are very few medical reasons to terminate a pregnancy. Perinatal mortality associated with some medical disorders, such as diabetes, has also been steadily decreasing.<sup>1,2</sup> It is critical that all health care professionals involved in the care of pregnant women with medical disorders to be aware of the latest developments in order to provide the best care for these women. The four articles in this issue are certainly helpful in this respect.<sup>5</sup>-

Four clinical principles are critical in the treatment of women with medical disorders. To begin, pregnancy has an impact on medical disorders because significant physiological changes occur in nearly every system in the body. Changes in hemodynamics may put

additional strain on the cardiovascular system, predisposing women with cardiac disease or hypertension to heart failure. The diabetogenic effects of pregnancy hormonal changes may result in gestational diabetes <sup>5</sup>, as well as making pre-existing diabetes control more difficult. Second, medical issues may affect the pregnancy. Diabetes can result in foetal macrosomia <sup>5</sup>, while chronic hypertension or kidney disease can result in foetal growth retardation. Third, physiological changes during pregnancy make diagnosing a medical disorder more difficult. Medical disorders can cause abnormal symptoms that are mistakenly attributed to pregnancy, resulting in a delay in diagnosis, whereas physiological symptoms and signs can lead to overdiagnosis of some medical disorders. Finally, medical disorders treated during pregnancy may differ from those treated in non-pregnant women. A pregnant woman has two patients: the mother and the foetus. The doctor and obstetrician must weigh the risks and benefits to both the mother and the foetus when deciding on treatment.

Proper counselling and preparation before a woman becomes pregnant is critical to ensuring the best possible pregnancy outcome. Before becoming pregnant, a woman should be informed about the risks of a medical disorder and/or medical treatment to both the mother and foetus so that she can make an informed decision about whether or not to become pregnant. Although uncommon nowadays, some medical conditions are associated with a high mortality risk (more than 25%). These women should be discouraged from becoming pregnant. However, it should be stressed that the final decision should be made by the woman herself after proper counselling. They should also be given proper contraception or sterilisation advice if they decide not to become pregnant. This reduces the likelihood of an unplanned pregnancy necessitating abortion. Some contraceptive methods may not be completely appropriate for women with certain medical disorders, and the efficacy and potential side effects, as well as the woman's medical condition, should be carefully considered before the most appropriate method is chosen. This may necessitate a high level of skill and experience.

When a woman decides to become pregnant, she should be properly prepared. Medication with potential foetal harm should be switched, if possible, to another medication known to be safe during pregnancy. Because a woman is usually pregnant for more than two weeks before the pregnancy can be diagnosed, it is preferable to change the drug (especially if it is teratogenic) before the woman becomes pregnant. Before attempting pregnancy, the medical condition should be well controlled. This has the potential to improve the foetal outcome. There is some evidence that good diabetes control reduces the risk of foetal anomalies in women who already have diabetes. Proper planning is also necessary to improve the maternal outcome. Elective cardiac surgery, for example, may be required prior to pregnancy to improve the woman's condition. Again, appropriate contraception advice is required while the woman waits for the medical condition to be controlled. Because pre-pregnancy counselling necessitates the expertise of both the obstetrician and the physician, clinics that include both parties are ideal for counselling and treating these women.

After the woman has conceived, the obstetricians and physicians must continue to work together. Other health care professionals may also be required to participate. Anaesthesiologists should be consulted early to determine the best method of pain control and to plan for anaesthesia for a caesarean section, whether it is an elective procedure or an emergency during labour. It is encouraging that anaesthesiologists in some hospitals (for example, Tsan Yuk Hospital) have begun to run assessment clinics for antenatal patients so that the patients can be prepared for labour and delivery management.

The need for contraception should be reconsidered after childbirth, and the best method should be recommended. It goes without saying that the best management of a woman's medical disorder necessitates a multidisciplinary approach with open communication among all staff members. A combined clinic with both physicians and obstetricians is ideal for treating more common medical conditions such as idiabetes or heart disease. A case conference with all of

the healthcare professionals who are treating the patient may be necessary at times. Collaboration is the only way for the specialties involved to ensure the best possible outcome for pregnant women with medical disorders.

#### **BACKGROUND**

#### 1)PREGNANCY AND CARDIAC DISORDER

Cardiac disease complicates 0.2–4% of all pregnancies in Western countries.<sup>1</sup> In developing countries like India, cardiac diseases complicate 2% of pregnancies and contribute to about one-fifth of all maternal deaths. Rheumatic valvular heart disease is most common cause in developing countries, comprising 56–89% of all cardiovascular diseases in pregnancy.<sup>13</sup>

#### **PHYSIOLOGY**

Early in the first trimester, hemodynamic changes begin. Plasma volume begins to rise in the sixth week of pregnancy and rises to 50% above baseline by the end of the second trimester. To facilitate the increase in cardiac output, the heart rate increases to about 20% above baseline.

```
    Peripheral resistance
    ↑ Uterine blood flow
    ↑ Blood volume (40–45%)
    ↑ Heart rate (10–20%)
    → or ↓ Blood pressure
    ↓ Pulmonary vascular resistance
    ↑ Venous pressure in lower extremities
```

Figure 1- hemodynamic changes during pregnancy

#### **DURING LABOR**

The hemodynamic changes that occur during labour and delivery are abrupt. With each uterine contraction, up to 500 mL of blood is released into the circulation, causing a rapid increase in cardiac output and blood pressure. During the second stage of labour, cardiac output is frequently 50% above baseline. Blood loss during delivery, as well as increased venous return and auto-transfusion from the uterus, may place the mother under significant hemodynamic stress. <sup>12,13</sup>

#### CLASSIFICATION OF CARDIAC DISEASE

Figure 2-NYHA functional classification of cardiac disease

Grade I	Patients have no limitations of physical exercise; ordinary activity does not cause undue fatigue, palpitations, dyspnea or angina	
Grade II	Patients have slight limitations of physical exercise; ordinary activity causes undue fatigue, palpitations, dyspnea or angina	
Grade III	Patients have marked limitations of physical activity, less than ordinary activity causes symptoms	
Grade IV	Patients have an inability to carry on physical activity without symptoms	

Figure 3-Risk score from CARPREG Study

Prior cardiac event (heart failure, transient ischaemic attack, stroke before pregnancy or arrhythmia)

Baseline NYHA functional class >II or cyanosis


Left heart obstruction (mitral valve area <2 cm², aortic valve area <1.5 cm², peak LV outflow tract gradient >30 mmHg by echocardiography)

Reduced systemic ventricular systolic function (ejection fraction <40%)

CARPREG risk score: For each above-mentioned CARPREG predictor that is present, a point is assigned.

Risk estimation of cardiovascular maternal complications 0 point 5%
1 point 27%
>1 point 75%

Figure 4: Modified WHO Classification of Maternal Cardiovascular Risk



#### EFFECT OF PREGNANCY ON CARDIAC DISEASE AND VICE VERSA

Due to physiological changes, there are several times during pregnancy with a known cardiac disorder when the risk of cardiac decompensation is especially high.<sup>13</sup>

- 1) The hemodynamic changes of pregnancy begin between 12 and 16 weeks of gestation.
- 2) Between 28 and 32 weeks of gestation, when the hemodynamic changes of pregnancy are at their peak and the cardiac demands are at their highest.
- 3) Labor and delivery are the most difficult times for pregnant cardiac patients.
- 4) Shortly after the baby and placenta are delivered. As a result of the sudden increase in blood volume

#### EFFECTS OF MATERNAL CARDIAC DISEASE ON FOETUS

Preterm delivery and foetal growth restriction are the most common causes of foetal morbidity. This is most likely due to a failure to maintain adequate uteroplacental circulation. And it is dependent on the severity of the heart's functional impairment and the chronic tissue hypoxia. When a mother has congenital heart disease, the risk of having a child with congenital heart disease increases. Fetal death in pregnant cardiac patients, most of whom have cyanotic heart disease. It also occurs in patients with Marfan syndrome who have acute aortic dissection and in cardiac patients who have significant functional impairment (class III and IV, NYHA classification). A poor outcome in these cases is related to the degree of maternal polycythaemia, which results in chronic hypoxemia.

#### 3) DIABETES AND PREGNANCY

Diabetes mellitus is a disorder of carbohydrate metabolism. It is caused by a combination of hereditary and environmental factors and is characterized by either inadequate secretion or inadequate action of insulin.

CLASSIFICATION OF DIABETES IN PREGNANCY

Noninsulin-requiring gestational diabetes mellitus (GDMNI): abnormal carbohydrate tolerance

with onset or first diagnosis during pregnancy that does not require insulin. Gestational

diabetes mellitus insulin requiring (GDMI): a condition characterised by abnormal

carbohydrate tolerance that develops or is diagnosed during pregnancy and necessitates the use

of insulin.14

**Class A**: abnormal carbohydrate tolerance in the nonpregnant state identified before the present

pregnancy that does not require insulin either before or during the pregnancy.

**Class B**: onset of insulin-requiring diabetes after 20 years, with a duration of less than 10 years.

Class C: onset of insulin-requiring diabetes between ages 10 and 20 with a duration of less

than 20 years, or duration 10–20 years regardless of age of onset.

**Class D**: onset of insulin-requiring diabetes prior to age 10 years, or duration greater than 20

years regardless of age of onset, or insulin-requiring diabetes with chronic hypertension, or

insulin-requiring diabetes with mild retinopathy.

Type E: Overt diabetes mellitus with calcified pelvic vessels l Type F: D

Class F: insulin- requiring diabetes with diabetic nephropathy (proteinuria greater than 500

mg in a 24-hour urine collection).

**Class R**: insulin-requiring diabetes with proliferative retinopathy.

**Class T**: insulin-requiring diabetes with renal transplant.

Class H: insulin-requiring diabetes with coronary artery disease.

16

#### CARBOHYDRATE METABOLISM IN PREGNANCY

Because of the gradual increase in insulin resistance, pregnancy is a diabetogenic condition.

There is an increased risk of hypoglycemia in early pregnancy due to increased insulin

sensitivity, nausea, and vomiting-mid-second and third trimesters when insulin resistance

begins to occur to provide nutrition to the growing foetus.

The diabetogenic effects of pregnancy are:

1) Insulin resistance:

Production of human placental lactogen, cortisol, estriol, and progesterone which all have anti-

insulin action

Increased destruction of insulin by the kidney and placenta (insulinase)

2) Increased lipolysis: The mother utilizes fatty acids for her caloric needs, sparing glucose for

the fetus

3) Changes in gluconeogenesis: Alanine and other amino acids, a primary gluconeogenic source

in the mother, is preferentially used by the fetus.

#### EFFECTS OF DIABETES ON PREGNANCY

Chronic complications occur due to a long-standing hyperglycemic state. This causes endothelial damage leading to a small vessel or extensive vessel disease. These include the following

1) Microvascular angiopathy

2) Macrovascular angiopathy

Diabetic cardiomyopathy may pose a risk of death. There is also a 10% increased risk of preeclampsia, and other diabetes complications include preterm labour, chorioamnionitis, polyhydramnios, and urinary tract infections. There is an increased risk of recurrent abortion in the case of uncontrolled diabetes. Dehydration from hyperemesis or diarrhoeal disease during the antepartum period, like febrile illnesses, can precipitate ketoacidosis, which can be life-threatening for the mother and cause sudden foetal death. Growth abnormalities, macrosomia, growth restriction and malformations, and chemical imbalances after birth, including hypoglycemia, hypocalcemia, hypomagnesium, and hyperbilirubinemia, are the most serious foetal risks. Fetal oxygenation problems due to Sudden fetal demise, chronic fetal hypoxia, and respiratory distress syndrome occur, and long-term sequelae include the development of type 2 diabetes mellitus.<sup>14,15</sup>

#### 4) HYPERTENSIVE DISORDERS IN PREGNANCY

Hypertension in pregnancy is defined as a systolic pressure level of 140 mmHg or higher or l Diastolic blood pressure of 90 mmHg or higher (Korotkoff V). 16,17

- Hypertensive disorders during pregnancy can be included into four well-defined groups: l Gestational hypertension
- Preeclampsia, eclampsia
- Chronic hypertension

Essential

Secondary

• Preeclampsia superimposed on chronic hypertension

Chronic hypertension in pregnancy is defined as hypertension before pregnancy or

before the 20th week of gestation, at least 4–6 hours apart on more than one occasion.

Or Persistence of hypertension for 12 weeks postpartum is also retrospectively

described as chronic hypertension. And the diagnosis of chronic hypertension is

straightforward if the patient is already on antihypertensives before pregnancy. 16,17

Chronic hypertension in pregnancy is subclassified as:

1 Mild hypertension: Systolic blood pressure of 140-159 mmHg or Diastolic blood

pressure of 90–109 mmHg.

1 Severe hypertension: Systolic blood pressure of 160 mmHg or greater or diastolic

blood pressure of 110 mmHg or greater.

#### **CAUSES**

- 1. Primary or essential hypertension
- 2. Secondary hypertension

#### Renal

Renal parenchymal disease (glomerulonephritis, reflux nephropathy, adult polycystic disease)

Renovascular hypertension (renal artery stenosis)

Endocrine l Diabetes with vascular involvement

Thyrotoxicosis

Pheochromocytoma

Primary aldosteronism

Cushing syndrome

Collagen vascular disease

Systemic lupus erythematosus

Scleroderma

Others

Aortic coarctation

Increased intracranial pressure

**PATHOPHYSIOLOGY** 

The most important determinants of blood pressure are cardiac output and PVR. Peripheral

vascular resistance is affected by humoral factors. And Cardiac output depends on cardiac

contractility and the intravascular volume status. Elevated blood pressure may result from

alterations in one or several of these factors. Essential hypertension starts with increased

cardiac output and normal PVR. A gradual increase follows this phase in PVR and a fall in

cardiac output. Most pregnant women with essential chronic hypertension are in the early

stages of hypertension and usually have elevated cardiac output and normal or mildly elevated

PVR and rarely show evidence of end-organ damage. Women with chronic hypertension have

a limited ability to counterbalance this increase in cardiac output by further decreasing their

PVR and maintaining their blood pressure under the normal limit. Subsequently, as a

consequence of this limited ability, their blood pressure starts to rise during 3<sup>rd</sup> trimester. 17,18

EFFECT OF CHRONIC HYPERTENSION ON PREGNANCY

Chronic hypertension in pregnancy is classified as either low or high risk.

Women with mild hypertension at the first visit, regardless of antihypertensive medication

treatment, are considered low risk. And without causing end-organ damage.

A low-risk pregnancy will be uncomplicated or encounter minor complications. A low-risk

patient may become high-risk later in pregnancy if she develops severe hypertension or

20

preeclampsia.

Risk factors for high risk include maternal age of more than 40 years, hypertension lasting longer than 15 years (long-standing hypertension), BP greater than 160/110 in early pregnancy (severe hypertension), diabetes, connective tissue disease, coarctation of the aorta (secondary hypertension) and concurrent cardiovascular and renal disease (end organ damage).

Maternal risks include exacerbation of hypertension, superimposed preeclampsia, congestive cardiac failure, pulmonary edema, intracerebral bleed, acute renal failure, abruption placentae with disseminated intravascular coagulation (DIC), and death.

The risk of preeclampsia in mild hypertension is upto 20%, but this increases to 50% with severe hypertension and 75% if hypertension is in the high-risk category. The incidence of abruptio placentae is 0.5–2% with mild chronic hypertension and increases to 3–10% in severe hypertension.<sup>18</sup>

Fetal morbidity and mortality is directly related to the severity of hypertension. Fetal risks include SGA, Premature birth.

#### EFFECT OF PREGNANCY ON CHRONIC HYPERTENSION

The physiological decrease in systemic vascular resistance in normal pregnancy results in a decrease in blood pressure, which has a nadir at 16–18 weeks of gestation and returns to prepregnant levels by the third trimester.

#### 2)PREGNANCY AND EPILEPSY

However, epilepsy is one of the most common neurological disorders that necessitates continuous treatment during pregnancy with known teratogens.

Seizures are the most common major neurologic complication encountered during pregnancy.

The primary treatment of these disorders must be learned by the practising obstetrician. The obstetrician must determine whether the medication will harm the developing foetus.

Physicians must conduct a risk/benefit analysis with the patient before proceeding with therapy.<sup>19</sup>

#### EFFECT OF PREGNANCY ON EPILEPSY

It has been taught that between 30% and 50% of patients experience an increase in seizure frequenc during pregnancy. The increase was linked to noncompliance with their medication regimen or sleep deprivation. Improvement in seizure frequency was associated with improved adherence to the drug regimen or a correction of sleep deprivation for the nine months preceding pregnancy, as stress is often associated with increased seizure frequency. Because of increased distribution and clearance volume, antiepileptic drug doses are required to be increased.

#### EFFECT OF EPILEPSY ON PREGNANCY

Most women with seizure disorders who become pregnant have an uneventful pregnancy with an excellent outcome.

Infants born to epileptic others had a smaller head circumference, according to research. This effect was observed in both untreated and medicated epileptic women. In neonates born to epileptic women, there is an increase in preterm labour, bleeding, pregnancy-induced hypertension, and a decrease in head circumference, primarily in women taking carbamazepine alone or in combination with phenobarbital.

In conclusion, women with seizure disorders are more likely to have FGR and stillbirth. Infants born ito mothers with seizure disorders appear to be smaller on average than their control counterparts. Even though they are smaller, they are usually within the normal gestational age range. Furthermore, preeclampsia is likely to be more common in mothers who have seizure disorders. However, the vast majority of pregnancies are uncomplicated, with no increase in complications over what is expected.<sup>19</sup>


#### 5) PREGNANCY WITH THYROID DISORDER

#### **PHYSIOLOGY**

The thyroid gland is a butterfly-shaped endocrine gland that is normally located in the lower front of the neck. The thyroid's job is to make thyroid hormones, which are secreted into the blood and then carried to every tissue in the body. Thyroid hormones help the body use energy, stay warm and keep the brain, heart, muscles, and other organs working as they should.

The thyroid gland can increase in size during pregnancy, This is usually only a 10-15% increase in size and is not typically apparent on physical examination by the physician. However, sometimes a significant goitre may develop and prompt the doctor to measure tests of thyroid function.<sup>20</sup>

Figure 5- Physiological hormone changes in pregnancy



#### PREGNANCY AND HYPOTHYROIDISM

Thyroid dysfunction is one of the common endocrine complications in pregnancy, especially hypothyroidism in pregnancy. Thyroid hormone (TH) is the most important endocrine hormone in the body, which can promote the synthesis of protein, RNA, DNA, and special enzymes in fetal tissues and cells, TH can regulate the metabolism of carbohydrates, calcium, phosphorus, fat, and other energy substances in pregnant women and fetus, and promote the growth and development of foetal bones and reproductive organs, and is very important to maintain the normal development and maturity of foetus.<sup>20,22</sup>

#### **CLINICAL FEATURES**

Lethargy, fatigue, increased weight which are also symptoms of pregnancy which makes diagnosis of hypothyroidism difficult.

#### EFFECT OF PREGNANCY ON HYPOTHYROIDISM

Pregnancy places significant demands on the maternal thyroid axis; for the first 18-20 weeks of pregnancy, the baby is completely reliant on the mother for thyroid hormone production. Furthermore, there is an increase in thyroxine binding globulin and thyroid hormone degradation by placental type 3 deiodinase<sup>13</sup>, which increases demand. In pregnancy, urinary iodine excretion is highest in the first trimester and decreases in the second and third trimesters. The baby's thyroid begins to produce thyroid hormone on its own by mid-pregnancy. The baby, on the other hand, remains dependent on the mother for adequate iodine intake, which is required to produce thyroid hormones. To ensure adequate thyroid hormone production, the World Health Organization recommends a daily iodine intake of 250 micrograms. The pregnancy hormone beta hCG stimulates the thyroid to produce thyroid hormone, which helps the thyroid axis meet the increased demands of pregnancy. TPO antibody positive women may

have a reduced thyroidal response to hCG<sup>21</sup>, according to new research. This could explain why women with thyroid autoimmunity who have positive thyroid peroxidase antibodies (TPO) have an increased risk of adverse obstetric outcomes that are not related to thyroid status.

#### EFFECT OF HYPOTHYROIDISMON PREGNANCY

Untreated or inadequately treated hypothyroidism has been linked to maternal anaemia, myopathy (muscle pain and weakness), congestive heart failure, pre-eclampsia, placental abnormalities, and postpartum haemorrhage (bleeding). Women with severe hypothyroidism are more likely to develop these complications. And it can impair the baby's brain development. Recent research suggests that children born to mothers who had mild untreated hypothyroidism during pregnancy may also have mild developmental brain abnormalities. Women who have hypothyroidism should have a TSH test as soon as their pregnancy is confirmed. One also should immediately increase their levothyroxine dose, because thyroid hormone requirements increase during pregnancy. If new onset hypothyroidism has been detected, the woman should be treated with levothyroxine to normalize her TSH values.

#### PREGNANCY WITH HYPERTHYROIDISM

Hyperthyroidism complicates approximately 0.2% of pregnancies [23]. Hyperthyroidism is defined by excessive thyroid hormone production due to an overactive thyroid gland.

The most common cause of pre-existing hyperthyroidism is Graves' disease, an autoimmune hyperthyroidism caused by stimulation of the thyroid gland by thyroid-stimulating hormone receptor antibody (TSHRAb). The differential diagnosis includes toxic solitary thyroid nodule, multiple nodular goiter, exogenous thyroid hormone, amiodarone ingestion, excess iodine intake, and subacute thyroiditis.<sup>22</sup>

#### CLINICAL FEATURES

Many of the typical features are common in normal pregnancy, including heat intolerance, tachycardia, palpitations, palmar erythema, emotional liability, vomiting and goiter.

The most discriminatory features in pregnancy are weight loss, tremor, a persistent tachycardia, lid lag and exophthalmos. The latter feature indicates thyroid disease at some time rather than active thyrotoxicosis. Thyroid-associated ophthalmopathy may occur before hyperthyroidism and is present in up to 50% of patients with Graves' disease. If thyrotoxicosis occurs for the first time in pregnancy, it usually presents late in the first or early in the second trimester.

#### **PATHOGENESIS**

Graves' disease is responsible for nearly 85% of cases of hyperthyroidism during pregnancy. Graves' disease is an autoimmune disorder caused by antibodies that stimulate TSH receptors. "Gestational transient thyrotoxicosis," which is limited to the first half of pregnancy, is more common than Graves disease as the cause of thyroid function tests demonstrating hyperthyroxinemia. This condition is diagnosed in about 1-3% of pregnancies and is characterised by elevated FT4 and suppressed serum TSH. 2 This frequency varies by location and is secondary to elevated hCG levels. It is frequently associated with hyperemesis gravidarum, which is defined as early pregnancy nausea and vomiting with more than 5% weight loss, dehydration, and ketonuria. Hyperemesis gravidarum affects 3-10 pregnancies out of every 1,000. 3 Other conditions linked to hCG-induced thyrotoxicosis include multiple gestation and hydatidiform thyrotoxicosis. A TSH receptor mutation that causes functional hypersensitivity to hCG is also a rare cause of pregnancy-associated hyperthyroidism. Hyperthyroidism in women of childbearing age may be caused by toxic multinodular goitre or toxic adenoma, or it may be caused by subacute thyroiditis, acute thyroiditis, iodine, amiodarone, or lithium therapy<sup>22</sup>

#### EFFECT OF PREGNANCY ON THYROTOXICOSIS

During pregnancy, thyrotoxicosis often improves, especially in the second and third trimesters. As with other autoimmune conditions, pregnancy causes a state of relative immunosuppression, and levels of TSH receptor-stimulating antibodies may fall, resulting in improved Graves' disease and a lower need for anti-thyroid treatment. Exacerbations may occur in the first trimester, possibly due to hCG production, and in the puerperium, possibly due to a reversal of the fall in antibody levels seen during pregnancy (especially if there has been improvement during pregnancy).<sup>21</sup> Graves' ophthalmopathy is unaffected by pregnancy.

#### EFFECT OF THYROTOXICOSIS IN PREGNANCY

If thyrotoxicosis is severe and untreated, it is linked to ovulation inhibition and infertility. Those who do become pregnant and do not seek treatment have a higher risk of miscarriage, foetal growth restriction (FGR), preterm labour, and perinatal mortality. Sinus tachycardia, supraventricular tachycardia, and atrial fibrillation can all result from thyrotoxicosis. If not properly managed, the mother may develop a thyroid crisis (storm) and heart failure, especially during delivery. The maternal and foetal outcome is usually good and unaffected by thyrotoxicosis in those who have good control on anti-thyroid drugs or who have previously treated Graves' disease in remission. In rare cases, goitre retrosternal extension can cause tracheal obstruction or dysphagia. This is especially problematic if the patient needs to be intubated.

#### FETAL AND NEONATAL THYROID DYSFUNCTION

Improvement in Graves' hyperthyroidism during pregnancy is frequently associated with a decrease in the titer of maternal serum TRAb concentrations and a shift from stimulatory to blocking antibodies. If antibodies do not decrease, they will cross the placenta and stimulate the foetal thyroid, resulting in foetal hyperthyroidism, as evidenced by tachycardia, intrauterine growth retardation, cardiac failure, and the development of foetal goitre.<sup>22</sup>

As a result of the transplacental passage of maternal TRAb concentrations, one to five percent of neonates born to Graves' disease mothers have hyperthyroidism. Because antithyroid drugs administered to the mother are cleared from the foetal circulation more quickly than maternal stimulating antibodies, the onset of neonatal hyperthyroidism may be delayed. Maternal euthyroidism is especially important in the later stages of pregnancy, because poorly controlled hyperthyroidism can cause suppression of the foetal pituitary thyroid axis due to thyroxin transfer through the placenta. The illness can last up to six months. There are no known adverse pregnancy outcomes associated with subclinical hyperthyroidism.

#### **DIAGNOSIS**

Serum TSH may decrease in the first trimester of normal pregnancy as a physiological response to the stimulating effect of hCG upon the TSH receptor. A peak hCG level typically occurs between 7- and 11-weeks gestation. In particular, a serum TSH below 0.1 mU/L (in some cases even undetectable may be present in approximately 5% of women by week 11 of pregnancy.<sup>22,23</sup>

Any subnormal serum TSH value should be evaluated in conjunction with serum TT4 (or FT4) and T3 values.8 The biochemical diagnosis of overt hyperthyroidism is confirmed in the presence of a suppressed or undetectable serum TSH and inappropriately elevated serum TT4/FT4, or T3.

#### 6) ASHTMA AND PREGNANCY

#### **PATHOPHYSIOLOGY**

•Asthma is a chronic inflammatory disorder of the airways characterized by increased responsiveness of tracheobronchial tree to multiplicity of stimuli with a major hereditary component

•This increased airway responsiveness and persistent sub- acute inflammation have been associated with genes on chromosomes 5, 11, and 12 that include cytokine gene clusters,  $\beta$ -adrenergic and glucocorticoid receptor gene, and the T-cell antigen receptor gene (McFadden, 2005)

•Around 30-40% of asthma patients report perimenstrual symptoms worsening. The possibility of female hormones influencing asthma appears obvious, though the exact mechanism is unknown. There is substantial evidence that female sex hormones have effects on several cells and cytokines involved in inflammation that are specifically attributed to oestrogens. B cell differentiation increases, T cell suppression activity and number decreases, and antibody production increases. Evidence suggests that progestrone can act as a glucocorticoid agonist and suppress basophil histamine release. Both oestrogen and progesterone are involved in eosinophillic infiltration in a variety of organs, and both can reduce the oxidative burst following phagocytic stimulation. Estradiol enhances eosinophillic adhesion to human mucus. Microvascular endothelial cells, the combined effect with the progesterone induces eosinophillic degrannulation. There appears to be a cyclic variation in lymphocyte β2 adrenoreceptor density in healthy women with higher levels during luteal phase. This upregulation is as a result of **progesterone rather than estrogen.**<sup>15,16</sup>

- •In asthmatic women, in fact there is downregulation of β2adrenoreceptors. As pregnancy progresses and progesterone levels increases, similar effects may be seen causing worsening in control of asthma in some pregnant asthmatic women. Maternal plasma cortisol levels increase with pregnancy. Cortisol's effect on asthma during pregnancy are more variable. Several prostaglandins play a major role in asthma as bronchodilators and bronchoconstrictors, amniotic fluid contain large amounts of these PGs. There is a 10–30-fold increase in PGF2-alfa during pregnancy. And its levels have been found to correlate with estrogen levels
- •In susceptible individuals, there is inevitably an environ- mental allergic stimulant such as influenza or cigarette smoke.
- •There is also a possible influence of fetal sex and maternal asthma during pregnancy. Reports have suggested that asthma attacks or worsening asthma during pregnancy who are associated with female fetus. The mechanisms leading to changes require further investigation, one possible cause there may be abnormal levels of placental enzymes that may lead to reduced fetal growth in female infants of pregnant asthmatic women <sup>16</sup>
- •Inflammation is caused by response of mast cell, lymphocytes, eosinophils, and bronchial epithelium. A number of inflammatory mediators by these and other cells include histamine, leukotrienes, prostaglandins, cytokines including IgE (Strunk and Bloomberg, 2006)
- •As F series prostaglandins and ergonovine exacerbate asthma, hence should be avoided if possible.

### ANATOMICAL CHANGES IN SOFT TISSUES OF RESPIRATORY TRACT DURING PREGNANCY

•Reversible airway obstruction from bronchial smooth muscle contraction, vascular congestion, tenacious mucus, and mucosal edema. Hyperemia, friability, mucosal edema, and

hyper secretion of the airway mucosa are most pronounced in the upper airways, especially during the third trimester

- •Nasal obstruction, epistaxis, sneezing episodes, and vocal changes may occur, and these may worsen when the individual lies down
- •Nasal and sinusoidal polyposis is often seen and tends to recur in women with each pregnancy.

Caution- nasal decongestant spray should be used with because of their long-term effect on the mucosa.

#### PHYSIOLOGIC CHANGES DURING PREGNANCY

- •Both hormonal and mechanical changes can influence the respiratory functions and can lead to an exacerbation of asthma
- •A progesterone mediated first trimester causes an increase in tidal volume leading to secondary increase in minute ventilation volume
- •Pregnancy induced hyperventilation leads to compensatory respiratory alkalosis, increase in PH may lead to more severe respiratory compromise than similar ABG in nongravid
- •Mechanical changes include elevation of uterus, secondary elevation of diaphragm, decreased diameter of chest, and increased intra-abdominal pressure.<sup>8</sup>

#### **CRITERIA FOR DIAGNOSIS**

- •A history of variable respiratory symptoms
- •Typical symptoms are wheeze, shortness of breath, chest tightness, cough
- •Usually have more than one of these symptoms
- •The symptoms occur variably over time and vary in intensity

•The symptoms often occur or are worse at night or on waking

•The symptoms often occur with or worsen with viral infections

•Measurement of FEV1 and FVC by spirometry: FEV1/FVC ratios <0.7 and > 20% diurnal

variation in PFFR for 3 or more days per week during a two week diary is diagnostic. 16

Effects of pregnancy on asthma: Conventional wisdom is that asthma in pregnancy follows the

"one-third rule"

•One-third will improve

•One-third will deteriorate

•One-third will remain unchanged.

Asthma during pregnancy has been associated with considerable maternal morbidity. Effects

are variable.

#### EFFECT OF ASTHMA ON PREGNANCY

Compared with women without a history of asthma, women with asthma have been reported

to have higher risks for complications of pregnancy even after adjustments for potential

confounders. 16,17

Risks are:

• Preeclampsia

• Gestational diabetes

• Placental abruption

• Placenta praevia

• Preterm birth

- Preterm premature rupture of the membranes
- Breech presentation
- Hyperemesis
- Pulmonary embolism
- Maternal intensive care admission
- Increased risk of congenital malformations associated with exacerbations in first trimester
- Increased incidence of cesarean section
- Status asthmatics—muscle fatigue with respiratory arrest, pnemothorax, pnuemomediastinum, acute cor pulmonale, and cardiac arrhythmias.

#### **FETAL EFFECTS:**

- With reasonable control of asthma, perinatal outcomes are generally good
- The fetal response to maternal hypoxemia is decreased umbilical blood flow, increased systemic and pulmonary vascular resistance, and decreased cardiac output. More severe maternal asthma, more is the fetal growth restriction
- Increased low birth weight
- Increased premature delivery
- Increased risk of fetal death Neonatal effects
- Increased neonatal hypoxemia
- Low newborn assessment scores

Increased perinatal mortality

#### 7) INFECTIOUS DISEASE IN PREGNANCY

Infection may occur at any time during gestation and their severity will vary depending on the virulence of the agent, the susceptibility and gestational age of the fetus, and the route of the infection. Route of transmission include The Routes of Transmission to the Fetus, Transplacental transmission (haematogenous), Transcervical transmission (relatively uncommon), Direct contact at birth.<sup>25</sup>

Secondary infections are usually not dangerous, due to production IgG antibioties produced by mother during the second time exposure will cross placenta and provide passive immunity for the fetus. During the first infection, the immune response of the mother is slow and it is characterized by the production of IgM that cannot cross the placenta, while the production of IgG occurs later during the course of infection. In this scenario, the fetus is more susceptible to damage if it acquires the infection because its own immune system is not completely developed.

#### **Factors Affecting Effects of Infection**

- Infecting dose
- Type and virulence of the organism
- Maternal response
- Route of infection
- Time (in gestation) of infection

#### **EFFECTS OF INFECTION**

- Teratogenic–Malformations such as congenital heart disease, microcephaly.
- Disruption Destructive brain damage, coagulation failure, antepartum and post partum bleeding
- Growth restriction Reduced cell numbers, placental damage, Preterm birth ,Low-birth weight, fetal distress, intra uterine death.
- Missed miscarriage and stillbirth.

#### 9) DENGUE AND PREGNANCY

dengue fever was first reported in 1902 in Penang, malaysia (Skae, 1902). It has since become a major public health problem. Dengue is a mosquito-borne virus, belongs to Flaviviridae family and transmitted via the Aedes mosquito, which include Ae.aegypti and Ae.albopictus. there are four serotypes of DENV (DENV 1, DENV 2DENV 3, DENV4).<sup>25,26</sup>

#### **CLINICAL FEATURES**

Dengue infection can present four different clinical syndromes: undifferentiated fever, classical dengue fever, dengue hemorrhagic fever, or dengue shock syndrome (DSS). Classical dengue fever is defined as an acute febrile illness with two or more other clinical manifestations involving headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestation, or leukopenia. Dengue hemorrhagic fever is characterized by fever, hemorrhagic tendencies, thrombocytopenia, and evidence of plasma leakage, as well as possible association with hepatomegaly and circulatory disturbances. Dengue shock syndrome is manifested when symptoms include rapid and weak pulse, narrow pulse pressure of less than 20 mmHg, and hypotension.

#### EFFECT ON PREGNANCY

Maternal death can be fatal outcome of dengue shock syndrome. DIC and acute kidney injury adverse outcome of pregnant women with DSS and needs critical care. Vertical transmission

## 10) TORCH AND PREGNANCY

## A)CYTOMEGALOVIRUS (CMV)

Cytomegalovirus is a double-stranded DNA virus member of the family of herpes virus.

Infection can potentially occur from close contact with different body fluids such as saliva, blood, semen, urine and cervical secretion .<sup>27</sup>

## **PATHOLOGY**

CMV enters the cell through fusion of the outer membrane of the cell and glycoproteins on the lipid envelope of virions. The DNA-containing protein capsid and the tegument proteins are released into the cell after the event of fusion. CMV infection recognizes two different stages: lytic and latent.

In lytic phase- DNA replication, structural components of the virion are assembled thus allowing the viruses to leave the infected cell.

In latent phase- minimization of viral gene expression, inhibition of the assembly and egress of new viral progeny. Latent phase can activate lyatic phase upon certain environmental, stimuli.

### **EPIDEMIOLOGY**

CMV is the most common cause of fetal infection occurring in 0.5–2% of all live births

#### **EFFECT ON FETUS**

- CNS (ventriculomegaly, intra-ventricular haemorrhage, intra-ventricular adhesions, periventricular echogenicities, sub-ependymal cysts, periventricular leukomalacia, microcephaly, lissencephaly, porecephaly, cerebellar agenesis, hypogenesis, hypoplasia and haemorrhage, microphthalmia).
- Fetal growth restriction (FGR).
- Placental enlargement.
- Gastrointestinal tract (Hepatomegaly, splenomegaly, echogenic bowel, intrabdominal and liver calcification, ascites)
- Heart (cardiomegaly, pericardial effusions and calcifications)
- Non-immunehydrops.

## **B) TOXOPLASMOSIS**

Toxoplasmosis gondi is a protozoan infection. Mother aquires infection by ingestion of uncooked or raw meat containing toxoplasma cysts. Water or food contaminated by oocysts excreted in the faeces of infected cats represents another source of infection. Transmission from the mother to the fetus occurs almost exclusively during a primary maternal infection, although in rare cases it may be due to reactivation of toxoplasma in immunocompromised patients.

#### **EFFECT ON FETUS**

**Frequency** of vertical transmission as high as 70% in 3<sup>rd</sup> trimester and during first trimester it is as low a 5-6% but the damage to the fetus is higher in the earlier stages of pregnancy.<sup>27</sup>

Overall risk of a symptomatic infection lesser than 5–8%.

# Features of congenital toxoplasmosis

- CNS abnormalities (ventriculomegaly, calcifications in the brain parenchyma, periventricular zone and caudothalamic zone, periventricular echogenicity or cysts.
- Ocular abnormalities (cataracts).
- GI abnormalities (hepatomegaly, liver calcifications, ascites).
- Placental enlargement/thickening.

# C)VERICECELLA AND PREGNANCY

Varicella zoster virus (VZV) is a highly contagious human alpha-herpes virus which causes varicella (chickenpox) and herpes zoster. Chickenpox is the consequence of a primary infection with VZV, herpes zoster is caused by the reactivation of the virus from its latency. Primary infection provides life long immunity, the virus persist in a latent form in the nucleus of the paraspinal cells and can potentially reactivate spreads through contact between the virus and the host is usually through the conjunctivae and the mucous membranes of the nasopharynx.

# Epidemiology

incidence varies according to the latitude and climate, with a peak during late winter and early spring in temperate climes.

The host can potentially transmit the infection from 2 days before to 5 days after the onset of the rash, until the vesicles crust over (7–10 days). Pneumonia is serious complication occurs in 5-10% and mortality rate of < 1%.

## **EFFECT ON FETUS**

The rate of vertical transmission during the first and the second trimester has been reported to be at around 8–9% and congenital varicella syndrome occurs in about 10% of the fetuses developing infection (0.4–2% of all infected mothers), especially if maternal infection is

acquired before 20 weeks of gestation. If delivery occurs between 5 days before and two days after the onset of the rash. In this scenario, the lack of an adequate immune response from the mother results in low levels of IgG in fetal blood, thus predisposing the fetus to neonatal varicella that occurs in up to 30% of the cases.<sup>28</sup>

### Features of Congenital Varicella Syndrome

- CNS abnormalities (mental retardation due to microcephaly and cortical atrophy)
- Limb hypoplasia
- Skin scarring
- Ocular abnormalities (cataracts, chorioretinitis)

# 8) HIV AND PREGNANCY

HIV infection remains a major global public health issue. Humans acquire it via the exchange of bodily fluids, mainly through unprotected intercourse, and women pass it on via mother-to-child transmission during pregnancy, childbirth, and breastfeeding. Other known means of transmission include the use of infected syringes by drug abusers and blood transfusions.

The human immunodeficiency virus (HIV) is the cause of the acquired immune deficiency syndrome (AIDS). There are five known human retroviruses (HIV-1, HIV2, HIV-I, HIV-II and HIV-IV) and three of them are associated with human disease. HIV-1, the most common cause of AIDS. 16,30

### **EPIDEMIOLOGY**

World Health Organization (WHO) in 2019, approximately 38 million people were living with HIV globally.2 In 2016, the American Foundation for Aids Research census showed that 51% of all adults living with HIV were women. In the absence of any intervention, mother to child trasmission ranges from 15%–45%. And Preventative strategies have reduced mother to child

trasmission to < 5%, with antiretroviral therapy (ART), there has been a 50% reduction in new HIV cases.

## **PATHOGENESIS**

The virus only infects susceptible cells that express in their surface a glycoprotein called CD4, which is recognized by the glycoprotein gp120 that is present in the viral envelope. The best known susceptible cell in humans is the CD4 or T4 helper-inducer T lymphocyte. Invasion of these cells by the HIV-1 virus, by reverse transcriptase enzyme trascripts RNA into DNA. And viral DNA in into host cell DNA And transcription of viral DNA into RNAs and translation of viral RNA into viral components and virus replicates by destroying lymphocytes which alters the immunity and that is characteristic of AIDS.<sup>30</sup>

### Fetal infection

The outstanding maternal factor is the severity of the disease that can be assessed immunologically by the number of CD4 cells or virologically by measuring the number of RNA

Copies.

risk of vertical transmission

- 0–10% if the viral load -1000 copies/ml
- 17% with viral loads 1000–10,000 copies/ml
- 33% if the viral load > 10,000 copies/ml.
- Rate of vertical transmission among all women with HIV infection on HAART
- 1% -1000 RNA copies/ml
- 6%-1000–10,000 RNA copies/ml
- 13% -10,000 RNA copies/ml

All infants of HIV-infected mothers have positive HIV serology as a consequence of the passive transfer of maternal antibodies. Levels of these antibodies decline gradually and by 6 months of age most non-infected newborns will be seronegative.

## 11)PREGNANCY AND JAUNDICE

The incidence of jaundice in pregnancy in India varies from 0.4 to 0.9/1000 deliveries. Maternal mortality is around 18%. Main causes of maternal mortality are coagulation failure, hemorrhage, hepatic coma, renal failure and septicemia. Incidence of preterm labor is increased and the perinatal mortality is around 23%.

Jaundice is yellow discoloration of skin, conjunctiva, sclera and mucosa associated with rise in serum bilirubin above 2 mg/dL (normal 0.2–01 mg/dL) Latent jaundice: 1–2 mg/dL. It occurs due to increased production of bilirubin or impaired hepatocyte transport or conjugation or impaired excretion of bilirubin into intestine .<sup>4</sup>

The occurrence of hepatobiliary disease with or without jaundice during pregnancy presents obstetricians and hepatologists with an intriguing and urgent diagnostic challenge. Advances in understanding and management of pregnancy-specific liver disorders, as well as hepatobiliary disease in general, have resulted in significant improvements in maternal and foetal outcomes..<sup>3</sup>




Figure 6 Mechanism of conjugation of bilirubin in liver

# .

### LIVER IN NORMAL PREGNANCY

In pregnancy plasma volume increases by 50%, but with disproportionate increase in red cell mass by 20%, there is resultant hemodilution. This phenomenon should be kept in mind during interpretation of all serum concentrations used in evaluation of hepatic function during pregnancy. Serum albumin decreases, serum cholesterol, triglyceride and fibrinogen increases. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), prothrombin (PT), bile acid levels are not affected. Serum alkaline phosphatase level almost doubles due to its placental isozyme bilirubin, gamma- glutamyltranspeptidase slightly decreases.

Jaundice is a clinical manifestation of liver disorders or hematological disorders or some conditions unique to pregnancy.

Liver disorders that occur in pregnancy can be divided into three groups:

- 1 Liver diseases unique to pregnancy
  - Hyperemesis gravidarum
  - Intrahepatic cholestasis of pregnancy
  - In pre eclampsia and eclampsia, HELLP syndrome
  - Acute fatty liver of pregnancy
- 2 Liver diseases coincidental to pregnancy
  - Viral hepatitis A, B, C, D, E herpes simplex
  - Malaria, sickle cell crisis, leptospirosis
  - Gallstones, Budd-Chiari syndrome
  - Drugs
- 3 Pregnancy in preexisting liver disease
  - Chronic viral hepatitis, hepatitis B virus (HBV), hepatitis C virus (HCV),
     nonalcoholic fatty liver disease
  - Portal hypertension, autoimmune hepatitis, Wilson's disease
  - Primary biliary cirrhosis, primary sclerosing cholangitis
  - Liver tumors

A careful clinical history, physical examination, appropriate laboratory tests and radiological investigations should allow a diagnosis within short time. Liver biopsy rarely required.

# <u>Important points in history</u>:

- Duration of jaundice, interval between symptoms and jaundice
- Exposure to contaminated food or water

• Exposure to medication over-the-counter (OTC), prescribed by physician, complementary or alternative, herbal or vitamin preparations, anabolic steroids, parenteral exposure, transfusions, intravenous abuse, tattoos, sexual activity, use of alcohol.

Past history of jaundice may suggest chronic hepatitis, cirrhosis, intrahepatic cholestasis
 or genetic nonhemolytic hyperbilirubinemia

• Family history of hemolytic anemia, sickle cell disease, congenital hyperbilirubinemia. <sup>4</sup>

# **Symptoms**

Yellow colouring of skin and eyes, pruritus, nausea, vomiting, weakness, fever, headache dyspepsia, anorexia, loss of appetite, fat intolerance, changes in color of urine (dark yellow) and stool (light colored), right upper quadrant abdominal pain, biliary colic, arthralgia, myalgia, rash, etc.

## a) Pregnancy and Jaundice

Appearance of jaundice within 2 weeks of constitutional symptoms like nausea, vomiting, anorexia may suggest hepatitis or calculus biliary obstruction. If such symptoms appear more than 2 weeks prior to jaundice, it may suggest chronic hepatitis or alcoholism or exposure to toxins.

Signs and symptoms of liver disease in pregnancy are not precise, but the underlying disorder can have substantial effects on maternal and fetal outcome. Early recognition can be lifesaving."

In addition to routine clinical examination, systemic examination and obstetric evaluation, palpation of liver for enlargement, surface consistency, tenderness along with splenic enlargement and examination for ascites is helpful.

Skin may show scratch marks due to pruritus and bruising due to disturbed coagulation. Spider telangiectasia on trunk, arms, and hands may be normal in pregnancy but its presence ay suggest chronic hepatocellular jaundice. <sup>4</sup>

## b) Intrahepatic Cholestasis of Pregnancy

Recurrent jaundice of pregnancy/cholestasis hepatosis/icterus gravidarum.

It is the second common cause of jaundice in pregnancy next to viral hepatitis.

Incidence 0.6%—variations due to genetic influence. Cause is unknown. High estrogen concentrations in susceptible or defects in secretion of sulfated progesterone metabolites may play a role. Some cases are related to many gene mutations that control hepatocellular transport systems (mutation of MDR 3 gene in progressive familial intrahepatic cholestasis). Drug like azathioprine impaired canalicular transport of bile acids and aggravate the disorder.

Main symptom is pruritus in late 2nd trimester, increases as pregnancy advances. Constitutional symptoms like anorexia, malaise are rare. Jaundice in 10% of cases. USG is helpful to exclude cholelithiasis and biliary obstruction. Pruritus usually precedes 3 weeks of abnormal biochemical tests and resolves 48 hours postpartum.

# **Fetal Complications**

MSL due to increased colonic motility by bile acids, fetal distress and meconium passage, preterm labor, CTG abnormalities, RDS, IUD.

Fetal monitoring by CTG on alternate day and weekly assessment of amniotic fluid followed by elective delivery at 38 weeks of pregnancy.

Figure 7: Comparison of different causes of jaundice in pregnancy

Disorders	Gestational periodat presentation	Prevalence	Symptoms	Specific laboratory tests	Outcome	Treatment
Hyperemes is gravidaru m	First trimester; resolves after 20 wk	<2% (primigravid)	Nausea and vomiting	AST, ALT <500 IU/L;ALT >AST; low TSH, bilirubin normal /mild rise	Electrolyte imbalance, complications of retching. Thiamine and vitaminK deficiency	IV fluids; thiamine pyridoxine; promethazine ondansetron
Intrahepati c cholestasis of pregnancy	Second trimester	<10% multifetal gestations	Pruritus is main symptom resolves in postpartum period	AST, ALT <1000 IU/L; GGT normal; bile acid levels high (10–14 umol /L; PT normal; bilirubin <6 mg/dL, clay stool, steatorrhea	Increased gallstones and risk for fetal distress, MSL increases. Reoccurs in subsequent pregnancy	UDCA, delivery if fetal distress is imminent or at 38 weeks
Eclampsia, preeclamps ia	Beyond 20 weeks; recurs	5% multiparous, multifetal gestations	High blood pressure, proteinuria, edema, seizures, renal failure, pulmonary edema	Uric acid level elevated	Maternal mortality, 1%; prematurity and fetal death, 5–30%	Labetalol, nifedipine, methyldopa, magnesium sulfate; early delivery
HELLP syndrome	Beyond 22 weeks and after delivery; 20% progress from severe eclampsia	0.5%	Abdominal pain, seizures, renal failure, pulmonary edema, liver hematoma and rupture	Platelets <100,000/ mm3; hemolysis; high LDH level; AST, ALT 70–600 IU/L; Uric acid normal / elevated. Bilirubin up to 5–6 mg% in terminal stage	Hepatic rupture, with 60% maternal mortality; DIC 20–40%; fetal death, 1–30%	Prompt delivery, correction of coagulopathy, magnesium sulfate, antihypertensiv e drugs
Acute fatty liver of pregnancy	Third trimester; 50% have eclampsia	1/13,000 primiparous, multifetal gestations	Progress quickly to FHF, diabetes insipidus, hypoglycemia	TC elevated. Platelets <100,000/ mm3; AST, ALT >300 IU/L; PT elevated; fibrinogen level low; bilirubin level increased <10 mg%; Hypoglycemia common. Uric acid elevated. CT scan may show fatty liver	DIC 75%, maternal mortality <20%; fetal mortality up to 45%	Prompt delivery; correction of coagulopathy, renal dysfunction, electrolyte imbalance. Liver transplantation controversial
Acute viral hepatitis	Any stage of gestation	No specific predilection but more common in women with risk factors like contaminated food and water or parenteral transmission or high risk sexual behavior	anorexia, headache. malaise, fever, epigastric pain may precede	ALT >1000 IU/ Bilirubin 5–20 mg% TC normal , uric acid and CT scan normal. DIC rare	Usually complete clinical cure except cases of chronic hepatitis B, HEV and HSV	Early delivery is not recommended

# c) Acute Viral Hepatitis

Most common cause of jaundice in pregnancy. No increased risk of fetal malformation but perinatal mortality is increased due to higher rate of prematurity and stillbirth.<sup>4</sup>

# **Early Delivery is not Required**

hepatitis D (B associated delta virus), hepatitis E. Immune response to virus causes hepatocellular necrosis.

Many infections are subclinical

- Symptoms like nausea, vomiting, headache, malaise may precede jaundice by 2 weeks
- Serum transaminase levels ranging from 400-4000 u/L and its peak may not correspond to disease severity
- S bilirubin levels are higher (5–20 mg/dL) may continuously rise.

Viral markers help in diagnosis.

• Coagulopathy can occur in fulminating hepatic necrosis"

Figure 8: Important features of different types of viral hepatitis

	Hepatitis A	Hepatitis B	Hepatitis C	
Virus	• 27 nm RNA picornavirus	DNA Hepadnavirus	Single-stranded RNA flaviviridae virus	
Mode of transmission	<ul> <li>Fecal-oral route</li> <li>Ingestion of contaminatedfood, water or blood</li> </ul>	Parenteral route, IV drug abuse, homosexuals, blood and blood products, vertical transmission	Same like hepatitis B, more prevalent in IV drug users, hemophilics and high risk sexual behavior, vertical transmission	
Incubation period	• 4 weeks	6 weeks to 6 months	• 6–10 weeks	
Antigens	Hepatitis A antigen	HBcAg core antigen     HBsAg surface antigen appear first,     HBeAg-antigen suggest presence of     viral particles and chronic infection     Sero+ve cases are at higher risk     of hepatocellular carcinoma	HCV core antigen	
Antibodies	IgM may appear as early as     5 days before symptoms     and persists for several     months	<ul> <li>Anti-HBc (IgM) appear within weeksand persists up to 22 weeks</li> <li>Anti-Hbc (IgG) appear after 6 weeks and persists longer.</li> <li>Anti-HBs appear after at 22 weeks and persists for years.</li> <li>Anti-HBe appear after 16 weeks and persists longer</li> </ul>	Anti-HCV antibodies may be detected after 15 weeks or may not be detectable.  It usually does not prohibit transmission. So seropositivity and screening program is not useful in pregnancy	
Chronic infection (hepatitis lasts longer than 6 months)		• 5–10% adults • 70–90% infants	86% of sero +ve cases have chronic infection	
Fulminating hepatic necrosis and long-term complications	Very rare	Higher rate of fulminating hepatic necrosis, cirrhosis and hepatocellular carcinoma	• Very slow progression to cirrhosis (20–30 years)	
Maternal mortality	Can occur in under- privileged population. Incidence very low	Higher incidence relatively	Does not affect course of pregnancy, no increase in maternal mortality	
Perinatal outcome	Increased rate of preterm birth	Increased rate of preterm birth, stillbirth with high viral load	Does not affect course of pregnancy, no effect on perinatal outcome even incases of high viral load	
Vertical transmission	No transplacental transmission but it can occur in NICU in postpartum period	Transplacental can occur. In postpartum period also through breast milk. Higher rate 85%	• 5–6%	
Prenatal screening	Not useful	Helpful to diagnose chronic hepatitis andin prevention of neonatal transmission	Not recommended	
Co-infection with HIV	No effect	Relatively more common with increased liverrelated morbidity	Does not worsen prognosisbut risk of vertical transmission is increased	
Immunization	<ul> <li>Active: Formalin inactivated vaccine to susceptible persons</li> <li>Passive: 0.02 mL/kg immunoglobulin for recent exposure during pregnancy</li> </ul>	High risk susceptible seronegative mother—Hepatitis B vaccine can be given during pregnancy For baby at birth Hepatitis B vaccine and immunoglobulin to neonate of hepatitis B seropositive mother. Complete vaccination lowers down the risk of transmission due to breastfeeding	No vaccine because antibodiesdo not prevent transmission	

Hepatitis D (Delta hepatitis)—Defective RNA virus (Hybrid particle with HBsAg coat and a delta core. Virus must co-infect with hepatitis B virus. Transmission is similar to hepatitis B. Chronic infection with B and D hepatitis is more severe and up to 75% of co-infected patients develop cirrhosis. Neonatal transmission is unusual in cases having vaccination of hepatitis B.

Hepatitis E—Waterborne RNA virus, enteric Transmission with epidemic outbreaks resembling hepatitis A. It is more severe during pregnancy with higher incidence of transplacental vertical transmission.

Herpes simplex virus: Many subclinical cases. Severe hepatitis in pregnancy and immunocompromised patients. Jaundice usually not present. Orogenital eruptions help in diagnosis. Confirmation by serology and inclusion bodies in liver biopsy. Mortality high up to 43%. Acyclovir is effective in treatment.

## d) Other Causes of Jaundice in Pregnancy

- Leptospirosis, malaria, sickle cell crisis and hemolytic jaundice are treated as in nonpregnant woman
- Gall-stones: Pregnancy increases cholelithiasis. It may present as biliary colic, acute cholecystitis or acute pancreatitis. USG is helpful in diagnosis
- ERCP with minimal fluoroscopy can be done
- Cholecystectomy may be required, open or laparoscopic depending up on stage of gestation.

### PREGNANCY IN PRE-EXISTING LIVER DISEASE

# **Chronic Hepatitis**

Chronic hepatic necrosis, inflammation, and fibrosis leading to cirrhosis caused by HBV, HCV viruses, or autoimmune chronic hepatitis

The severity of the disease and the presence of portal hypertension influence pregnancy outcome. Because the long-term prognosis is poor, the woman should be counselled about the possibility of a liver transplant. Pregnancy termination and sterilisation.

# **Autoimmune Hepatitis**

Autoimmune hepatitis is a progressive liver disease that predominantly affects women of all ages and can manifest at any time during gestation and the postpartum period.<sup>4</sup>

The disease activity is usually attenuated during pregnancy, and dosages of medication can be decreased because of the state of immune tolerance induced by the pregnancy.

Flares occur in 11% of patients during gestation and up to 25% in the postpartum period.<sup>7</sup>

There is an increased risk of prematurity, low-birth-weight infants, and foetal loss.

Pregnancy does not contraindicate immunosuppressive therapy. Both prednisone and azathioprine (FDA category D at dosages <100 mg/day) are considered safe during pregnancy and lactation.

## Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

Primary biliary cirrhosis and primary sclerosing cholangitis are autoimmune diseases that can overlap with autoimmune hepatitis.

Pregnancy is rare in these conditions and carries a high risk of prematurity, stillbirths, and liver failure.

In patients with primary biliary cirrhosis, pregnancy can induce a new-onset pruritus or worsen a pre-existing pruritus."

Diagnosis is not different from that in the nonpregnant woman. Ursodeoxycholic acid is considered FDA category B and can be continued safely in pregnancy."

Primary sclerosing cholangitis is rarely described in pregnancy; pruritus and abdominal pain seem to be the major symptoms. Alkaline phosphatase and alfa-glutamyl transferase levels are elevated. Diagnosis relies on clinical and ultrasound findings. No specific treatment exists for primary sclerosing cholangitis, but ursodeoxycholic acid and stabilization of cirrhosis, when present, have been associated with good outcome.

### Wilson's Disease

Wilson's disease is an inherited autosomal recessive defect of copper transport.

Fertility in Wilson's disease is decreased but can improve with therapy. Treatment should be initiated before conception and should not be interrupted during pregnancy, because of the risk of fulminant liver failure. The treatment of choice in pregnancy is zinc sulphate 50 mg three times daily (FDA category C), because of its efficacy and safety for the foetus.

Patients who are treated with d-penicillamine (FDA category D) or trientine (FDA category C) before pregnancy require a dose reduction by 25—50% of that in the pre- pregnancy state

especially during the last trimester, to promote better wound healing if a caesarean section is to be performed.<sup>3</sup>

# **Cirrhosis and Pregnancy**

Usually infertile but women with symptomatic cirrhosis and pregnancy have poor outcomes. Hepatic failure, variceal haemorrhage, preterm delivery, FGR as well as maternal death can occur.

### Portal Hypertension and Oesophageal Varices

Intrahepatic or extrahepatic flow resistance may cause portal vein pressure to rise. Bleeding from oesophageal varices can be severe and fatal, especially if caused by cirrhosis. Controlling bleeding can be accomplished through endoscopic, band ligation or sclerotherapy, balloon tamponade, or trans jugular intrahepatic portosystemic stent shunting. Pregnancy after Liver Transplantation.

Close monitoring is required for hypertension, graft rejection, pre-eclampsia, and renal dysfunction. Perinatal mortality has also increased.

A coordinated team of senior obstetricians, hepatologists, haematologists, intensivists, neonatologists, and physicians should manage jaundice in pregnancy.

Early detection, timely obstetric intervention, improved foetal surveillance with anticipation, recognition, and proper management of complications such as haemorrhage, liver failure, renal dysfunction, coagulopathy, encephalopathy, acidosis, and cardiovascular stroke, as well as advanced neonatal services, have all improved maternal and neonatal outcomes..

Good antenatal care, early detection and treatment of preeclampsia, and screening and prophylaxis against viral hepatitis will reduce the incidence of jaundice during pregnancy.

### **AIMS AND OBJECTIVES**

- 1. To study the Clinical profile of pregnant women with medical disorders.
- **2.** To study the feto-maternal outcomes

## **METHODOLOGY**

The study was conducted in DEPARTMENT OF OBSTETRICS AND GYNECOLOGY OF SHRI B.M PATIL MEDICAL COLLEG AND RESEARCH CENTRE (BLDE)DEEMED TO BE UNIVERSITY, VIJAYPUR, from January 2021 TO 31<sup>ST</sup> April 2022. This was a prospective observational study, including pregnant women with medical disorders according to inclusion criteria.

## **TYPE OF STUDY**

A prospective observational study.

## **SOURCE OF DATA**

All pregnant women with medical disorder visiting the department of obstetrics and gynaecology, willing to participate will be included as per inclusion and exclusion criteria as mentioned below.

# **INCLUSION CRITERIA**

All pregnant women with the medical disorder such as

- 1. Cardiac disorders
- 2. Thyroid disorders
- 3. Epilepsy
- 4. Asthma
- 5. Chronic hypertension
- 6. Type 1 and Type 2 diabetes mellitus
- 7. Autoimmune disorders
- 8. Infection disease like HIV, HBsAg, CHICKENPOX

## **EXCLUSION CRITERIA**

- Pregnancy-induced medical complications like (pregnancy-induced hypertension and HELLP syndrome, cholestasis of pregnancy, acute fatty liver of pregnancy, gestational diabetes mellitus)
- Postpartum cardiomyopathy

## SAMPLE SIZE CALCULATION

• With 20%<sup>2</sup>, anticipated Proportion of anaemia and Hypothyroidism among medical disorder in pregnancy, the study would require a sample size of **246** patients with 95% level of confidence and 5% absolute precision.

Formula used

• 
$$n=\underline{z^2 p*q}$$

$$d^2$$

Where Z=Z statistic at  $\alpha$  level of significance

d2= Absolute error

P= Proportion rate

q = 100-p

# STATISTICAL ANALYSIS

- The data obtained was entered in a Microsoft Excel sheet, and statistical analysis will be performed using statistical package for the social sciences (Version 20).
- Results were presented as Mean (Median) ±SD, counts and percentages and diagrams.
- Categorical variables were compared using the Chi-square test.
- Association between medical disorder in pregnancy and Outcome was compared using the Chi-square test.
- P<0.05 will be considered statistically significant.

### METHOD OF COLLECTION OF DATA

In this study 246 pregnant women with medical disorders either diagnosed preconceptionally or diagnosed during routine antenatal screening were explained about the nature of the study and written and informed consent were taken.

Patients' sociodemographic datas was collected and chief complaints, past medical history, any surgical correction done for medical disease and obstetric history, menstrual history and family history were taken. The general and systemic examination was done.

Baseline investigations like Complete Blood Count, Peripheral Blood Smear, Liver Function Test, Renal Function Test, Random Blood Sugar, HIV test, HBsAg test, Routine urine and Obstetric USG done in all patients and necessary investigations depending upon suspected underlying medical conditions was done.

All pregnant women with medical disorder receiving standard medical line of management as per diagnosis reached, observed from the time of hospitalisation either to wards or to intensive care unit and the mode of delivery, intrapartum and post-partum events were studied. Pregnant women and neonates were followed up till the discharge or death. maternal and fetal outcomes were noted.

WHO definitions will be used to define patients with premature birth, stillbirth, abortion, primigravida, multipara, maternal mortality and low birth weight. Statistical analysis will be done by standard methods. Values will be expressed as mean  $\pm$  standard deviation, counts and percentages and diagrams.

### **INVESTIGATIONS:**

- HB%
- PT/INR
- HbA1c
- Random blood sugar
- Thyroid Profile
- LFT
- RFT
- HIV AND HBsAg
- OBSTETRIC USG
- 2D ECHO, CT SCAN, MRI

### **REVIEW OF LITERATURE**

1) Dang Arbinder et al<sup>31</sup> (2010) concluded that obstetric cholestasis is a progressive condition, and an increase in liver function test results may indicate that the foetus is in danger of dying and must be delivered immediately. When it comes to acceptable upper limits of liver function test results, obstetricians are at a loss. If expectant management is continued for an exceedingly long period of time and an infant dies of asphyxia, the obstetrician is chastised for inaction. If the obstetrician decides to avoid asphyxia by immediately inducing labour and performing a caesarean delivery, the criticism may be viewed as unnecessary interference. A genetic, metabolic predisposition may also play a role in pathogenesis, influencing disease severity and outcome. A hereditary pattern of pregnancy cholestasis has been described, and autosomal dominant transmission has been proposed.

- 2) Wiwanitkit V et al<sup>32</sup> (2010) Chicken pox is a common viral infection that causes fever and discrete vesicular lesions. This infection is widespread in developing countries, particularly in tropical countries. Chicken pox can affect pregnant women, making it a serious obstetrical concern. The author elaborates and discusses chicken pox in pregnancy in this paper. The clinical presentation, diagnosis, treatment, and prevention are summarised briefly. Furthermore, the effects of chicken pox on pregnancy and vertical transmission are documented.
- 3) Vatti RR et al<sup>33</sup> (2011) Asthma is the most common serious medical condition that can complicate pregnancy, according to research. A third of pregnant women with asthma will have their symptoms worsen, a third will have their symptoms improve, and a third will have no change. The primary goal is to keep asthma under control for the sake of maternal health and well-being, as well as foetal maturation. Important patient education should cover the use of controller medication, avoiding asthma triggers, and treating asthma exacerbations as soon as possible. Asthma management should ideally begin during the preconception period. Pregnant women should avoid both active and passive smoking because it is the most modifiable risk factor for asthma. An increased risk of congenital malformations is associated with acute asthma exacerbation during the first trimester. Asthma that is poorly controlled is linked to low birth weight, preeclampsia, and premature birth. With a few exceptions, medications used to control asthma in the non-pregnant population are generally the same in pregnancy. The preferred controller therapy is inhaled corticosteroids (ICS). The preferred ICS is budesonide. Long-acting B-agonists (LABA) are the preferred ICS add-on therapy.

Viral infections and non-adherence to ICS are major triggers for asthma exacerbations during pregnancy.

- 4) Navabakhsh B et al<sup>34</sup> (2011) Hepatitis B virus (HBV) infection has been identified as a global public health issue. In endemic areas, HBV infection occurs primarily during infancy and early childhood, with mother-to-child transmission (MTCT) accounting for roughly half of chronic HBV infection transmission routes. MTCT prevention is a critical step in reducing the global burden of chronic HBV. Natal transmission accounts for the majority of MTCT, and giving newborns immunoprophylaxis is an excellent way to prevent natal transmission. Prenatal transmission accounts for the majority of MTCT that is not preventable through immunoprophylaxis. Because of the link between prenatal transmission and maternal viremia, some authors believe it is reasonable to prescribe lamivudine to women with a high viral load (more than 8 to 9 log 10 copies/mL). In addition to concerns about HBV transmission to the child, the combination of HBV infection and pregnancy raises a number of unique management issues. Chronic HBV infection during pregnancy is usually mild, but it can flare up after delivery or when therapy is stopped. Antiviral medications are indicated in a small subset of HBV-infected women with rapidly progressive chronic liver disease.
- 5) Borgia G et al<sup>35</sup> (2012) revealed that chronic hepatitis B virus (HBV) infection affects approximately 350 million people worldwide. Because of several peculiar and somewhat contentious aspects, managing HBV infection during pregnancy is difficult. The goal of this review is to provide a tool that will assist physicians in managing HBV infection during pregnancy. This review focuses on (1) the effect of HBV infection on pregnancy and the effect of HBV infection on pregnancy; (2) the potential viral transmission from mother to newborn despite at-birth prophylaxis with immunoglobulin and vaccine; (3) possible prevention of mother-to-child transmission

through antiviral drugs, the type of antiviral drug to use considering efficacy and potential teratogenic effect, as well as the timing of administration and discontinuation; and (4) the evidence for the use of elective lscs Vs vaginal delivery and breast feeding.

- 6) Nanda S et al<sup>36</sup> (2012) observedIn the United Kingdom, cardiac disease is the leading cause of maternal mortality. Cardiomyopathy, myocardial infarction, ischaemic heart disease, and thoracic aortic dissection are the leading causes of cardiac death in pregnancy. Rheumatic heart disease in pregnancy has resurfaced as the number of migrant women in the UK has increased. Women who have uncorrected congenital heart disease or who have had corrective or palliative surgery may have difficult pregnancies. Women who have metal prosthetic valves must make difficult decisions about anticoagulation during pregnancy, and they are at an increased risk of haemorrhage. Not all women with significant heart disease are able to meet pregnancy's increased physiological demands. Pregnant women with heart disease require a multidisciplinary approach that includes obstetricians, cardiologists, and anaesthetists. This allows for appropriate monitoring of maternal and foetal well-being, as well as planning and documentation of elective and emergency delivery management. This article discusses the most common cardiac conditions encountered during pregnancy, as well as their antenatal and intrapartum management.
- 7) Ramprasad M et al<sup>37</sup> (2012) Thyroid disorders are common in pregnancy, with subclinical hypothyroidism being the most common. Because of the complex hormonal changes that occur during pregnancy, it is important to remember that thyroxine requirements are higher. The recommended reference ranges for TSH in the first trimester are 0.1 to 2.5 mIU/L, 0.2 to 3.0 mIU/L in the second trimester, and 0.3 to 3.0

mIU/L in the third trimester, according to recent American Thyroid Association (ATA) guidelines. Maternal hypothyroidism is a treatable condition linked to an increased risk of low birth weight, foetal distress, and delayed neuropsychological development. Because conception is difficult, hyperthyroidism in pregnancy is uncommon. The majority of them are caused by Graves' disease, though gestational hyperthyroidism is a possibility.

8) Stagnaro-Green A et al<sup>38</sup> (2012) demonstrated that the thyroid gland is significantly stressed during pregnancy. Total T(3) and T(4) levels rise by 50% during pregnancy as thyroxine-binding globulin levels rise by 50%. Serum TSH levels fall during the first trimester and rise during the second and third trimesters, but not to pre-pregnancy levels. Hypothyroidism affects up to 3% of pregnant women. Subclinical hypothyroidism during pregnancy is linked to an increased risk of miscarriage and preterm delivery, as well as a decrease in the child's IQ. Although overt hyperthyroidism affects less than 1% of pregnant women, it has been linked to an increased risk of miscarriage, preterm delivery, and maternal congestive heart failure. Thyroid autoantibodies are linked to an increased risk of breast cancer in euthyroid women. Postpartum thyroiditis affects 5.4% of all pregnant women; additionally, 50% of women who are euthyroid in the first trimester but test positive for thyroid autoantibodies will develop postpartum thyroiditis. The need for the essential nutrient iodine increases during pregnancy and in breastfeeding women, and the effect of mild iodine deficiency treatment on maternal and foetal outcomes is being evaluated in a prospective study. The pros and cons of universal screening for thyroid disease during pregnancy are still being debated.

- 9) Giles W et al<sup>39</sup> (2013) Asthma is one of the most common medical conditions among women of childbearing age, according to a study. There is now evidence that asthma is not a benign condition in terms of maternal and foetal health. Despite this, there are a number of issues that arise in the management of such women. Because pregnant women and/or their clinicians believe they pose a risk to the foetus, optimal asthma treatments are often discontinued or reduced. There is also a lack of clinician awareness of the pregnancy complications of asthma.
- Murphy VE et al<sup>40</sup> (2015) Asthma is a common comorbidity during pregnancy, and its prevalence in the general population is rising. Exacerbations are a major clinical problem during pregnancy, requiring medical attention in up to 45% of women and resulting in poor outcomes for mothers and babies, such as low birth weight and preterm delivery. Effective asthma management in pregnancy aims to keep asthma under control while also preventing exacerbations. This is accomplished by attempting to avoid symptoms during the day and night while maintaining lung function and normal activity. Maintaining foetal oxygenation is also an important consideration during pregnancy. Guidelines recommend that asthma advice and reviews be provided prior to conception, as well as actively managing asthma during pregnancy with regular 4-weekly reviews and the provision of a written action plan. Improvements. Treatment adjustment using an eosinophilic lung inflammation marker, the exhaled nitric oxide fraction, has shown success in reducing pregnancy exacerbations. The use of an algorithm that adjusted inhaled corticosteroids based on the fraction of exhaled nitric oxide and added long-acting -agonists when symptoms remained uncontrolled resulted in fewer exacerbations, more women on inhaled corticosteroids but at lower mean doses, and improved infant

respiratory health at 12 months of age. More research is needed to determine whether this strategy can improve perinatal outcomes and be successfully implemented in clinical practise.

- 11) Yalamanchi S et al<sup>41</sup> (2015) revealed that recognising and managing thyroid disease during pregnancy is difficult, with contradictory recommendations from various professional organisations. They conduct a review of the literature on the diagnosis and treatment of gestational hypothyroidism and hyperthyroidism. They also go over thyroid nodules, postpartum thyroiditis, and thyroid cancer. The evidence clearly shows that overt hypothyroidism and hyperthyroidism should be treated, but there is disagreement about how to treat subclinical hypothyroidism and thyroid antibody positive euthyroidism, as well as whether pregnant women should be screened for thyroid disease. Appropriate thyroid disease management during pregnancy is critical for maternal and foetal health, particularly the recognition and treatment of hypothyroidism and thyrotoxicosis.
- 12) Nazarpour S et al<sup>42</sup> (2015) It was discovered that pregnancy has a significant impact on thyroid function in both healthy and thyroid dysfunction women. Thyroid dysfunction is relatively common among pregnant women. The goal of this review was to raise awareness and provide a review of the negative effects of thyroid dysfunction on pregnancy outcomes, including hyperthyroidism, hypothyroidism, and thyroid autoimmune positivity. For this review, appropriate keywords were used to search Medline, Embase, and the Cochrane Library for relevant English manuscripts. They used randomised clinical trials, cohort studies (both prospective and retrospective), casecontrol studies, and case reports. Thyroid disorders in non-pregnant women studies and

articles of poor quality were excluded. Overt hyperthyroidism and hypothyroidism both have a negative impact on pregnancy outcomes. Abortion, anaemia, pregnancy-induced hypertension, preeclampsia, placental abruption, postpartum haemorrhage, premature birth, low birth weight, intrauterine foetal death, increased neonatal respiratory distress, and infant neurodevelopmental dysfunction were all linked to overt hypothyroidism. The effect of subclinical hypothyroidism and thyroid antibody positivity on pregnancy outcomes, on the other hand, was unclear. While some studies found that pregnant women with subclinical hypothyroidism or thyroid autoimmunity had a higher risk of placental abruption, preterm birth, miscarriage, gestational hypertension, foetal distress, severe preeclampsia, and neonatal distress, as well as diabetes, others did not. While the effects of overt thyroid dysfunction on feto-maternal morbidity and its long-term impact on childhood development have been clearly identified, data on the early and late complications of subclinical thyroid dysfunction during pregnancy or thyroid autoimmunity are lacking.

13) Voinescu PE et al<sup>43</sup> (2015) Over a million women with epilepsy in the United States are of childbearing age, necessitating careful consideration of not only the type of antiepileptic drug, but also the dosage, in the event of a planned or unplanned pregnancy. Careful antiepileptic drug selection can reduce the potential adverse effects of antiepileptics drugs while maintaining seizure control for the health of not only the patient, but also the mother and unborn foetus. In the last 20 years, the number of treatment options has increased significantly, and remarkable progress has been made in characterizing the risks that antiepileptic drug pose to pregnant women and fetuses. Teratogenesis data are now robust, and there is a growing body of data on

neonatal/obstetrical outcomes and neurodevelopmental problems associated with each anti-epileptic drug.

- 14) Elkayam U et al<sup>44</sup> (2016) showed that the incidence of pregnancy in women with cardiovascular disease is increasing, owing primarily to an increase in the number of women with congenital heart disease reaching childbearing age and changing demographics associated with maternal ageing. Although most cardiac conditions are well tolerated during pregnancy and women can give birth safely and with good outcomes, there are some cardiac conditions that cause significant maternal and foetal morbidity and mortality. The goal of this paper is to review the available published reports and make recommendations for the management of pregnant women with high-risk cardiovascular conditions.
- 15) Alemu A et al<sup>45</sup> (2016) Thyroid dysfunctions such as hypothyroidism, thyrotoxicosis, and thyroid nodules have been discovered to develop during pregnancy, resulting in abortion, placental abruptions, preeclampsia, preterm delivery, and reduced intellectual function in the offspring. Maternal thyroid hormone plays an important role in foetal neurologic development and maternal health, according to epidemiological data. It has been proposed that the harmful effects of thyroid dysfunction can extend beyond pregnancy and delivery to affect neuro-intellectual development in the child's early life. The maternal thyroid gland faces a significant challenge during pregnancy, as hormone requirements increase due to an increase in thyroid-binding globulin, the stimulatory effect of HCG on TSH receptors, and increased peripheral thyroid hormone requirements. Early abortion, preterm delivery, neonatal morbidity, and other obstetrical

complications are all associated with maternal thyroid dysfunction. Early detection of thyroid dysfunction in pregnant women, as well as treatment of thyroid dysfunction during pregnancy, is critical for avoiding both foetal and maternal complications caused by thyroid dysfunction. The goal of this review was to evaluate the thyroid function changes that occur during pregnancy, the various disorders and their maternal and foetal implications, laboratory diagnosis, and the best ways to manage these conditions.

- 16) Borgelt LM et al<sup>46</sup> (2016) In the United States, more than one million women with epilepsy are of childbearing age, and over 20,000 babies are born each year. Patients with epilepsy who become pregnant face risks such as changes in seizure frequency, maternal morbidity and mortality, and congenital anomalies caused by antiepileptic drug exposure. Appropriate epilepsy management during pregnancy may include frequent monitoring of antiepileptic drug serum concentrations, potential preconception switching of antiepileptic medications, dose adjustments, minimising peak drug concentration with more frequent dosing, and avoidance of potentially teratogenic medications. Preconception planning should ideally be done to reduce risks to both the mother and the foetus during pregnancy. Recognizing the benefits and risks of current and emerging therapies is critical, especially with revised pregnancy labelling in prescription drug product information. This review will outline the risks of epilepsy during pregnancy, examine various recommendations from leading organisations, and provide an evidence-based approach to managing epileptic patients before, during, and after pregnancy.
- 17) Patel SI et al<sup>47</sup> (2016) demonstrated that the clinical management of pregnant women with epilepsy on antiepileptic drugs presents unique challenges. The goal of treatment is to achieve optimal seizure control while exposing the foetus to as few antiepileptic

drugs as possible in order to reduce the risk of structural and neurodevelopmental teratogenic effects. This paper examines the following key issues concerning pregnant women with epilepsy: antiepileptic drug pharmacokinetics, clinical management of antiepileptic drugs ,seizure frequency, major congenital malformations, neurodevelopmental outcomes, perinatal complications, and breast feeding are all topics covered.

- 18) Sarladevi et al<sup>48</sup> (2016) This study found a significant frequency of thyroid disorders (11.6%), particularly hypothyroidism in pregnant women, as well as subclinical and overt hypothyroidism (6.4% and 2.8%, respectively). Although pregnancy-related hyperthyroidism is rare, the effects on the mother and foetus are serious. Early detection of thyroid abnormalities and rapid treatment initiation are crucial due to the significant influence that maternal thyroid disorders have on mother and foetal outcomes. Therefore, it should be thought of universally screening expectant women for thyroid disorders, especially in a nation like India where there is a high prevalence of undetected thyroid disorders.
- 19) Dadhwal V et al<sup>49</sup> (2017) There is conflicting data on the effect of HIV infection and antiretroviral therapy (ART) on pregnancy outcome. The study's goals were to compare pregnancy outcomes in women with and without HIV infection, as well as to assess the effect of HAART on pregnancy in HIV-infected women. This is a prospective case record analysis of 212 HIV-infected women who gave birth in an Indian tertiary health care centre between 2002 and 2015. The pregnancy outcomes of HIV-infected women were compared to the outcomes of 238 HIV-uninfected controls. Women were given

ART to prevent mother-to-child transmission according to a protocol that changed throughout the study period. The impact of ART use on preterm birth and foetal growth restriction (FGR) was investigated. Preterm birth, FGR, and anaemia were more common in HIV-infected women (9.4%, 9.9%, 5.2%) than in uninfected women (7.6%, 5%, 3.8%), but this did not reach statistical significance (P-value >0.05). The prevalence of PIH, diabetes mellitus, and pregnancy intrahepatic cholestasis was comparable in both groups. The mean birth weight of HIV-infected women's neonates (2593.60499g) was significantly lower than that of HIV-uninfected women's neonates (2919459g) [P-0.001]. Admissions to neonatal intensive care units were also considerably higher in infants born to HIV-infected mothers (P-value=0.002). Preterm labour and FGR were less common in HIV-infected women on ART. Pregnancy outcomes in HIV-infected women can be gotten better with good antenatal care and a multidisciplinary team approach.

20) Adam K et al<sup>50</sup> (2017) found that patients with cardiovascular disease represent a significant cohort at risk for complications during pregnancy. The normal physiologic changes of pregnancy could further compromise the hemodynamics of various cardiovascular conditions, resulting in clinical deterioration and even death. The fetus of a gravida with cardiovascular disease also has an increased risk of morbidity, including an increased risk of inherited cardiac genetic disorders, fetal growth restriction, and premature delivery. These complications also increase the risk for antenatal and perinatal mortality. Ideally, the management of a patient with cardiac disease who is considering pregnancy should start with pre-conception counselling that outlines the maternal and fetal complications associated with her particular cardiac disorder. The pregnancy is best managed by a dedicated team of specialists in maternal-

fetal medicine, cardiology, cardiovascular surgery, anaesthesiology, and neonatology, preferably in a tertiary care centre.

- 21) Baral G et al<sup>51</sup> (2017) studied that the most frequent medical condition in pregnancy is hypertension, which is followed by kidney and urinary tract infections. Acute illnesses and Endocrine issues can impact pregnancy as well. The third common category of medical illnesses includes viral infections and endocrine problems. Therefore, for better results, pregnancy management calls for interdisciplinary intervention.
- 22) Bhaskar Narayan et al <sup>52</sup> (2017) concluded that despite a significant decline in maternal death overall, treatable medical conditions-related maternal mortality and morbidity have not declined in recent years. The training of doctors in the treatment of pregnant patients, particularly pre-conception counselling, needs to be improved as part of the answer. Early diagnosis of acute sickness and effective management of chronic illnesses are clearly beneficial, and most medications and many radiological tests can be utilised during pregnancy.
- 23) Khuda I et al<sup>53</sup> (2018) showed that in the context of local culture and misconceptions regarding epilepsy, Saudi practitioners need a careful management plan for women with epilepsy that satisfies all the patients' needs and ensures their spouses' understanding. Such a management strategy needs to incorporate careful selection and monitoring of anti-epileptic drugs and regular counselling of patients. Female epileptic patients in the reproductive age group, no matter whether they are pregnant or not, should be managed

by safest drugs from the earliest with folic acid supplementation along with adequate pre-marriage/conception counselling. All antiepileptic drugs are potentially teratogenic. However, valproic acid, phenytoin, phenobarbitone, and topiramate are least favoured for use. Monotherapy is preferred over polytherapy, and the least possible dose should be used. During pregnancy, many epileptic women may need monthly drug level monitoring and dose readjustments. Normal vaginal delivery is safe in epileptic women. Post-partum follow-up with anti-epileptic drug titration may be required.

- 24) Sushruta Shrivastava et al<sup>2</sup> (2018) concluded that Pregnancy-related illnesses are complex and have a large potential to harm both the mother and the foetus. Early diagnosis allows for simple treatment with little negative consequences on the mother or foetus. Therefore, these illnesses require early discovery, timely treatment, and consistent follow-up. Most significantly, patients who receive enough information regarding danger sign awareness and timely access to medical facilities will enhance maternal and foetal outcomes.
- 25) Bonham CA et al<sup>54</sup> (2018) observed Asthma during pregnancy is a common and growing threat to the health of women and their children. The current article reviews recent findings in the epidemiology of asthma during pregnancy, demonstrating the numerous short- and long-term risks to mother and foetus from poorly controlled maternal asthma. They also discuss new evidence that active asthma management during pregnancy can improve, if not completely eliminate, these negative outcomes. Recent high-quality trials examining best asthma treatment methods are reviewed and synthesised to provide an evidence-based pathway for comprehensive asthma treatment

in the outpatient setting. Safe and effective medications for asthma during pregnancy, as well as nonpharmacologic interventions, are discussed, and treatment options for related pregnancy conditions, such as depression, rhinitis, and gastroesophageal reflux, are presented. Throughout, they emphasise the importance of a thorough patient evaluation, patient education, objective measurement of asthma control, and frequent and supportive follow-up. The cardiovascular and respiratory physiology of pregnancy is discussed, as well as its implications for the management of asthma patients, including those who require intubation and mechanical ventilation. An approach to the critically ill pregnant patient with status asthmaticus is detailed when outpatient asthma management has failed. Multidisciplinary teams of pulmonary specialists, obstetricians, primary care providers, nurses, pharmacists, and asthma educators enhance patient care.

- 26) Wilkerson RG et al<sup>55</sup> (2019) Chronic hypertension, gestational hypertension, preeclampsia-eclampsia, and chronic hypertension with superimposed preeclampsia were discovered to be the four categories of hypertensive disorders of pregnancy. These conditions are among the most common causes of maternal and foetal morbidity and mortality. Proper diagnosis in the emergency department is critical for initiating appropriate treatment and minimising potential harm to the mother and foetus. When blood pressure exceeds 160/110 mm Hg or there are other severe features such as acute kidney injury, elevated liver function tests, severe abdominal pain, pulmonary oedema, or central nervous system disturbances, prompt management should be initiated.
- 27) Braunthal S et al<sup>56</sup> (2019) Hypertensive disorders of pregnancy, which include preexisting and gestational hypertension, preeclampsia, and eclampsia, have been found to complicate up to 10% of pregnancies and to be a significant cause of maternal and

perinatal morbidity and mortality. Despite differences in guidelines, there appears to be agreement that severe and non-severe hypertension with evidence of end-organ damage must be controlled; however, ideal target ranges below 160/110 mmHg remain a source of debate. This review discusses the definition, pathophysiology, therapeutic goals, and treatment agents used in pregnancy hypertensive disorders.

- 28) Sushila Chaudhary et al<sup>58</sup> (2019) concluded that Hypertensive disorders in pregnancy were found to be the most common, followed by anaemia and liver disease. Medical disorders in pregnancy are considered high risk and must be managed through a team effort and intensive care setup.
- 29) Somers EC et al<sup>57</sup> (2020) Autoimmune diseases are more common in women than in men, and pregnancy-related factors such as hormonal modulation and foetal microchimerism may influence the risk of maternal AID in the future. Optimizing reproductive health in women with AIDS necessitates a continuum of multidisciplinary care that begins long before the desire for pregnancy is expressed. Family planning is essential in order to time pregnancy when the disease is stable and to allow for medication adjustments. When using contraception, the method chosen must take underlying disease and laboratory features into account. Options for preserving ovarian health and fertility should be considered for females undergoing gonadotoxic therapy, even if they are not planning a future pregnancy. Multispecialty care, as well as close monitoring during pregnancy and the postpartum period, improves both maternal and foetal outcomes when treatment regimens compatible with pregnancy are maintained to control underlying disease activity.

- 30) Wang H et al<sup>59</sup> (2020) Asthma in pregnancy is a serious health concern, according to the findings. Physiological changes and drug compliance during pregnancy can have varying effects on asthma control, and the level of asthma control and the side effects of asthma medications are closely related to the adverse perinatal outcomes of mother and foetus. This article provides an update on the available literature regarding the alleviating or aggravating mechanisms of asthma in pregnancy, as well as diagnosis, disease assessment, and systematic management, in order to provide new guidance for physicians, obstetric joint doctors, and health care practitioners.
- 31) Couillard S et al<sup>60</sup> (2021) It was discovered that to update obstetric care providers on asthma management. The most common comorbid chronic illness in pregnancy is asthma. Uncontrolled asthma increases the risk of maternal, foetal, and neonatal complications, according to convincing evidence. Unfortunately, one in every four pregnant women does not use an inhaler, and it is likely that decreased adherence, rather than pathological changes, explains uncontrolled maternal asthma. Surveys of patients reveal a desire for information and reassurance. Although some molecules are preferred during pregnancy, there is currently no reason to refrain from taking any asthma medication, old or new. Blood eosinophils and fractional exhaled nitric oxide are effective biomarkers for predicting asthma attacks and the likelihood of responding to inhaled steroids. In addition, practice-changing trials in mild asthma
- **32) Sirilert S et al**<sup>61</sup> (**2021**) exclaimed that this review aimed to provide an update on the impact of pregnancy on the natural course of hepatitis B virus (HBV) infection and also on the impact of HBV infection on adverse pregnancy outcomes, including mother-to-

child transmission (MTCT). For the literature review, original research articles, review articles, and guidelines were narratively reviewed and comprehensively validated. The databases of PubMed, EMBASE, and CINAHL were carefully searched for articles in English on topics related to HBV infection, pregnancy, and vertical transmission from 1960 to May 2021. Immunological changes during pregnancy such as suppression of Th1 response and induction of Th2 immunity lead to an impaired immune reaction to HBV and stimulate viral activity along with the reduction of CD8 T cells to escape immune detection. The impact of pregnancy on the natural course of chronic HBV infection seems to be minimal, while pregnancy can increase morbidity and mortality in the case of advanced HBV hepatitis or cirrhosis. Importantly, hepatitis flare or alanine aminotransferase (ALT) flare can occur during pregnancy and is more common during the postpartum period due to the interaction between HBV and the immune response. Interestingly, the impact of HBV infection on adverse pregnancy outcomes is more serious than ever thought. Updated evidence indicates that pregnancies with chronic HBV infection increase the risk of preterm birth and gestational diabetes, especially in cases of positive hepatitis e antigen (HBeAg).

33) Blaszczyk B et al<sup>62</sup> (2022) showed that Epilepsy affects an estimated 60 million people worldwide, with women accounting for half of those affected. One-third of epileptic women are of childbearing age. Childbirth rates in women with epilepsy are approximately 20-40% lower than in the general population, which may be due in part to a lower number of these women being in relationships. Lower fertility in women with epilepsy may be related to the disease, but it is primarily due to the treatment. Valproate, an antiepileptic drug that inhibits histone deacetylases, may influence the expression of

genes involved in cell cycle control and differentiation. Clearly, this drug is linked to the risk of malformations, though other antiepileptic drugs may also cause birth defects, albeit to a lesser extent. The main mechanism responsible for all negative effects of prenatal exposure to valproate seems inhibition of histone deacetylases. Animal studies show a reduction in the expression of genes involved in social behaviour and an increase in hippocampal cytokines. Valproate-induced oxidative stress may also contribute to neural tube defects. Interestingly, paternal exposure to this antiepiptic drugs in mice may trigger neurodevelopmental disorders as well although a population-based cohort study does not confirm this effect. To lower the risk of congenital malformations and neurodevelopmental disorders, a single Antieptic drugs at the optimal dose and supplementation with folic acid is recommended. VPA should be avoided in women of childbearing age and especially during pregnancy.

# **RESULTS**

# **SAMPLE SELECTION**




Table 1: Socio-demographic data


Age Group				
Age group	Frequency (N=246)	Percentage (%)		
18-25 years	120	48.8%		
26-30 years	84	34.1%		
31-35 years	34	13.8%		
>35 years	8	3.3%		
The mean age of the study pyears and maximum age of 3		ears with minimum age of 18		
Distribution of the locality				
Locality	Frequency (N=246)	Percentage (%)		
Rural	162	65.9%		
Urban	84	34.1%		
Distribution of the Obstetri	c history			
Gravida	Frequency (N=246)	Percentage (%)		
Primigravida	87	35.4%		
Multigravida	159	64.6%		
Distribution of Study Popul	lation according to POG			
Period of Gestation (POG)	Frequency (N=246)	Percentage (%)		
28-32 weeks	7	3.6%		
33-36 weeks	35	13.4%		
>37 weeks	veeks 203 82.5%			
The mean gestational age of the study population was 37±4.5 weeks				

In this study, majority of women were in the age group 18-25 years (48.8%) and mean age group was  $26 \pm 4.58$  years. The mean gestation age was  $37 \pm 4.5$  weeks and 65.9% belonging to rural area and 34.1% belonging to urban area. Most cases were multigravida - 64.6% and the primigravidae were 35.4%.(Table 1)

**Table 2: Distribution of the medical conditions** 

<b>Medical Conditions</b>	Frequency	Percentage (%)
Thyroid abnormality	108	43.8%
Infectious diseases	45	18.2%
Epilepsy	27	10.97%
Total Cardiac diseases	25	10.16%
RVD Positive	10	4.0%
Diabetes mellitus	9	3.65%
Asthma	8	3.25%
Hypertension	6	2.43%
Dengue fever	3	1.2%
Typhoid	3	1.2%
Others (Renal disease and hyperbilirubinemia)	2	0.8%

Figure 9: Distribution of Medical Condition



In our study the number of cases of thyroid disorders in pregnancy were 108 (43.9%), which includes hypothyroidism 106 (43.0%) and hyperthyroidism (0.8%), infectious diseases were 45 (18.2%) in which hepatitis B 40(16.2%), three (1.2%) rickettsial fever, two(0.8%) torch group of infection, one (0.4%)varicella and epilepsy were 27(10.97%), total cardiac diseases were 25 (10.16%), RVD positive were 10(4.0%), diabetes mellitus 9 (3.65%), asthma were 8 (3.25%), chronic hypertension were 6 (2.43%), dengue fever were three (1.2%), typhoid were three (1.2%) and other diseases were two (0.8%) which included renal disease(1) and hyperbilirubinemia(1). (Table 2)

 $\begin{tabular}{ll} \textbf{Table 3: Distribution of Medical conditions among Preconceptionally diagnosed vs Diagnosed in Antenatal period } \end{tabular}$ 

Medical conditions	_		Diagnosed in Antenatal Period (N= 69)		Total (N=246)
	Frequency	Percentage	Frequency	Percentage	
Hypothyroidism	82	33.33%	24	9.7%	106
Hepatitis B	25	10.16%	15	6.09%	40
Cardiac Disease	21	8.5%	4	1.6%	25
Epilepsy	21	8.5%	6	2.4%	27
RVD	8	3.3%	2	0.8%	10
Type 2 diabetes mellitus	7	2.8%	2	0.8%	9
Bronchial Asthma	6	2.4%	2	0.8%	8
Hypertension	4	1.6%	2	0.8%	6
TORCH Infection	2	0.8%	0	0	2
Hyperthyroidism	1	0.4%	1	0.4%	2
others	1	0.4%	1	0.4%	2
Dengue	0	0	3	1.21%	3
Typhoid fever	0	0	3	1.21%	3
Varicella Zoster	0	0	1	0.4%	1
Rickettsial fever	0	0	3	1.21%	2




Figure 10: Distribution of medical condition among Preconceptionally diagnosed vs Diagnosed

In Preconceptionally diagnosed, 82 (33.33%) patients had hypothyroidism, 25 (10.16%) patients had hepatitis B, 21 (8.5%) patients had cardiac Disease, 21 (8.5%) patients had epilepsy, 8 (3.3%) patients had RVD, 7 (2.8%) patients had Type 2 diabetes mellitus, 6 (2.4%) patients had bronchial Asthma, 4 (1.6%) patients had chronic hypertension, 2 (0.8%) patients had TORCH Infection, 1 (0.4%) patient had hyperthyroidism and 1 (0.4%) patients had renal disease

Patients diagnosed with medical condition during Antenatal Period, 24 (9.7%) patients were diagnosed with hypothyroidism, 15 (6.09%) patients were diagnosed with hepatitis B, 4 (8.5%) patients were diagnosed with cardiac disease, 6 (2.4%) patients were diagnosed with epilepsy, 2 (0.8%) patients were diagnosed with RVD, 2 (0.8%) patients were diagnosed with Type 2 diabetes mellitus, 2 (0.8%) patients were diagnosed with bronchial Asthma, 2 (0.8%) patients were dengue was diagnosed in three patients (1.2%). Three (1.21%) patients were diagnosed with typhoid fever, two (0.8%) with rickettsial fever, one (0.4%) with varicella Zoster, and one (0.4%) with hyperbilirubinemia.


Association of medical condition with preconceptionally diagnosed and diagnosed during antenatal period was statistically significant (p=0.002). (Table 3)

Table 3A - Distribution of Cardiac diseases

Cardiac disease	Total no. (N=25)	Percentage (%)
Rheumatic heart disease	9	36%
ASD	5	20%
RHD with Mitral Valve	4	16%
Prolapse		
RHD with Mitral Valve	2	8%
Stenosis		
VSD	2	8%
Ebstein Anomaly	2	8%
Aortic Regurgitation	1	4%

Among the cardiac disorders 9 (36%) were rheumatic heart disease, RHD with valve involvement were six (24%), in which mitral valve prolapse were four (16%) and mitral valve stenosis were two (8%), congenital anomaly were nine (36%) in which atrial septal defect were five (20%), ventricular septal defect were two (8%) & ebstein Anomaly were two (8%) and one with aortic regurgitation (4%). (Table 3A)

Figure 11: Distribution of Cardiac Diseases




**Table 4: Distribution of the mode of delivery** 

Mode of delivery	Term	Preterm	TOTAL (percentage)
Vaginal delivery	100	17	117 (48.0%)
LSCS	103	25	128 (52.0%)
TOTAL	204	42	245

Out of 245 deliveries 204 deliveries were term and 42 were preterm in which 117 (48%) patients delivered vaginally and 128 (52%) patients delivered through LSCS. Among the vaginal deliveries, 100 were term deliveries and 17 were preterm deliveries and among the LSCS, 103 were term and 25 were preterm. (Table 4)

Figure 12: Indication for LSCS



Among the 128 LSCS cases, 56 (43.7%) were indicated due to previous LSCS, , 18 (14.0%) due to fetal distress, 16(12.5%) due to PROM with severe oligohydraminos, 12 (9.3%) due to CPD, 6 (4.6%) due to severe oligo, 6 (4.6%) due to PE with severe oligohydraminos, 3 (2.3%) due to maternal request, 3 due to acute axacerbation of asthma 3 (2.3%), 2(1.5%) due to chronic hypertension with superimposed PE, 2(1.5%) due to previous pregnancy, 2(1.5%) due to Bad obstetric history with incontrolled diabetes and 2(1.5%) due to twin gestation with breech first twin.(Figure 12)

**Table 5: Distribution of the Medical Conditions and the Maternal Outcome** 

Medical conditions	Total (N=246)	ICU Admission	Improved & Discharged (N=245)	Death (N=1) (Due to pulmonary embolism)	Intrapartum Complication (Peripartum hysterectomy) (N=2)
Hypothyroidism	106	2	106	0	0
Infectious diseases	45	0	45	0	1
Epilepsy	27	0	27	0	0
Cardiac Disease	25	5	25	0	0
RVD positive	10	0	10	0	0
Type 2 diabetes mellitus	9	0	9	0	0
Bronchial Asthma	8	3	7	1	0
Hypertension	6	1	6	0	0
Dengue	3	1	3	0	1
Typhoid	3	0	3	0	0
Others	2	0	2	0	0
Hyperthyroidism	2	0	2	0	0

Among 246 cases, 12 were admitted in ICU. Out of 12 cases, 5(41.6%) had cardiac diseases, 3(25%) with bronchial asthma, 2 (16.6%) with hypothyroidism, one each with chronic hypertension(8.3%) and dengue fever(8.3%). And 2 patients had intrapartum complications and ended up in peripartum hysterectomy. There was one maternal mortality of patient with bronchial asthma. (Table 5)

Table 5A: Medical Conditions and Mother ICU Admissions

<b>Medical conditions</b>	Total	Yes (N=12)	Indication	
	(N=246)			
Hypothyroidism	106	2	Severe anaemia and antepartum eclampsia	
Cardiac Disease	25	5	Moderate Pulmonary artery hypertension	
			with pulmonary edema. And Postpartum	
			monitoring	
Bronchial Asthma	8	3	Acute exacerbation of asthma	
Hypertension	6	1	Chronic hypertension with superimposed PE	
			With pulmonary edema	
Dengue	3	1	Dengue fever with thrombocytopenia, with	
			hypovolemic shock with peri partum	
			hysterectomy due to atonic PPH	

Out of 246 subjects 12 (4.8%) patient had ICU admission, with ICU stay of average duration 5 to 6 days. Cause for ICU care was Is explained in the table above (Table 5A) and out of 246 patients enrolled in the study the associated risk factors were severe anemia, antepartum eclampsia and PPH(Table 5A)

Table 5B - Maternal mortality	
Total no. maternal death during study period	18
Maternal death associated with maternal condition	01

During study period total number of meternal deaths were 18, among one (5.5%) was in the study cases which was known case of asthma. And death was due to cardiopulmonary arrest secondary to pulmonary embolism. (Table 5B)

Table 6 -Distribution of Medical Condition and Neonatal Outcome

Medical conditions	Total (N=246)	Live (N=239)	IUD (N=9 )	NICU admission (N=57)	Perinatal death (N=3)	Improved
Hypothyroidism	106	107(twin1)	1	18	1(septic shock)	106
Hepatitis B	40	38	1	3	1(pulmonary hemorrhage)	38
Epilepsy	27	28(twin-1)	0	12(1-twin)	0	28
Cardiac Disease	25	24	1	6	0	24
RVD	10	10	0	3	0	10
Type 2 diabetes mellitus	9	6	3	3	1(severe RDS)	5
Others	9	9	0	4	0	9
Bronchial Asthma	8	5	3	2	0	5
Hypertension	6	6	0	3	0	6
Dengue	3	3	0	2	0	3
Hyperthyroidism	2	2	0	1	0	2

Total number of IUD in our study cases were 9. They were notice in cases with bronchial asthma, type 2 DM, cardiac diseases, hepatitis B, hypothyroidism. Total number of nicu admissions were among study cases were 57 and among them there were 3 perinatal death and the underlying cause were septic shock, pulmonary hemoarrhage and severe RDS. (Table 6)

**Table 7 A: Distribution of the Fetal Outcome** 

Fetal outcome	Frequency (N=247)	Percentage (%)
IUD	9	3.65%
Alive	239 (2 twins)	95.1%
Preterm	42	17.0%
Term	203	82.5%
NICU Admission	57	22.8%
Perinatal death	3	1.2%

Among the 247 neonates, 238 (95.1%) were live birth including two twins in which 203(82.5%) were term deliveries and 42 (17.0%) were preterm deliveries and 57 (22.8%) neonates had NICU admission. There were 9 (3.65%) IUDs and 3(1.2%) perinatal deaths.(Table 7)

Figure 13: Fetal Outcome




Table 7B- Medical condition and perinatal death

Maternal medical condition and Perinatal	death
Total no. of perinatal death during study period	10
No. of perinatal death with maternal medical condition	03

Among the 3 (30%) perinatal deaths with maternal medical conditions, with the maternal Hepatitis B the cause of death was pulmonary haemorrhage with 900gms birth weight and preterm delivery being the associated risk factor with POG at the time of delivery being 29 weeks, with maternal hypothyroidism the cause of death was severe RDS with 1100gms birth weight and preterm delivery and severe oligohydraminous being the associated risk factors with POG at the time of delivery being 32 weeks and with Type 2 maternal diabetes mellitus the cause of death was septic shock with 900gms birth weight and preterm delivery being the associated risk factor with POG at the time of delivery being 28 weeks. (Table 7B)

**Table 8 : Medical condition complicating pregnancy** 

Medical Condition (total number)	Medical condition complicating pregnancy	Associated maternal complication (no. of cases)	Foetal complication (no. of cases)
Bronchial Asthma (8)	5(62.5%)	severe anemia (1) PIH (2)	preterm delivery (2) IUD (3) Low birth weight baby (1)
Epilepsy (27)	2(7.4%)	-	preterm deliveries (2)
Chronic Hypertension (6)	4(66.6%)	2 super imposed PE	preterm deliveries with FGR (3) IUD (1)
Cardiac diseases (25)	8 (32.2%)	-	preterm deliveries (5) LBW (3) IUD (1)
Hypothyroidism (106)	25(23.1%)	3 Severe anemia 12 PIH	Preterm deliveries (18) IUD (1) Perinatal death (1) (Septic shock)
Type 2 diabetes mellitus (9)	6(66.6%)	2 bad obstertrics 3 PIH	preterm deliveries (3) IUD (3) perinatal death (1) (severe RDS)
RVD (10)	2(20%)	-	preterm deliveries (2)
Dengue (3)	2(66.6%)	2 dengue fever with thrombocytopenia and 1 peripartum hysterectomy (atonic PPH)	preterm delivery (2)
Infectious disease (46) Hepatitis B (40)	6(13.0%)	1peripartum hysterectomy (atonic PPH)	preterm deliveries (4) peri partum death (1) (pulmonary hemorrhage)
Toxoplasma (1)			Preterm delivery with previous history of mental retarted baby (1)

Medical disorder complicating pregnancy have been explained above.(Table 8)

**Table 9: Pregnancy complicating Medical Disorders** 

Medical Condition	Pregnancy complicating	Complications (no.	omplications (no. of cases)		improved
(Total number)	medical disease no.	Exacerbation existing medic condition(no.)	of Unmasking the medical condition(no.)		
Bronchial Asthma (8)	5(52.5%)	Preconceptionally diagnosed of asthma with pulmonary oedema (3)	Antenatally first time with asthma (2)	3	4
Cardiac Disease (25)	08(32.0%)	preconceptionally diagnosed presented with breathlessness (NYHA class 3) or palpitation (4)	first time presented with murmurs antenatally (4)	5	10
Epilepsy (27)	9(33.3%)	Convulsion Episode  preconceptionally diagnosed (3)  1st time in 1st trimester (6)		0	9
Hypertension (6)	4(66.66%)	Uncontrolled hypertension  Preconceptionally diagnosed with (2)	Newly diagnosed antenatally (2)	1	4
Hypothyroidi sm (108)	29(26.8%)	preconceptionally diagnosed with TSH > 10 (5)	New cases with TSH > 10 (24)	2	2
Type 2 diabetes (9) mellitus	7(77.77%)	Uncontrolled diabetes hba1c >6.5 (5)  Preconceptionally diagnosed (5)  New cases (2)		0	7

pregnancy complicating medical disorder have been above. (Table 9)

#### **DISCUSSION**

The present study was a prospective observational study. This Study was conducted from January 2021 to 31<sup>st</sup> April 2022 in the Department of B.L.D.E (DEEMED TO BE UNIVERSITY) SHRI B.M. PATIL Medical College Hospital and Research Centre. Total 246 patients were included in this study which was 10% of total admission during study period.

Study conducted on medical disorder in pregnancy conducted by **Sushila Chaudhary et al**<sup>58</sup> and **Sushruta Shrivastava et al**<sup>2</sup>, majority of the mothers were in the mean age group 25.08±2. and more than 50% women presented at 37 weeks or above and study cases were belonging to maximum rural area by 53%.

Similarly in our study of the pregnancy with medical diseases, the mean age group was  $26 \pm 4.58$  years and more than 50% women presented at 37 weeks or above. Mostly Belongs to rural area (65.9%). But in case of type 2 diabetes out of 9 cases 5 cases were from urban which was about 55.5%, due to urbanisation, sedentary life style, unhealthy diet and late marriages (>30 years), this was Supported by another study conducted by **Lt gen SR mehta et al**<sup>81</sup>.

In our study showed that, most common medical condition was hypothyroidism [106(43.9%)] which was statistically significant (p< .00001) (Z=11.1817). complications associated with hypothyroidism in our study is compared with various study as shown in the table below (Table 10)

Table 10-Feto maternal outcome in women with hypothyroidism

Complication	PIH	Preterm delivery	IUD
In this study	11.3%	16.9%	0.9%
Alemu A et al <sup>45</sup>	-	20%	-
Sarladevi et al <sup>48</sup>	9.3%	7.8%	1.56%
Sahu MT et al <sup>66</sup>	9.8%	10.3%	2.5%
Ajmani et al <sup>67</sup>	22.3%	5.8%	1.7%

It is found that thyroid dysfunctions such as hypothyroidism, thyrotoxicosis and thyroid nodules may develop during pregnancy leading to abortion, placental abruptions, preeclampsia, preterm delivery and reduced intellectual function in the offspring.

Table 11-Seroprevalence of HBsAg positivity among antenatal female in different studies

Study	Year	Location	Sample size	Prevalence rate
In our study	2021	Bijapur	246	16.2%
Bakthavachalu et al <sup>68</sup>	2012	Bangalore	500	7.8%
Paranjothi et al <sup>69</sup>	2009	Krishnagiri	762	5.1%

Prevalence of hepatitis varies across India. In our study prevalence rate is significant due to increased screening of pregnant woman during antenatal period.

Hepatitis B infection has no increased risk of fetal malformation but perinatal mortality is increased due to higher rate of prematurity and stillbirth. In our study preterm delivery among HBsAg positive were 10% in comparison the with study conducted by **Reddikh et al**<sup>86</sup> where preterm delivery was 21% among 850 cases. and another study by **Ka yu Tse et al**<sup>70</sup> all, preterm deliveries were 4.7% which was significant as compared with HBsAg negative control cases.

Epilepsy in pregnancy, study conducted by **Roopa malik et al<sup>64</sup>** included 55 patient with epilepsy in which 8 were newly diagnosed and among eight Antiepileptic cases, three in second

and five in third trimester medically managed and continued with pregnancy had no maternal and foetal complications. similarly in our study six out 27 cases were diagnosed epilepsy antenatally four were second trimester and three in third trimester and were managed medically. Pregnancy was continued with no maternal or foetal adverse effect. And among known cases of 21, 2 cases had episode of convulsion in 3<sup>rd</sup> trimester and had preterm delivery and 1 patient had convulsion in postpartum period managed medically required antiepileptic dose was escalated to remain seizure free.

Another study conducted by **Raji** C **et al**<sup>63</sup> included 110 epilepsy cases and they have observed that there was no significant increase in the risk of pregnancy or delivery complications. In most cases, pregnancy and childbirth pose no undue risks. similar observations were seen in our study. In the same study out of 110 cases 12 cases had preterm delivery which was 11.4%, where as in our study two patients out of 27 had preterm delivery which accounts for 7.4 %.

Out of 25 pregnant women with cardiac diseases, RHD (60%) was the commonest cardiac diseases and followed by ASD (20%) in congenital heart disease. Increased trend in congenital diseases in comparison with other studies, primarily due to the increased number of women with congenital heart disease reaching childbearing age by early diagnosis and prompt treatment at early age.

Table 12 -Incidences of cardiac disorders in pregnancy in various in comparison our study

Studies	Total no.	RHD(%)	Congenital heart
			diseases
In our study	25	15 (60%)	10 (40%)
Murali subbaiah et al <sup>87</sup>	100	64 (64%)	36 (36%)
Saima salam et al <sup>88</sup>	90	51(56.6 %)	13.3 (12)
Tanvi Kumar et al <sup>89</sup>	42	24 (57.14%)	12 (28.57%)

Table 13- Fetal outcome in cardiac diseases in comparison with other studies

Studies	Total no.	Preterm delivery	Low birth	IUD
			weight	
In our study	25	5(20.0%)	3 (12%)	1(4.0%)
Verena Stangl et al <sup>90</sup>	93	22 (22.0%)	14 (16.7%)	1(1.1%)
Murali subbaiah et al <sup>87</sup>	100	26 (26%)	42(42%)	2 (2%)

Complications of cardiac diseases during pregnancy study conducted by **Murali subbaiah et al**<sup>87</sup>, 25 out of 100 developed functional deterioration which was 25%, 4 cases developed pulmonary edema which is 4%. In our study 6 patients developed functional deterioration (24%) and 4 patient developed pulmonary edema (16%).

Cardiac diseases in our study had significant maternal and fetal morbidity with comparison to other studies. Due to increased morbidity and mortality rate in cardiac diseases, the pregnancy should start with pre-conception counseling that outlines the maternal and fetal complications associated with her particular cardiac disorder.

Table 14- Feto-maternal complications in bronchial asthmatics in comparison with other studies

Study	Acute	Associated PIH	Preterm term	LBW
	exacerbation of			
	asthma			
In our study	66%	25%	25%	12.5%
by Ram Hari	48.17%	10.18%	-	-
et all <sup>73</sup>				
Schaz M et	46%	-	-	-
al <sup>74</sup>				
Babu Lal	-	20%	13%	7.7%
Meena <sup>75</sup>				

Asthma was associated with high maternal and fetal morbidity and mortality rate which is also supported by review study conducted by **Z** Ali et al<sup>62</sup>.

Study conducted by **Jenny E Gunton**<sup>76</sup> where Pregnant women with type 2 diabetes were 12, 36% developed PIH and preterm deliveries were 27.3% and IUD were 5.3% and in our study 33.3% associated PIH and 33.3% were preterm deliveries, 33.3% were associated with IUD. In our diabetic pregnant women had increased fetal morbidity and mortality and perinatal mortality.

Study conducted by **S Banarjee et al**<sup>77</sup> where perinatal death was 4.16%, where as in our study perinatal death in type 2 diabetic women were 10%.

**Anil Kapur et al**<sup>65</sup> states that previously unknown type 2 diabetes mellitus (DM), is a common medical condition during pregnancy, necessitating universal screening for all pregnant women, including first trimester screening.

Pregnancy-induced metabolic changes in women with type 2 diabetes necessitate closer treatment titration to ensure glycemic control is optimised early in pregnancy to reduce the risk of foetal hyperinsulinemia.

Women with type 2 diabetes have the same rates of major congenital malformations, stillbirth, and neonatal mortality as women with type 1 diabetes, but they are at a higher risk of perinatal mortality.

Study conducted by **Chaitra S, et al**<sup>79</sup> showed 2.7 were chronic hypertension cases, 0.34 % were preeclampsia superimposed on chronic hypertension, where as another study by **Roberts et al**<sup>80</sup>, showed 0.6 % were chronic HTN and 0.3% women had preeclampsia superimposed on chronic hypertension. In our study 2.7% were chronic hypertension 0.8% were preeclampsia superimposed on chronic hypertension.

Study conducted **Baha M. Sibai,et al**<sup>81</sup> preterm deliveries by 33% in our study preterm deliveries were 50% which Was also supported by study conducted by **Chun ye et al**<sup>82</sup> where 52% were preterm delivery. In our study pregnant women with chronic hypertension also showed 50% FGR and 12.5% IUD.

Medical condition complicating pragnancies, most commonly due to hypertensive disorders by 66.6%, type 2 diabetes mellitus by 66.6%, dengue by 66.6%, asthma by 62.1%, thyroid disorders by 23.1% and infectious diseases by 13.0%. in this study more than 50% of hypertensive disorders and type 2 diabetes, asthma and dengue fever have maternal and fetal adverse outcome. (Table 8)

Studies of medical disorder in pregnancy conducted by **Sushila Chaudhary et al**<sup>58</sup> and **Baral G et al**<sup>51</sup> concluded that hypertensive disorder were commonest medical disorder during pregnancy increasing maternal moratlity and morbidity.

Study conducted by **Neelakandan Ramya**<sup>83</sup> dengue in pregnancy, out 16 cases 56% had preterm delivery and 31% had thrombocytopenia and in our study 66.6 % had preterm delivery with thrombocytopenia and intra partum complication.

Study conducted by **Milind Chandurkar** showed that, Among various infective diseases, Malaria, Viral Fever and Dengue fever were most common diseases causing maternal morbidity.

Pregnancy complicating medical disorder by unmasking the medical condition or exacerbating the exist medical condition. Pregnancy complicating diabetes by 77.7%, chronic hypertension by 66.6%, asthma by 52.5%, cardiac condition by 32% and epilepsy by 33.3%. (Table 9)

Pregnancy complicating medical disorder is statistically significant than medical condition complicating pregnancy. Hence pregnancy is avoided in some medical disorders. And preconception diagnosis and prompt treatment of medical disorder is important in improving maternal and fetal outcome.

### **SUMMARY**

- In our study, most of the patients were 18-25 years of age which was statistically significant.
- Our study showed that, higher number of patients had Multigravida which was statistically significant.
- We showed that, most of the patients were >37 weeks of Gestation which was statistically significant.
- Our study showed that, most of the patients had Thyroid abnormality which was statistically significant. Followed by infectious disease.
- Medical conditions were associated with increased maternal and fetal mortality and morbidity with increased incidence of maternal associated complications such as preeclampsia and eclampsia, severe anemia, pulmonary edema and also by exacerbation of existing medical disorders. And adverse fetal outcome were preterm deliveries, low birth weight, FGR, neonatal sepsis, sudden intra uterine death and perinatal death.
- Pregnancy complicating diseases were more significant than disease complicating pregnancy.

#### **CONCLUSION**

Medical disorders in pregnancy are multifactorial and present with great potential of adversity affecting the maternal and foetal outcome. The maternal mortality and morbidity resulting from treatable medical conditions has not decreased in spite of decrease in overall mortality. These conditions need early detection, prompt initiation of treatment and regular follow up to decrease the effect on mother and the fetus. Management of these patients including preconceptional counselling, prompt recognition of acute illness and optimal treatment of chronic condition is of clear benefit and most of the drugs and even radiological investigations in this modern era can be used during pregnancy.

In our study even though the pregnancy complicating medical conditions were more significant than medical conditions complicating the pregnancy, the effect of medical conditions whether diagnosed pre-conceptionally or antenatally did not have much impact on feto-maternal outcome unless they were well controlled. The commonest medical conditions were hypothyroidism and other endocrine disorders.

Education of the patients regarding the awareness of the danger signs and their seeking for help from the medical facilities available in time will help in improving the feto-maternal outcome. Therefore, management of pregnancy requires multidisciplinary approach and interventions as and when needed for better outcome.

# **LIMITATIONS OF THE STUDY**

In spite of every sincere effort my study has lacunae.

The notable short comings of this study are:

- 1. The sample size was small. Only 246 cases are not sufficient for this kind of study.
- 2. The study has been done in a single centre.
- 3. The study was carried out in a tertiary care hospital, so hospital bias cannot be ruled out

## **BIBILOGRAPHY**

- 1. Magriples U, Copel JA. Obstetric Management of the High-Risk Patient. InMedical complications during pregnancy 2004 Jan 1 (pp. 1-14). WB Saunders.
- 2. Shrivastava S, Malik M. Medical disorders in pregnancy and pregnancy outcome: a retrospective analysis. Int J Reprod Contracept Obstet Gynecol. 2018;7:2419-2.
- 3. American Society for Reproductive Medicine; American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice. Prepregnancy counseling: Committee Opinion No. 762. Fertil Steril. 2019 Jan;111(1):32-42.
- 4. Cunningham F, Leveno K, Bloom S, Hauth J, Rouse D, Spong C. *Williams Obstetrics:* 23<sup>rd</sup> Edition. 23rd Edition. McGraw-Hill Education; 2009. pp. 215–26.
- Murray SS, McKinney ES. Foundations of maternal-newborn and women's health nursing: Elsevier - Health Sciences Division; 2013
- 6. Ramírez-Vélez R. Pregnancy and health-related quality of life: a cross sectional study. *Colombia Médica*. 2011;42(4):476–81.
- 7. Fasihi Harandy T, Anoosheh M, Ghofranipour F, Montazeri A, Ahmadi F, Mohammadi E, et al. Health-related quality of life in Iranian breast cancer survivors: a qualitative study. *Payesh.* 2012;11(1):73–81.
- 8. Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R, Ibiebele I, Gardosi J, Day LT, Stanton C. Stillbirths: Where? When? Why? How to make the data count? *The Lancet*. 2011;377(9775):1448–1463.
- 9. Central Statistics Agency. *Ethiopian Demographic and Health Survey. Addis Ababa*. 2011;2012:115–116. Accessed on 19/11/2018.
- 10. Marshall J, Raynor M, editors. *Myles Textbook for Midwives*. Sixth ed. London: ELSEVIER; 2014.

- 11. Desire DT, Julia B. Modifiable antenatal risk factors for stillbirth amongst pregnant women in the Omusati region, Namibia. *African Journal of Primary Health Care & Family Medicine*. 2016;8(1):1054. [PMC free article] [PubMed] [Google Scholar]
- 12. Endris M, Deressa T, Belyhun Y, Moges F. Seroprevalence of syphilis and human immunodeficiency virus infections among pregnant women who attend the University of Gondar teaching hospital, North-West Ethiopia: a cross sectional study. *BMC Infect Dis.* 2015;15:111.
- 13. Hong Kong College of Obstetricians and Gynaecologists. Ter- ritory-wide audit in obstetrics and gynaecology. Hong Kong, 1994.
- 14. Tan K. Impaired glucose tolerance in pregnancy. HKMJ1997;3:381-7.
- Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. Treatable Mechanisms in Asthma. Mol Diagn Ther. 2021 Mar;25(2):111-121. doi: 10.1007/s40291-021-00514w. Epub 2021 Feb 11. PMID: 33570719; PMCID: PMC7956930.
- 16. Couillard S, Laugerud A, Jabeen M, Ramakrishnan S, Melhorn J, Hinks T, Pavord I. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022 Feb;77(2):199-202. doi: 10.1136/thoraxjnl-2021-217325. Epub 2021 Aug 6. PMID: 34362839; PMCID: PMC8762000.
- 17. <u>Sirinart Sirilert</u>. Hepatitis B Virus Infection in Pregnancy: Immunological Response,
   Natural Course and Pregnancy Outcomes J Clin Med. 2021 Jul; 10(13): 2926. Published
   online
   2021
   Jun
  - 29. doi: 10.3390/jcm10132926PMCID: PMC8267880PMID: <u>34210105</u>
- 18. Krassas G, Karras SN, Pontikides N. Thyroid diseases during pregnancy: A number of important issues. Hormones. 2015;14:59-69.

- 19. Li Y, Meador KJ. Epilepsy and pregnancy. CONTINUUM: Lifelong Learning in Neurology. 2022 Feb 1;28(1):34-54.
- 20. Stagnaro-Green A, Abalovich M, Alaxander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-125.
- 21. Su PY, Huang K, Hao JH, et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: A prospective population-based cohort study in China. J Clin Endocrinol Metab. 2011;96:3234-41.
- 22. Centers for Disease Control and Prevention Website. Sexually transmitted disease guidelines. Available from: http://www.cdc.gov/std/treatment/2006/rr5511.pdf. [Cited in 2010].
- 23. American Academy of Pediatrics. Committee on Infectious Diseases. In: Pickering LK.
  2000 Red book: Report of the committee on infectious diseases. 25th ed. Elk Grove Village,
  Ill.: American Academyof Pediatrics; 2000. pp. 309-18.
- 24. Zimmerman LA, Reef SE. Rubella (German measles). In: Longo DL, Fauci AS, Kasper DL, et al., (Eds). Harrison's Principles of Internal Medicine. 18<sup>th</sup> ed. New York: McGraw Hill; 2012.
- 25. Dontigny L, Arsenault MY, Martel MJ, et al. Rubella in pregnancy. J Obstet Gynaecol Can. 2008;30(2):152-68.
- 26. Singhal P, Naswa S, Marfatia YS. Pregnancy and sexually transmitted viral infections. Indian J Sex Transm Dis. 2009;30:71-8.
- 27. Mark RS. Cytomegalovirus infection: Treatment and medication. Available from: http://www.emedicine.medscape.com. [Updated in2009].
- 28. Sauerbrei A. Review of varicella-zoster virus infections in pregnant women and neonates. 2010;2(2):143-52.
- 29. Congenital and perinatal cytomegalovirus infection (CMV). The Mercks

- manual online medical library. Available from: http://www.merck.com/mmpe/sec19/ch279/ch279b.html. [Cited in 2010].
- 30. Fetal infections. Practical guide to high risk pregnancy and delivery. A south Indian perspective. Fernando Arias. 3<sup>rd</sup> ed.; 2008
- 31. Dang A, Agarwal N, Bathla S, Sharma N, Balam S. Prevalence of liver disease in pregnancy and its outcome with emphasis on Obstetric cholestasis; An Indian Scenario.

  J Obstet Gynecol India. 2010;60(6): 413-8
- 32. Wiwanitkit V. Chicken pox in pregnancy: An obstetric concern. Indian Journal of Dermatology. 2010 Oct;55(4):313.
- 33. Vatti RR. Suz anne S. Teuber. 2011. Asthma and Pregnancy. Clinic Rev Allerg Immunol. DOI.;10.
- 34. Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, Poustchi H. Hepatitis B virus infection during pregnancy: transmission and prevention. Middle East journal of digestive diseases. 2011 Sep;3(2):92.
- 35. Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World journal of gastroenterology: WJG. 2012 Sep 9;18(34):4677.
- 36. Nanda S, Nelson-Piercy C, Mackillop L. Cardiac disease in pregnancy. Clinical Medicine. 2012 Dec;12(6):553.
- 37. Ramprasad M, Bhattacharyya SS, Bhattacharyya A. Thyroid disorders in pregnancy. Indian journal of endocrinology and metabolism. 2012 Dec;16(Suppl 2):S167.
- 38. Stagnaro-Green A, Pearce E. Thyroid disorders in pregnancy. Nature Reviews Endocrinology. 2012 Nov;8(11):650-8.
- 39. Giles W, Murphy V. Asthma in pregnancy: a review. Obstetric Medicine. 2013 Jun;6(2):58-63.
- 40. Murphy VE. Managing asthma in pregnancy. Breathe. 2015 Dec 1;11(4):258-67.

- 41. Yalamanchi S, Cooper DS. Thyroid disorders in pregnancy. Current Opinion in Obstetrics and Gynecology. 2015 Dec 1;27(6):406-15.
- 42. Nazarpour S, Tehrani FR, Simbar M, Azizi F. Thyroid dysfunction and pregnancy outcomes. Iranian journal of reproductive medicine. 2015 Jul;13(7):387.
- 43. Voinescu PE, Pennell PB. Management of epilepsy during pregnancy. Expert review of neurotherapeutics. 2015 Oct 3;15(10):1171-87.
- 44. Elkayam U, Goland S, Pieper PG, Silversides CK. High-risk cardiac disease in pregnancy: part I. Journal of the American College of Cardiology. 2016 Jul 26;68(4):396-410.
- 45. Alemu A, Terefe B, Abebe M, Biadgo B. Thyroid hormone dysfunction during pregnancy: A review. International journal of reproductive biomedicine. 2016 Nov;14(11):677.
- 46. Borgelt LM, Hart FM, Bainbridge JL. Epilepsy during pregnancy: focus on management strategies. International Journal of Women's Health. 2016;8:505.
- 47. Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Therapeutic advances in neurological disorders. 2016 Mar;9(2):118-29.
- 48. Saraladevi R, Nirmala Kumari T, Shreen B, Usha Rani V. Prevalence of thyroid disorder in pregnancy and pregnancy outcome. IAIM. 2016;3(3):1-11
- 49. Dadhwal V, Sharma A, Khoiwal K, Deka D, Sarkar P, Vanamail P. Pregnancy outcomes in HIV-infected women: experience from a tertiary care center in India. International Journal of MCH and AIDS. 2017;6(1):75.
- 50. Adam K. Pregnancy in women with cardiovascular diseases. Methodist DeBakey cardiovascular journal. 2017 Oct;13(4):209.
- 51. Baral G, Joshi R, Subba P, Pokhrel S, Baree ZA. Medical disorders of pregnancy among Inpatients at tertiary level Hospital. NJOG. 2017;23(1):8-11

- 52. Bhaskar Narayan, Catherine Nelson-Piercy, Medical problems in pregnancy, Horizons In Medicine, Clinical Medicine 2017 Vol 17, No 3: 251–7
- 53. Khuda I, Aljaafari D. Epilepsy in pregnancy: A comprehensive literature review and suggestions for saudi practitioners. Neurosciences Journal. 2018 Jul 1;23(3):185-93.
- 54. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest. 2018 Feb 1;153(2):515-27.
- 55. Wilkerson RG, Ogunbodede AC. Hypertensive disorders of pregnancy. Emergency Medicine Clinics. 2019 May 1;37(2):301-16.
- 56. Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE open medicine. 2019 Apr;7:2050312119843700.
- 57. Somers EC. Pregnancy and autoimmune diseases. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020 Apr 1;64:3-10.
- 58. Chaudhary S, Singhal SR, Chauhan MB, Gupta A, Dalal M. Study of medical disorders in pregnancy among inpatients at a tertiary care hospital in Haryana, India. Int J Reprod Contracept Obstet Gynecol 2019;8:3770-3.
- 59. Wang H, Li N, Huang H. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Canadian Respiratory Journal. 2020 Feb 22;2020.
- 60. Couillard S, Laugerud A, Jabeen M, Ramakrishnan S, Melhorn J, Hinks T, Pavord I. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022 Feb;77(2):199-202. doi: 10.1136/thoraxjnl-2021-217325. Epub 2021 Aug 6. PMID: 34362839; PMCID: PMC8762000.
- 61. <u>Sirinart Sirilert</u>. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes J Clin Med. 2021 Jul; 10(13): 2926. Published

- online 2021 Jun
- 29. doi: 10.3390/jcm10132926PMCID: PMC8267880PMID: 34210105
- 62. Z. Ali, A. V. Hansen & C. S. Ulrik (2016) Exacerbations of asthma during pregnancy: Impact on pregnancy complications and outcome, Journal of Obstetrics and Gynaecology, 36:4, 455-461, DOI: 10.3109/01443615.2015.1065800
- 63. Raji C, Sekar D. Prospective study of feto-maternal outcome in epilepsy in pregnancy in a tertiary care hospital. Int J Reprod Contracept Obstet Gynecol. 2017;6(11):5055-9.
- 64. Swati S, Ekele BA, Shehu CE, Nwobodo EI. Hypertensive disorders in pregnancy among pregnant women in a Nigerian Teaching Hospital. Niger Med J 2014;55:384-8.
- 65. Anil Kapur, Harold David McIntyre, Moshe Hod, Type 2 Diabetes in Pregnancy, Endocrinology and Metabolism Clinics of North America, Volume 48, Issue 3,2019, Pages 511-531
- 66. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome.

  Archives of Gynecology and Obstetrics, 2010; 281(2): 215–220.
- 67. Ajmani Sangita Nangia, et al. Prevalence of overt and subclinical thyroid dysfunction among pregnant women and its effect on maternal and fetal outcome. The Journal of Obstetrics and Gynaecology of India, 2014; 64(2): 105- 110
- 68. Bakthavatchalu S. Hepatitis B surface antigen carrier state among asymptomatic pregnant women and its correlation with vertical transmission. Int J Res Pharm Sci. 2012;2(3):111–20.
- 69. Paranjothi S, Vijayarani H. Prevalence of hepatitis b virus surface antigen in pregnant women attending a private hospital in krishnagiri. Adv Bio Tech. 2009;9(5):38–40.

- 70. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol. 2005 Nov;43(5):771-5. doi: 10.1016/j.jhep.2005.05.023. Epub 2005 Jun 29. PMID: 16139923.
- 71. Vesha GD, Andrea K, Carl RH, Katherine AW. Medical and surgical illnesses during pregnancy: perspectives on immediate and long term out comes. Mayo Clin Proc. 2016;91((9):1151-4.
- 72. Magriples U, Copel JA. Obstetric Management of the High-Risk Patient. In Medical complications during pregnancy 2004 Jan 1 (pp. 1-14). WB Saunders.
- 73. Ghimire, R. H., Pokhrel Ghimire, S., & Ghimire, A. (2016). Exacerbation of Asthma during Pregnancy: Fetomaternal Outcomes. *Journal of Nobel Medical College*, 5(2), 32–36. <a href="https://doi.org/10.3126/jonmc.v5i2.16314">https://doi.org/10.3126/jonmc.v5i2.16314</a>
- 74. Gynecol. 106 (2005) 1046-54. [8] Schalz M, Dombrowski MP, Wise R et al, Asthma morbidity during pregnancy can be predicted by severity classification, J Allergy Clin Immunol. 112(2003) 283-88.
- 75. Meena BL, Singh V, Sameja P, et al. A study of neonatal and maternal outcomes of asthma during pregnancy. Int J Res Med Sci 2013; 1:23-27. <a href="https://doi.org/10.5455/2320-6012.ijrms20130206">https://doi.org/10.5455/2320-6012.ijrms20130206</a>.
- 76. Gunton JE, Morris J, Boyce S, Kelso I, McElduff A. Outcome of pregnancy complicated by pre-gestational diabetes--improvement in outcomes. Aust N Z J Obstet Gynaecol. 2002 Nov;42(5):478-81. doi: 10.1111/j.0004-8666.2002.00478.x. PMID: 12495089.
- 77. Banerjee S, Ghosh US, Banerjee D. Effect of tight glycaemic control on fetal complications in diabetic pregnancies. J Assoc Physicians India. 2004 Feb;52:109-13. PMID: 15656043.
- 78. Dombrowski MP, Bottoms SF, Boike GM, Wald J. Incidence of preeclampsia among asthmatic patients lower with theophylline. Am J Obstet Gynecol 1986;155:265-7

- 79. Chaitra S, Jayanthi, Sheth AR, Ramaiah R, Kannan A, Mahantesh M. Outcome in hypertension complicating pregnancy in a tertiary care center. The New Indian Journal of OBGYN. 2017; 4(1):42-6
- 80. Roberts CL, Albert CS, Morris JM, et al. Hypertensive Disorders in Pregnancy: A Population-Based Study. Medical Journal of Australia. 2005; 182: 332-35
- 81. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia.

  Obstet Gynaecol. 2003;102:181–192.
- 82. Ye C, Ruan Y, Zou L, Li G, Li C, Chen Y, et al. (2014) The 2011 Survey on Hypertensive Disorders of Pregnancy (HDP) in China: Prevalence, Risk Factors, Complications, Pregnancy and Perinatal Outcomes. PLoS ONE 9(6): e100180. <a href="https://doi.org/10.1371/journal.pone.0100180">https://doi.org/10.1371/journal.pone.0100180</a>
- 83. Ramya, Neelakandan & Shankar, Prabhu. (2015). Dengue in Pregnancy. Journal of Medical Science and Clinical Research. 3.8
- 84. Mehta SR, Kashyap AS, Das S. Diabetes Mellitus in India: The Modern Scourge. Med J Armed Forces India. 2009 Jan;65(1):50-4. doi: 10.1016/S0377-1237(09)80056-7. Epub 2011 Jul 21. PMID: 27408191; PMCID: PMC4921440.
- 85. Shefali AK, Kavitha M, Deepa R, Mohan V. Pregnancy outcomes in pre-gestational and gestational diabetic women in comparison to non-diabetic women--A prospective study in Asian Indian mothers (CURES-35). J Assoc Physicians India. 2006 Aug;54:613-8. PMID: 16941791.
- 86. Reddick KLB, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. *J Viral Hepat*. 2011;18(7):e394-e398.

- 87. Subbaiah, M., Sharma, V., kumar, S. *et al.* Heart disease in pregnancy: cardiac and obstetric outcomes. *Arch Gynecol Obstet* **288**, 23–27 (2013). https://doi.org/10.1007/s00404-013-2730-2
- 88. Salam S, Mushtaq S, Mohi-ud-Din K, et al. Maternal and fetal outcome in pregnancy with heart disease in tertiary care hospital in India. Int J Reprod Contracept Obstet Gynecol 2017;6(9):3947–3951. DOI: 10.18203/2320-1770.ijrcog20174041.
- 89. KUMAR, Tanvi; TANDI, Rishman; THALLA, Amritaa. Maternal and perinatal outcome in heart disease complicating pregnancy. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, [S.l.], v. 10, n. 10, p. 3725-3731, sep. 2021. ISSN 2320-1789
- 90. Stangl V, Schad J, Gossing G, Borges A, Baumann G, Stangl K. Maternal heart disease and pregnancy outcome: a single-centre experience. Eur J Heart Fail. 2008 Sep;10(9):855-60. doi: 10.1016/j.ejheart.2008.07.017. Epub 2008 Aug 28. PMID: 18760667.



B.L.D.E. (DEEMED TO BE UNIVERSITY) Date 22 01 202

(Declared vide notification No. F.9-37/2007-U.3 (A) Dated. 29-2-2008 of the MHRD, Government of India under Section 3 of the UGC Act, 1956)

The Constituent College

SHRI. B. M. PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE

## INSTITUTIONAL ETHICAL CLEARANCE CERTIFICATE

The Institutional ethical committee of this college met on 11-01-2021 at 11-00 am to scrutinize the synopsis of Postgraduate students of this college from Ethical Clearance point of view. After scrutiny the following original/corrected and revised version synopsis of the Thesis has been accorded Ethical Clearance

**Title:** Pregnancy with medical disorders: A prospective clinical study at a tertiary care hospital

Name of PG student: DrMonika Kanni, Department of Obst/Gynaec

Name of Guide/Co-investigator: Dr Aruna.M.Biradar, Associate Professor of Obst/Gynaec

CHAIRMAN, IEC

Institutional Ethical Committee B L D E (Deemed to be University) Shri B.M. Paul medical College,

VIJAYAPUR-555103 (Karnataka)

Following documents were placed before Ethical Committee for Scrutinization:

- 1. Copy of Synopsis / Research project
- 2. Copy of informed consent form
- 3. Any other relevant documents.

## CONSENT FORM

B.L.D.E. (DEEMED TO BE UNIVERSITY) SHRI B.M.PATIL MEDICAL COLLEGE

HOSPITAL AND RESEARCH CENTER, VUAYAPURA-586103

INFORMED CONSENT FOR PA	RTICIPATION IN DIS	SERTATION/RESE	ARCH
I, the undersigned,	_ DO WO_	aged	Vestre,
ordinantly resident of	TOTAL CONTRACTOR STATE OF THE PARTY OF THE P	Unicipal School Selection County	
Shri. B. M. Patil Medical College I	Hospital and Research	Centre has examined	me thoroughly
061at	(place) and it ha	n been explained to n	ne in my own
language that I am suffering from			
disease condition mimic following			
that she is conducting dissertation's	research titled "Pregna	mcy With Medical I	Disorders:
A Prospective Clinical Study At	A Tertiary Care Ho	opital" under the x	uidance of Dr ARUNA BIRADAR
		SASSING CREEKING ST	re, the pre-operative, operative, post-
me that during the conduct of t complications, most of them are condition and in rare circumstance available. Further Doctor has infor-	this procedure like and treatable but are not a m, it may prove fatal d moved me that my partial ful reference to the treat suffering or cure of the that information given b	tverse results may be anticipated hence the lespite the anticipated cipation in this study tment of other similar disease I am sufferin by ma, observations a	nade
assessed by the person other than a			
The Doctor did inform me that the	44 BARRAN		
information given by me, I can ask	any clarification durin	e treatment/study	
related to diagnosis, the procedure			s. At the same
time I have been informed that I ca	an withdraw from my p	articipation in this stu	ady at any time
if I want or the investigator can ten	minate me from the str	dy at any time from t	he study but
not the procedure of treatment and		그 사람이 되었다.	
After understanding the nature of d	lissertation or research.	diagnosis made, mo	de of
treatment, I the undersigned Sort	No. of the Control of	under my	full
conscious state of wind serve to us	etinionts in the said see	annola discontation	

Signature of patient

Signature of doctor:

## PROFORMA Programy with Medical Description A Resemble Climat State at a Totally Care Risonal **MANUT** ACE: DESCRIPTION NUMBER (LP No.): DATE OF ASSESSMENT, ADDRESS AND FIGHE NUMBER: DESCRIPTION SUBJECT TRUCKS. CHEF COMPLANTS: BESTORY OF PRESENT ILLNESS MATURY OF PROSENT PRICE ANCY PRINT TRIMENTERS SECOND TRIMESTEE. STREET CHIEF MARITAL HISTORY CONSTRUMENTATION A L A D DMEG EDO 100 MEDICAL HISTORY: DIAGNOSIS I PHINATAL ANTENATAL TREATMENT WHITCH'S DURATION ON HOGERARIA DISEASE COMPLECATIVO INCOMANCE. PREGNANCY DETERIORATING MEDICAL DISORDER: PERSONAL HISTORY GENERAL PRESENT EXAMINATION POLSE BLOOD PRESSURE RESPRATORY BATE.

TEMPERATURE

WEIGHT

THEODIS

PALLON	
ETHER.	Ellistication.
CYNOSIS	5P84E)
CLUBIENG	MEAC
LYMPHADENOPATHY.	
EDEMA:	
CARDIOVARITHAR SYSTEM:	
RESPECTORY SYSTEM	
PER AUDIOMEN.	
PRESENTATION:	
9KVESTRATION9	
Bigg PT-BIR	(BlAke RB-
LFT	
REC	
mov = moving	
Through Fredie To . T+ . T	101
196	
50102	
CT-MANA	
MRE	
MODE OF DELIVERY	
VAGRAL DELIVERY - PRETERM	PLAN TERM
LEGAL EMENGENCY PRETERN	PERMITTER
LITCUAL TREELERS	FILLTERM
BURGATION	
DATE OF DELIVERY.	
FORTAL OUTCOME:	
SES	
BURTH WEIGHT-	
ANIAR SCORE tons = =	Texa-
NICL ADMINION VEN	

NO

STEN-

INDICATED

DOBATION OF STAY -

DATE OF DISCHARGE

MATERIAL DETCOME:

KIN ADMENSION YEROR NO

BYTES DUBATION

VENTILATOR SUPPORT: YES OR NO

IF YES - DURATION

INOTHORIC SUPPORT: YES OK NO.

F YES DOLLS LIGHT

DUBATHIN OF BOSPITAL STAY -

DATE OF DISCHARGE.

REMARKS.

IMPROVED - DESCRIPTION CHARGE AGAINST MEDICAL ADVICE:

IF DEATH CALVE OF DEATH

DUBATION

2 TAXES PROMES IN COMMENT AND AN ARRAL MIGHT MIGHT LIMETE LIMETE CAMES HOMEO IN HELT HAND IN								10	HILLI HIPEO - AKTED KZCZO
1 DEZM HRT. S 15 GMB KANNE BRAN WEST AND FINITE WELVE WRITE HOR C 11 HILLINGARD II 2 DEZM SROBE 25 GMB ANGE BRAN WEST WORT WELVE WEVE HOR C 1 HILLINGARD III			EZ ARSEM ARSEM ARSEM ARSEM ARSEM PRESE MARKH MARKH MARKH UTER CEPAS 19.9 MEGAT NE				E 10 E 10		HIII (896) - 44
<ul> <li>BIZZY SAKON ZS CRIEZ ARYSK URSAN ANGER ANGER URCHE UNCHE UNCHE KON O E HELTOCRAFIO III</li> <li>BIZZY SAKOTI ZE ZEZYM OCYWE REURAL ANGER ANGER UNCHE UNCHE UNCHE UNCHE SCOM PREMI URBIE III</li> </ul>		11 14 6/150 SI 31 15 6/150 SI	SE ROZER HACEN ROZEN RAZER HACEN ROZER HAGEN BORN BORN BYTER CEDAG HEE REGAL NE SE ROZER HACEN ROZEN RAZER HACEN ROZER HAGEN BORN BYTEN CEDAG HEE REGAL NE						IIII 1880 - 10 pr
1 2022 SAMPE 22 1745 YUAN DEGAN WOSH WOSH WHOSH UNEVERNEVE BREV HONCO IS HELTICEANID BE	III (I CAROLTADPI HEMENEN NO YES (III SI	71 11 0/100 101	SE PRESE ABSEN AGGEN AGGEN AGGEN PEDAL HAGMI KARMI NARMI UTER CEPAS 12 NEGAT NE	CAN TO WITH . EYE .	HIHI LAWES TERM PREVIOUNCE 2.1	THE MEET THE			IIIII IBM) - PA
2 SIZH MARKI SE SISKI CIKAG BURAL MOTE MOTE UNCTE UNCTE UNCTE HORO 1 PRIMI IIIII II			SE ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HIGHN HIGHN HIGHN LITTER CEPAS HILL REGAL HE			110 60			IIIII (H)(s) - (r)
TREAM GECTS IN CHANG SHINK LIBRAR MICHT RICHT HELYT BRETT MICH OF A HILLT HINKE IN CONTROL OF THE THINK HINK AND A HILLT HINK HINK AND A H			SEASON WITH AND AND WITH AND WITH HAVE BORN BOTH TOWN CONS. IT REAS NO.  2 AND MICH AND AND AND WITH AND MADE WITH MARK WITH TOWN CONS. IT WEAT NO.			1 00 MLT	E YES 2 H) E HO	117	HIII (856) - 44
IN STEELY CORNER OF ISSUE 775574 BURBL WIGHT WIGHT WHERE UNERE WHERE WORD OF IS MULTICIPATED IN			SE ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HORM, MORNI HORM; UTER CEPAS 11.5 NEGAT HE			S YES TRANS SALI			IIIII IBBs) - P
<ul> <li>3027 HARD</li> <li>424 HOLD DESIR WITH WITH UNCLEDING HOLD</li> <li>41 HOLDGRAD II</li> </ul>		II 11 AFCDR SI	EZ KOSEM KOSEM KOSEM KOSEM KOSEM KOSEM MIKOM KORMI MORMI UTER CEPAS (1).Z HEGAT ME				E #0		IIIII (HFR) - VI
O 2027 SERNA SE 2022 TANAN BERANDAN PANTA DIKETURAK PUNCHE KANDO 15 MINISTRANDA O 2027 SANCE 25 GERIM MARKO URBAN AND SE AND SE DIKETURAK PUNCHE KANDO 15 MENGGAND BE		A SAFER SS II HAFER SS	S ADER MEET MOET MEET MEET MEET MACH MOET MACH MACH MITTER CEDIG 11.1 TEGAT ME S ADER MEET MOET MEET MEET MEET MACH MACH MACH MACH MET CEDIG 11.1 TEGAT ME			S YES MIREN SALI S YES RESPIL SALI			HIII (89%) - yr
M 2022 SATIN 24 2015 YUAY BURAL WOOD WOOD LIKETE WELVE DIETE HORD 1 HALTI HINN N		E SHEEK SS					E 10		IIIII IIIA) · · · · · · · · · · · · · · · · · · ·
II 2027 SATAL 24 2002 KERUS BURBL WOOD WOOD LINCOR LINCOR LINCOR BOND 2 PRING HILLI II		II 14 AFERR 155	EE ADSER ADSER ADSER ADSER ADSER ADSER HOSEN HOSEN HOSEN WIERL CEPUS - 18.1 HEGAT HE	SAL III - TAKE			E 7ES ( 18)	45	CHIHI 1999) - PT
IN 2027 PRACT 25 2005 YOAM BRAN HOST RIVET WETT UNITY UNITY BRETT FOR C 1 PRINCIPAL HOST		71 11 6/1500 165 51 11 6/1500 162					E 80 E 80		HIII BRO . PI
II BIZH SENDI 32 2015 BIZH SENDI COST COST DEST DEST DEST DEST DEST DEST DEST DE		II SATOR SE					E YES 6 YES	2 YES	( IIIII 1996) - P
M SIZZA SUMAN I ZE ZEISEN YOAM DROAF WOOD WOOD LINCHE UNEVELUNETE MORIO II PREMI-IIIIII II	III BICARDI BOTO REMININO BO BO IZ 111	71 11 0/1500 155	SE ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HIROM NORM HIROM LITER CEPAGE 12 NEGATIFO	9T 91 12 12 12 17	HIHI LAWES TERM AND CS FEMAL 22 ?	110 60	E #0		IIIII IBK - P
31 STEAM RENUD 31 HOLLY YOUNG BEAR WAS A WAS THE BLACK ON EAST ON CO. C. HILLIGEN IN		71 SAFDA SA					E 80		IIIII IIOK
S 2027 AART OF 1927 CHASE BURNER WELF HAVE UNDER UNDER HER KAN OF ENEUTRINOUS STATES OF STATES O			II PREZENSKEN AGREN AGEN AGEN AGEN KALLAT HAGNI KROMI HAGNI DITER CERIK 11.4 REGAT ME II agen agen agen agen agen agen agen agen				E 10 E 10		HIII (856) - 45
22 2027 SHOEE 23 2010 SHOW RURAL WHITE AND FLOREST UNITED BEFOR MAD A CHILLTERING BY			SI AGREM ANGEN AGREM AGREM AGREM AGREM AGREM HAGMI MARIM HARM LITTER CEPAG (IL.) REGAT ME				E 80		IIIII (89%) - V
34 2027 SHILDS - 27 1955 KANNE RURAL WOOD ROOTE ENCITE UNEVER HOREO - CHILLTI HIIII II			SI ABSEM AUSEM ABSEM ABSEM ABSEM ABSEM PEDAG MIARM MARHI MARHI UTER CEPAS 11.2 MEGAT ME			EYES RESPE ENCH			HIII (89%) - ya
SE SECUL SELVA DE SECES ALMAN CURAL MOST AND FEMERE METY EMERY EMERY CONTROL OF HILLTONIAND IN			II ADZIA ANCEN ADZIA ANCEN ADZIA NATIN ADZIA NATIO NORIO HOLIN IETZA CZONA (EL REGAL NE II adzia ancen adzia anzen ancen adzia natio norio norio netro czona (el regal ne			YES PETEL CALL YES IDOR 21 ALL		462	( IIIII 1896) - yr IIIII 1896) - yr
20 2027 SHUPO 25 2025 YUAYO USAAN WASSA WASSA ANDER UNEEKE UNEEKE WARE OF HELETE HINNE HE		A HAPTIN SI					E 80		IIII BK
38 2022M SANTO - 24 2004 RELLU RURAL MINOSO MINOSO AMERICALURENCI DECON - 2 MULTICERATID III		11 K AFDA SI	IA ABSEM AUSEM ABSEM ABSEM ABSEM ABSEM PRESS MARKH MORNI MORNI UTER CEPAS 41.4 MEGAT PA				E NO		IIIII IIIIK · yı
ST 2027 LAXYH 20 1950 YUAY URAH NASH NASH KAST KAST URCTE URCTE URCTE URCTE KAN C FRIH INNN U ST 2027 SOUNG 55 CREEK AFFIL EURAL NASH RUST KAST URCTE ARHIT CAME KAN C S HULTI INNN U		A SAMBA SE B SAMBA SA				S NO ALTI S NES RESPII 2 ALTI	E 80		HIII (89%) - y -
S SIZH MARKE IS SHE MAYER REAL WOOD WOOD HER WHEN CHECK CHECK WAS A PHILIT HIRM IN						THE REPT CALL		10	IIIII IIIV
22 STEEPH HAIHL 25 25159 AIP SU RURAL NIFOSP AIPOSP UNEITE UNEVE CAME! SECON 5 MULTICRAPID III	III 9 DEBG TAA REVIONO PES NO 91 HI	71 11 MEDR 151	SE PRESE ABSEN AGEN AGEN AGEN AGEN KOSEN HIGHI HORHI HIGHI UTER CEPAS 7.2 NEGAT NE	SAN SS SERU SERU LING	HIHH LAWES TERM EMED FEMAL 2.3 7	LYCS RESPL SALE		10	IIIII HOTH - PT
22 ZEZM KARES 25 KEMES YOAM KERAL WOST RICHT HEFTE HEFTE HARE C 1 HELTE HINNE H 34 ZEZM SARRA 27 HEREN YOAM KERAL WOST RICHT HEFTE HARE C 1 HELTE HINNE H			ES ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HABEM HABEM HABEM LITER CEPAS — 15 MEGAT ME				E M)		IIIII (HFR) - 4**
SH 2027 SARRA 27 HIGH YUAYI GURL MODI RIYOT HICTE UNIYE UNIYE KWE C		11 11 AFTER 152 71 11 AFTER 155	N AREST ANSEN AREST AREST ANSEN AREST HARM BYON BYON OTTER CONK . IS REGALING In press arest arest arest arest arest arest harm byon byon otter conk . Is regaling		HIHI LAWES TERM PREVIOUS 23 1		E 80 E 80		HIII (898) - 19
a 2022/1 HECKN 23 (SIN) SAVAD BURBL W/OST AVVST UNCH UNEM UNEM HORO 2 PRINCESTO III	II 98094480701 (18) 80 80 80 II 40		78 ARSEN ARSEN ARGEN ARGEN ARGEN BULDT HIROM HORM, WIRM LITER CERVIS 11.1 HEGAT PO	SATE NE CREMITORNI	HILL MARKET TERM MALE 2.5 7	1 80 ALT			IIIII (HFR) - yr
22 STEET ANTE SE SPISE YOAR BURKEL MINETS HENDER HERTE WHEN DE SPISHE HINNE IN			THE STATE OF THE STATE AND SETS FROM THE STATE OF THE STA			110 ALT			HIII (8/k) - (4
SE 2027 PORA 26 2009 SINDO BURBLINOS PROSEDENCE UNITY UNITY ENCH CAS MULTI BUBBLI Se 2027 Sindo 20 905M your burblinos prosedent unity unity bodo 2 multicorto bi			SE ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HOREM MORRH MORRH UTER (CEPAS II.) MEGAT PO SE ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM ABSEM HOREM HOREM UTER (CEPAS II.) MEGAT PO				E 10 E 10		HIII (896) - 44 HIII (896) - 44
4 STEEN CORNE SE 7556 KANNLORGAN WOOD WHO IN LINCYCONCURENCE HOR O CHILLTO CORNE	III (1 NOSAC BOT OLBES/LENO BO BO BO IS 11	71 11 0/100 155	BE ADDEM ANDEM ADDEM ANDEM ANDEM ANDEM HORM: MORM: MORM: UTER CEDIAGO (BLA MEGAT PO	911 49	HITH LAWES TERM PETAL HALE SS I 1	110 4.0	E NO		IIIII IBISO - ya
4 302H SIDHA 35 KSHG YUAYI KURAL WOOD ANOD LIKEYE UNEYE HAM O 5 HULTI HIHIH HI			EZ ARREM ARREM ARREM ARREM ARREM ARREM ARREM HORM, HORM, MITER CERAS 14.4 MEGAT PO	91 9	HIHI HARM TERM FEMAL 2.3 I		E 80		IIIII ISSN - P
a 2024 SANCE 25 DIEN YUAN BERAL WOST RICHT HEFTE HEFTE HATE CONTROL CHILLTI DIEN II a 2024 preet 22 2005 Yuan beral wost richt hefte hefte hate 5 shilt inne ii		12 11 of CSR 151 11 11 of CSR 151	II ADSENDANCEN ADDEN ANSEN ANDEN HADEN HADEN HADEN DITER CEPAS (E.) RECALL PA II Adden anden anden anden anden haden haden haden haden haden haden baten anden anden anden anden anden haden haden baten haden haden haden haden haden haden haden baten haden baten bat	90 10	HIHI LANES TERM PREM HALE 12 I		E 80 E 80		IIII (886) - yr
# 3127 LADER 33 HISTE YOA'N BURBL WOOD ROOD LINETE UNEVERHENDED. IS HILLTERHIND IN			12 AGREEN ANSEM AGREEN AGREEN AGREEN AGREEN HAGEN MORNI HORINI UTER CEPAGE IL7 REGIAT FO				E 80		IIIII IBIN).
4 DECH SEREC SESSES SESSES YUAY RERAL WORK ROOM ENCIR ENCIR ENCIR HORE 7 HELTER HIRE E			EE ARSEM ARSEM ARSEM ARSEM ARSEM ARSEM ARREM HORM: MORNI HORM: SOFT A CEPAR 48.1 MEGAT PO				E #0		IIIII (#7%) - ya
<ul> <li>BIZER ARCHE SE ZEGE VOAM DEAR HOST HOST FREE UNITY ALLOW MAN OF E MILTE HINNE DE DE BIZER SENTE SE GAME VOAM EURAL HOST HOST ENCYT UNITY ENCYT MAN OF SENTE SENTENCE</li> </ul>		71 SEMESA SE 71 SEMESA SE	OF ADJECT AND EN ADJECT AND EN ADJECT THAN EVEN THAN THE COPY OF ALL REGALD FOR ADJECT AND EN ADJECT AND ADJECT AND EN ADJECT AND END EN ADJECT AND END EN ADJECT AND END END EN ADJECT AND END END END END END END END END END E				E 80 E 80		HIII (896) - yr
4 BIZH RHOS - 33 GHZ YUAN RURAL WHOSH RHOSH ENGST ENGINE ENGINE HART HART HARD - 41 HELT HARD H		II 16 AFERS SI			HIHI LAWES TERM PREMI MALE 12 I		E 80		IIIII (M/8) -
A BEZA WIECE IS HICK YOUR BURBLINGS WOOD BUCKE UNEVENIENCE WOOD ( ) FRING HILLI II		71 - 11 AFGA - 151	SE ADSEM ANSEM ADSEM ADSEM ANSEM ADSEM HORM: MORM: HORM: UTER CEPAGE I MEGAT PO	911 15 12	HILLI HARM TERM HALE 1 7	LYES PETAL 1 ALF			HIIII (H)(c) - (r)
IN 2027 MARK CO 2012 YUAN KURU MOD ROOD HOUTE URIYE BACTE MOD CO CO HUTTI HINI H		A SAFER SI II HAFER SI					E 80 E 80		IIIII (H)(s) -
<ul> <li>BEZZY PRACY</li> <li>BERN KHARE DERKE WORD ROOTE ROOTE HETTE METTE METTE WORD</li> <li>SEZY PRACA</li> <li>BEZZY PRACA</li> <li>BERN KHARE DERKE WORD ROOTE HETTE METTE METTE METTE WORD</li> <li>SHELTT HINIE HE</li> </ul>							E 80		IIII (896) - yr
II DIZZI AARTI I ZE IIKIN JAANG RURAL WOOD AVOOD UNCHE UNCHE HOREO - E PRING IIIIII II	II 9 8054C BOT OL N BO BO N X 111	71 S AFDR 52	SE ADSEM ANSEM ADSEM ANSEM ANSEM ANSEM HORM: NORM: NORM: UTER CEPAG HI MEGAT PO	911 9 12	HILL BOOM TERM HALE ! I	110 60	E #0		IIIII IBINI - P
M 3027 MURIC 25 2005 YUAN BURAL WOOD WOOD WETE UNEVERHOUSE HORIS CHILET HINN II						110 ALT 110 ALT	E 80		HIII (MA)
IN 2027 UNAN 25 ZEEM YOAM GERL WOTERNOTE HERT UITYE HERTE MOEC 1 HELTE HINNE I In 2027 Betef 25 Den kange eere wort hoof uitye erte moec 1 helte hinne i		II 14 AFER SE 71 SEAFER SE					E 80		IIIII IIIVO
D STEET PORCE IS 1995 SHOW RURAL WOOD WHOTH UNCOLLUNCYCLUNCYCHOOL OF HILLTH HIRING III	III 34 XDSACHOTOL 6 NO NO NO SC 100	71 14 AFER 63	ES ADSEM ADSEM ADSEM ADSEM ADSEM ADSEM HORM: NORM: HORM: UTERL CEPAG - 11.2 MEGAT PO	OTT IF C2 TSKLI	HIHH HORM TERM FEMAL 2.2 7	110 60	E 110		HIII (HPR) - yr
II 3224 SAREL 27 1350 YUAN USAR WOST WOST UNCH UNCH UNCH HOSTO - 3 FERN HILLI II	H 5 100 24 (1070) 2 (10 10 10 10 10 10 10 10 10 10 10 10 10 1	31 11 MEDA SI	SI ADER MACEN ADER ADER MACEN ADER RICH ROCK HARM TACH CERW 11.1 RECALLEY Si ader macen ader ader macen ader rich bock harm tach cerw 11.1 recalley	91 1 3	HIHI LOWES PRETE PRETE HALE 25 7	TYES PETAL TALK THO ALK			IIIII (H)6) - (1)
W 2027 BARCO 24 SIZIN YUAN BURBU MUST RICHT UNCTV UNCTV UNCTV RICH (2 PRINC UNI W 2027 Rendo 24 Sizin Yuan burbu must richt unctv unctv unctv rich (2 princ uni un	III 5 80/24 ( BOTO) 5 80 80 80 80 72 15 III 5 80/24 ( BOTO) 6 80 80 72 15	A THREEK SA	SE ARRECH MASCH MASCH MASCH MASCH MASCH HARM HORM HORM HIG PC CEPAS 12.1 ECAN PV	911 M St	HIND HARM TERM HENGE TERME 2.5 7	EMES LOVIN EACH	E 10 E 10		IIII (896) - yr IIIII (896) - yr
W 2027 MARKA 25 49543 CHAOF BURBL W/OSP W/OSP UNEST UNEST UNEST BORD I MULTICIPATIO II	H 980945070 230 80 80 90 91 HI	SI 10 APERS 50	IS PRESE ABSEN ABSEN ABSEN ABSEN ABSEN HORM: NORM: HORM: UTER CEPAS 5.8 NEGATION	911 11 000 5071	HILL LAWES TERM PREVIOUS 2 7		0.80		IIIII MOTA III
13 THE STATE OF TH			SE ADER KNETK ADER ADER KNETK ADER KNOM KNOM KNEM DITER CERK HER REGALDY. Graden knetk ader ader knetk ader knom knom knem diter cerk hergaldy.				E #0		HIIII (H)(c)
H 2027 SEND 24 SESS MEAT TURN WEST WOOD DESCRIPTION OF STREET WITH STREET		71 11 6/150 152 11 11 6/150 151					E 80 E 80		HIII (89%) - yr
M STEETH VEEKS 25 22755 YOAM DEGAN WOOD WHOSE WHERE UNEVELOPETE HOR O 2 PERHA HINNE II	II 9 80545 BOTOL (C B) BO BO BO II (III	71 11 0/100 101	EZ ARSER ARSEN ARSEN ARSEN ARSEN ARSEN HARMI HARMI HARMI UTERL CEPAS — 15 NEGAT PA	gn n	HIHH LAWER TERM OLIGIN HALE 2.5 7	110 60	E #0		HIII HER) - PT
M 2027 HR. S 23 395H YUAY BURAL WO IT AND IT UNETE UNEXT UNEXT HORE 2 HELT INNI II		H 11 MESS 55					E 80 E 80		HIII (856) - 44
DE SECTION CAPECE ES MECH MAGGE ELERAL MAGE PROFE EMETE LIMETY EMETE EMETE MAGGE CAPACITATION OF A MALTINEARIN DE Mental sange es magge quar desar mage profe emete limete unety emple nom o e fillet delle de de la company de		A SANDA SI II NANDA SA					L 110 D 160		HIIII WAY! prinddick yn
M 2027 LAXY 20 201 YUAY DISAF WAS ANAS AND LIKETE DIEVE BORD ( ) FISH HIND D	III SERVISACEROTOLREVILLARO RO RO EL ES	41 S ACOR SC	EZ ARSER ARSEN ARGEN ARGEN ARGEN BULDI HIROMI KVAMI KIRAMI UTER CERRIS 11.4 NEGAT PI	OTT 19 SEM ALCAL	HIHI LAWES TERM LAYOF FEMAL 1.0	110 60	E #0		IIIII IHIXI) - yı
N MICH CAUTS IS SING YOAM AURAL WOLD WOLD HOUSE UNCLUDING HER MAD C 2 PRINT HILL IN	III SIANSAG ROTO I MENJEMBER 180 180 180 191 191	71 15 67 1592 152	EN ADDEM ANDEM ANDEM ANDEM ANDEM ANDEM HARMH HARMH HARMH BYTER CEPAN S.S. MEGAT PA	91 P.	HIND HORM TERM PENAL S.1 I		E 80 E 80		HIII 1878) - yr
N 2027 KANSO DI KOMPI UNAN URAH MINDI RINDI DIKETU UNEN URETE KAN O DI PRINDI DI DI 2027 BANG DI MERCE NASAR BURNI MINDI RINDI DIKETU UNEN URETE KAN O DI HULETI DIDIH DI	II 0.8054C80T01855(138) 80 80 80 83 (2)	II 14 AFERS SS	SI AGREM ANSEM AGREM AGREM AGREM AGREM MAGNI MAGNI MAGNI MATER CRAIS FOLL MEGAT PA	91 92 194	HILL BOOM TERM HALE 25 7				IIII (898)
22 STEEN MEELA 21 SIEGE KAMMERURAL WOOD AND DE LINCTE LINCTE HOUR OF HE PRINT HINDE DE	III S NOSAC BOT OLBEZANIA BO BO BO II 152	N KARDA KI	OF ADSERT ARSEN ADDERT ARSEN ARSEN ARSEN ARSEN HARM BYRNI BYRNI UTER CERVIS (IL) BECAT PY	911 41 1346	HIHI LIMES TERM PREM HALE 2.5 ?	110 60	E 80		HIII HAN
N 2027 SERVE 20 SMSS YORK REAL WOST WORT HERT DIETE WELVE HOR C C FILET HINN N N 2027 Laden 20 SSS Yahra Real Wost wost beter diety erzy erzy hor C c filet hinn n			IN SOCIA MACEN MAC				E 10 E 10		HIII HRO - PI
N 2027 POOR 18 2007 YOAN BEGAN WOST WOST WAS BURGED BACK BARRES WOOD 2 PERM BIRING BE	III 8 890 6 3007 MENONO NO NO 12 43	II 15 AFCRA 152	EN KOSER AUSEN KOSEN KOSEN KOSEN KOSEN HIGEN KORNI HIGEN UTERL CEPUS - 18.2 POSITI ME	(4) (9)	HILL HARM TERM HALE 5 ?	110 60	E 110		HILL HAN . Y
22 DIZZM SANTO - 23 MISSE ATTAC BERAF WAS IN AND FRANCE UNEXCURENCE WAS C - S MULTICERATIO III			IN PRESE PRESE MALEN MASEN MASEN MALEN HARM HARM HARM ETAY CEPAN I NEGAT HE				E NO		HIIII (H) (v)
N 2027 ACSA 23 2027 22441 USAN MOST ANOS LIKETE UNEVER DEZTE KNO C 1 SEGNICIANO I N 2027 REND 35 2024 ANOS EURAL MOST ANOS LIKETE UNEVER DEZTE KNO HILET HILITE HILI		91 91 61 61 61 71 5 61 61 91							HIII (876) - PT
III 30224 BASAR - 25 40210 YUARI OEGAR NOOS NOOS NOOS HUCTE UREVE DREVE DROVE OF HUCT ONION O	III 8 K/C/O BROKU 128 BO BO BO BI 118	II 11 MEDR 65	EI AGSEN AGSEN AGSEN AGSEN AGSEN AGSEN HAGHI HAGHI HAGHI UTER CEGAS 11 NEGAT HE	W K	HIHI LAWES TERM PREM FEMAL 2.5	110 60	E #0		HIII (HPA) - yr
II 31274 APARS 35 41776 AT POSEURAL MIGOS AND SEPRE QUICK NO HOM O I HULTI HINN II		71 11 97592 51		SAN HY SENSIALY	HIHI LANCS TERH WORS FEMAL 3 HIHI -	N) 004	1465 1465	1 451	( IIIII III)) · III
TO STEEN BASES IN 1956 MADEL REPORT HOW IT HAVE IT HAVE AN ACT WHITE OF CLOCK HAND IN STREET WAY OF AN ACT WAS A 1974 TOTAL REPORT WHICH HAVE AN ACT WAS A 1974 TOTAL REPORT WHICH HAVE A 1974 TOTAL REPORT WAS A 1974 TOTAL R		41 5 A/CS 51 71 11 A/CS 11	THE STATE OF THE S				E NO D YES S YES	180	(440 MIII (440 MIII) (440 MIII)
M SECON PORCE - 12 MINUS MULAN BURBL WIGST WIGST WINST MICHE NOT DIRECT MORE - 2 PROMICESTED III	III (I KOCZO BOTO) (RI NO 1925 YES (RI (III	41 K AKKA KK	SE PRESE HASEN HOSEN HASEN HASEN HASEN HARM NORM HARM LITER CEPAN E.A NEGAT NE	(A) 11	HILL HILL TERM HALE 13 · ·	10 (0)	1 455 1 455		HIHH HOTH HOTHER DEED DEE TO PLEHOMARY ELLD
		II 11 MESS SI							IIIII ISIN
IN 2022/ SERNA SE SAMES SAME REAR MOST ANOTE MACHE MACHE MACHE MACHE AND A CHETT MANN OF ARREST MACHE	III 9 K/CO MAKU 1 MO 125 YES II 120 III 9 K/CO Menus 10 YES 21 111	TI TERRETOR EST	SE ADIZEN KANTEN KOZEN KOZEN KANTEN KOZEN HIGIM KIROM HITEN CERKA HEL HELGAN KE Be preze kanten kozen kozen kanten kozen higim kozen higim eter cerka ete ete ete kanten	ANI DI TSHII	HILLI HORM TERM HALE 25 5		E 80 E 80		IIII (896) - Pr
III STEEZH SUMIT - 24 SOATH TALAG RURAL NAOSH ANOSH UMEDR UMEDR CAME' MOR O - 2 PRIMH IIIIII II	III 9 K/C/O SYRIP (0 N) NO N) II 191	II 14 AFER SI	IZ ADDEM ADDEM ADDEM ADDEM ADDEM ADDEM HORM: NORM: NORM: UTER CEPAS 11 HEGAT NE	(6) II	HIHH LAWES TERM HOMPI HALE 12 7	110 60	E #0		HIII (MAS) - Pa
IN SIZEN YUAN SI 1820 BAGE URBAR WOOD AND FUNCTIONAL CAME. IZ CON ( MILETI HIIII II	III 91 K/C/O TAGLE 121 HO HO HO 71 121	II KAKK KI	SI ADSEM ADSEM ADSEM ADSEM ADSEM ADSEM HORM, KVRM, KVRM, UTER CEDIK: 12.5 MEGAT ME	(4) 12	HILLI HILL TEXH FEMAL 2.5 7	S MES RESPI S ALT	E #0		HIII HIM) - P
<ul> <li>3227 56694 21 1919 YUAN 1894 NOST ROST ROST BETT BETT BOT (1968) 1918 B</li> <li>3227 YOAR 23 2019 YUAN 1894 NOST ROST BETT BETT BETT SCORE (2968) 1918 B</li> </ul>		II SHOR SI	IN WOCH WATER WOTEN WATER WATER WHICH WASHING MILES COME HET BEZON KE.  TO WOOTH WATER WOTEN WATER WATER WHICH WASHING MILES COME HET BEZON KE.	ANT NO COCH TOTA		S HO ALTI S MES RESPII S ALTI	E 10 E 10		HIII (122) - (133) HIII (139) - (2
N SIZZA CEETS IZ YEARS YOUNG ERROR WOOD WAS IN UNCOUNTIES WHEN CHEVE WHEN WHEN HOR O I HILLTI HINN II	II 9 K/C/O NU 180 NO NO II 44	71 11 6/10/6 152	SI ADSEM ARSEM ADSEM ADSEM ARSEM ADSEM RIGHM HORM; HORM; UTER CEPAS 5.5 MEGAT HE	S61 97 52	HILL SURH TERM HALE ELL I	110 60	E #0		HIII (HFR) - yr
NE STEEZH SERECE - 23 MISTER DARWE BERRE WEGST WEGST WHERE UNEVERWEITE HOR O - 5 HELETE HEIRE HE			IZ AGREM ANCEN AGREM AGREM ANCEN AGREM MIGHT MIGHT MIGHT WITH UTER CECHNIC 11.1 MEGATINE	(GI 19 · · · · · · · · ·	HIHI HORM TERM FEMAL 2.7 7		I N)		HIII HIM) · · · · · · · · · · · · · · · · · · ·
NE STEEM PREET TO RESEST KNEW BURNE WHOSE WHOSE UNEVENIENCES SECONE ( PRINT) HINDE III	III 15 K/C/O TAGUL 120 NO NO NO NI 120	II 11 HYCUK 103	WARE THE MEN AND AND THE		HILL HORSE TERM HOLE 25 7	1 H) ALT	E 10		HIII HPS) - ya
	III 95 K/C/O TAGLE 121 HO HO HO IZ 111	II 14 APERA 152	IS ADDEM ANSEM ADDEM ADDEM ANSEM ANDEM HIROM NORMI HIROM UTER CEPAS 11.4 MEGATINE	CAN SI	HILL BOOK TEEN HALF ! !	LYCS RESPILES AUT	E NO		HIIII IUIAA
M SIZAN GROA IS SZENT TATAN KURAL AND D AND D LIMETE UNION LIMETE SCOR 7 MULTISTAND IN M Sizan sutan is hald albac kural and d and d limete union limete scor 7 multistand in	9 K/C/0 TAPLE 121 H0 H0 H0 H2 14     9 K/C/0 TAPLE 121 H0 H0 H0 H3 H3 H3   9 K/C/0 TAPLE 141 H0 H0 H0 H0 H1 H4	II 40 ACCA 52 II 40 ACCA 51 71 40 ACCA 51	S ANDER MACEN ANDER ANDER MACEN MACEN MACH MACH MACH METER CECHA M.C. MEGAT ME SI ANDER MACEN ANDER ANDER MACEN MACH MACH MACH MACH MACH CECHA LL MEGAT ME SI ANDER MACEN ANDER ANDER MACH MACH MACH MACH MACH MACH CECHA CECHA LL MEGAT ME	SAN S	HILL HARM TERM HALE S E	1 H) ALT	E #0		HIII (HPs) - (7) HIII (HPs) - (7)
BORDA GRAMA S STREET TARGET LUBEL AND OF LUBERT LUCET L		H MACOR SI H MACOR SI H MACOR SI H MACOR MI	S ACT WITH MITH MITH WITH MITH MITH MITH TITLE CON HILL MICH MIT S ACT WITH MITH MITH MITH MITH MITH MITH TITLE CON 11 MICH MITH S ACT WITH MITH MITH MITH MITH MITH MITH MITH CON 11 MICH MITH S ACT WITH MITH MITH MITH MI	(GA) 15 · · · · · · · · · · · · · · · · · ·	HILLI HARM TERM HALE 5 6 Hilli Harm Term Hale 2.4 7 Hilli Langs Term Fren Hale 2.1 7	S NO ALT S YES RESPI 14 ALT	E 80		HIII (896) - ya HIII (896) - ya
			STAGE WITH WICH WITH WITH WITH WITH WITH THE COVER 11 MICHAEL STAGE STAGE WITH WITH WITH WITH WITH WITH WITH WITH	CGE SS	HIND HARM TERM HALE 5 6 HIND HARM TERM HALE 2.4 7 HIND LAWES TERM PREVI MALE 2.1 7 HIND LAWES TERM PREVI MEMAL 2.5 7	9 60 KLT 9 725 RESPI 14 KLT 9 60 KLT	E N) E N) E N)		
BORDA GRAMA S STREET TARGET LUBEL AND OF LUBERT LUCET L	11		\$ 422 HAZE 4622 HAZE 4622 HAZE 1865 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 663 HAZE 1865 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1865 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1865 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1865 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1865 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1863 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1863 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1863 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1864 1866 1866 1172 COV - 11 KEND KE \$ 422 HAZE 1862 HAZE 1862 HAZE 1864 1866 1866 1172 COV - 11 KEND KE \$ 423 HAZE 1862 HAZE 1862 HAZE 1864 1866 1866 1172 COV - 11 KEND KE \$ 424 HAZE 1862 HAZE 1864 HAZE 1864 1866 1866 1172 COV - 11 KEND KE \$ 424 HAZE 1862 HAZE 1864 1864 1864 1866 1866 170 COV - 11 KEND KEND KEND HAZE 1864 1866 1866 1866 1866 1866 1866 1866	CGAT SS	INIUI MILINI TERM MILE S 6 Iniui Milini Term Mile 2.4 7 Iniui Langs Term Mile 2.1 7 Iniui Langs Term Mile 2.2 7 Iniui Langs Term Mile 2.2 7 Iniui Milini Term 7 7044 2.1 7	5 NO 64.0 5 YES RESPI 14 64.0 5 NO 64.0 5 NO 64.0 5 NO 64.0	E NO E NO E NO E NO		HIII (896) - ya HIII (896) - ya
SECOND SECTION SECTION THAN THE MENT HAVE BUT HE SECTION			S ACCE MATERIA MATERIA MATERIA MATERIA TOTO, CONF. 11 CEGATICA CONF. 12 CEGATICA CON	GAT ST	UNIO BATHA TORM MALE 2 C UNIO BATHA TORM MALE 24 7 UNIO LAWEST TORM PARTA MALE 21 7 UNIO LAWEST TORM PARTA MALE 22 7 UNIO LAWEST TORM PARTA TORM 22 7 UNIO BATHA TORM TORM 23 7 UNIO BATHA TORM TORM 23 7 UNIO BATHA TORM TORM 23 7	110 641 1145 RESPI 44 641 110 641 110 641 110 641 1145 PRETE 41 641	E H0 E H0 E H0 E H0 E H0 E H0		
STATE ORGANIC CONTROL OF CONTROL WAS ARREST AND ARREST CONTROL OF CONTROL OO CONTROL OF CONTROL OF CONTROL OF CONTROL OO CONTROL OO CONTRO		H MATER CO.	\$ 0022 MEZ	GSH SE	HIND WHAT TOOK HALE S C HIND WHAT TOOK HALE SA S HIND WHAT TOOK HALE SA S HIND WAST TOOK PREVIOUS SE SE S HIND WAST TOOK PREVIOUS SE SE S	1 10 ALP 1 YES RESPII 14 ALP 1 10 ALP 1 10 ALP 1 YES PRETE 18 ALP 1 10 ALP	E 80 E 80 E 80 E 80 E 80 E 80 E 80		
STATE CONTROL OF CONTROL AND ANY PROPERTY CONTROL OF CONTROL      STATE CONTROL OF		H 4402 C	\$ 0000 1000 1000 1000 1000 1000 1000 10	SSI S	HORN HATCH PARK 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 10 ALP 1 YES RESPII 14 ALP 1 10 ALP 1 10 ALP 1 10 ALP 1 YES PRETE 18 ALP 1 10 ALP 1 YES SALP	E 80 E 80 E 80 E 80 E 80 E 80 E 80		
2021 GOALS   2020 TANK BURS WATER AND PROTECTION CONTINUES   74 MILLSON   74 MILL			\$ 0021 HEZ BOST WEET WEET WEET HIS NOW HIS TITLE CONF. IT	SSA SA	HOLD MATE TOOK MALE 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1905   6409   194 6409   195 64	E HO E HO E HO E HO E HO E HO E HO E HO		
SECTION SERVICES     SECTION THAN INCREMENTATION SECTION SECTION     SECTION TO A RESIDENCE AND A REPORT SECTION		Mark   1	\$ 0000 M 2000 M	SSI S- SSI SI S- SSI SI	HILL MATERIAN PALCE 1 COMMINISTRATION CONTROL TO A COMMINISTRATION CONTROL CON	1   1   1   1   1   1   1   1   1   1	E 80 E 80 E 80 E 80 E 80 E 80 E 80 E 80		
STATE CORN. SECTION THAN THE PROPERTY CONTROL OF THE PROPERTY CORN.     STATE CORN. SECTION THAN THE PROPERTY CORN. SECTION TO THE PROPERTY CORN.     STATE CORN. SECTION THAN THE PROPERTY CORN. SECTION THAN THE PROPER	1	Mark   1	\$ 0000 M 1000 M	SS	HOLD MATERIA TOOM MALE TO A FORM MALE TOOM MATERIA TOOM M	1	C M C M C M C M C M C M C M C M C M C M		
STATE CONTROL OF CONTROL AND		H MATER SI H MATER SI	\$ 0000 1000 1000 1000 1000 1000 1000 10	SS 15	MINI MAN TOOM   MALE   1	1900   ALP	C NO C NO C NO C NO C NO C NO C NO C NO		
STATE CORN. SECTION THAN THE PROPERTY CONTROL OF THE PROPERTY CORN.     STATE CORN. SECTION THAN THE PROPERTY CORN. SECTION TO THE PROPERTY CORN.     STATE CORN. SECTION THAN THE PROPERTY CORN. SECTION THAN THE PROPER			\$ 0000 1000 1000 1000 1000 1000 1000 10	SSA SA	HOLD MATE TOOK MALE AS TO ME M	1	C M C M C M C M C M C M C M C M C M C M		

10 3000 SHITS - SE 2010 KASHI BERSERVOT HOUT BEETE BETTE BEETE BIKKO - E HU	ULTI MINI MINI BEKACA TRA TEREVIA NO NO NO 15 19 H CERCOR COL	SE ARCON ARCON ARCON ARCON ARCON HARCH WARM WARM BYOM STITLE COME AT RECENT MEGAT SEE SE SCRIPT TREES,		IIIII 1954 - PI
DE SECH DAGE IN 1996 THAN ELBAL HAT BUT HATT BETT BETT BITCO 1900 DE SECH CIKKE IN 1997 THAN ELBAL HAT HAT BUT BETT BETT BETT BITCO 1800		SE ANSZEN ANGSZEN ANGSZEN ANGSZEN ANGSZEN HARDEN MORNEN MORNEN OTZER CERVAS – 1 MEGAZET MEGAZET ANGSZEN ANGS		IIIII 1934 - VI
HE SECON WREEK OF COMES WACHE BEING WOOD WOOD UNCOF ENEMY ENEMY OF AN	RHO HIII IIII 9 1/200 TAOTI ( 100 100 100 10 71 191 71 6 AFGR (SI	IR ARECH RESER RESER RESER RESER RESER RESER ROSCH ROSCH ROSCH ROSCH CEDIK 19.1 REGRE REGRET 198 4 - TERRE-	IIIIII BARHITEEH HALE S I SHA ALIFE HA	IIIII IHRI
	ULTI IIII III III II 11 12 KCAO TAADTI 10 100 100 100 115 115 115 115 115 115	ES ANDRI ANDRE ANDRE ANDRE ANDRE ANDRE MENNE MENNE METER COPINS HELL MOSA INSCAL ES 12 TEMPO SE ANDRE ANDRE ANDRE ANDRE ANDRE ANDRE MENNE MENNE METER COPINS HELL MOSA INSCAL ES TEMPO TEMPO ANDRE ANDRE ANDRE ANDRE ANDRE ANDRE MENNE METER COPINS HELL MOSA INSCAL ES		IIIII IRRA
HE SECON YORK SO SEED RELICA BEING MOST MOST UNETE BEETE BREVE HORO ( HU	ILLTI IIIIII IIIIII III II XXCO TARTI IS BO BO BO 70 HI II 11 AFER HIS	THE ARREST ARREST ARREST ARREST ARREST HARM HARM WIRTH LITTLE CEPAS (12.1 MEGA) MEGA) IS 1 MIN.		IIIII IMA
	ULTI IIII III III III 21 K/C/O TAOTI GEO KO KO 72 19 71 14 A/COR 155 ULTI III III III III II II II II II II II	DI BASEN BASEN BASEN BASEN BASEN BASEN BASEN HARM MORN HORN-LUTER CEPAS HEA RECORD RECORD HIS 1.1. Es basen basen basen basen basen basen harm horn-horn-luter cepas hez began record 72 (2. Tibit)		HIII (892) - 44
	UTININI NINI AKKATATI AN NA NA KASI II ANGA SI Utinini nini sakatati an na na na na ii saga si		HIND LONGS TERM SEVER PENAL 12 7 1 NES RESPI 1 SALIFE NO HIND ROLE 1 1 NO ALIFE NO	IIII 1920 - 171 IIII 1920 - 171
	ULTI HINNE HINNE SERVICIO TROPE SER NO NO NE ASE RE ALARGAR ASE	IR ARECH ARECH ARECH ARECH ARECH ARECH HARM HARM UTERL CEPAS — 15 REGALINEGAL — 15 T. S.	HIND LANCE TERM FREN FEMAL 2.3   1 100 MURE 10	IIIII 1981
	ULTI HINN HINN 3 KX (O TAGTI \$ 200 KG KG KG KG KG T 41 AF ATGA KG KG ULTI HINN HINN 4 KX (O TAGTI \$ 200 KG	ES ANZON ANGER ANGER ANGER ANGER ANGER HORSM HORSM HORSM LETTEL CETAS HE HECCAN		HIII 1951 ·
III 30024 HALAI - 25 12705 YUAYI BURSL WOOD WOOD UNCIY UNCIY UNCIY UNCIY KWOO - 6 HU	ULTI IIIIII IIIIII 31 K/2(O TADTI 11 NO NO NO N 121 N 11 AFAYSDR 155	BI AMEEN AMEEN AMEEN AMEEN AMEEN AMEEN HOWEN HOWEN HOWEN LITEL CERUS IS INCOMPRESANT IN	HIND LONGS PRETE RUSCO HALE 22 7 1 MES PRETE OF AUTO NO	IIIII IBN - y
<u> </u>	RHI-HIHH HIHH   4 K/C/OTAGT    2 NO   10   NO   NO   14   71   14 A/CGA   12 Rhi-Caath Hihh   4 K/C/OTAGT    2 NO   10   NO   NO   14   71   14 A/CGA   12	E BASEN BASEN BASEN BASEN BASEN BASEN BASEN HARM MORN HORN-LUTELL CEPUS - 12 MEGAT MEGAT - 9 TO RE- Th Basen basen basen basen basen basen basen horn-horn-lutel - (EPUS - 12,2 Megat megat - 9 blo) - Seri Tsi -		HIIII HASA- ya
	12 SCHOOL II EL E (N M M2 TOTOLOGIA IIIIIIIIII	D 4400 4400 4500 4500 4500 4400 4400 4600 46	· · · · IIIIII LAYEE TEEH PROPERENAL 2,5   1 160 ALPEE 80	HIII HAA
	RHOIMMININ SIXXOTAAT 210 KO KO II 19 71 9.000 12 Rhigandinin sixxotaat 210 ko ko II 19 1 9.000 15	IS AREST ARCEN ARCEN ARCEN ARCEN ARCEN HARCH WARM WARM LITTLE CEPAS 15.5 MEGAT NEGAT HE	HIND LAWES METER PROM HALE 15 7 1 NO ALTHE NO     HIND LAWES METER SEVEN REMAIL 25 7 1 MES FASETR 1 ALTHE NO	IIIII 1858 - 61
	REMICRATIO IIII II SEKKO TAOTI (2 B) 100 100 10 10 10 10 14 ANSOR (5 Remining iiii 3 Kaco taoti (3 b) 100 100 11 101 101 14 ANSOR (5)	THE HEIZEN ARKES ARKES ARKES HAVEN HAVEN HOWN HOWN DETECTIVE HELD RECORD HEIZEN ARKES HAVEN HAV HAVEN HAVEN HAVEN HAVEN HAVEN		HIII 1924 - ya
IN 1822 A STANK - 18 STREET STANK BROOM MADE MADE MADE BRETT BRETT HAND - 18 DK	RHO-IIIII IIIII 9 X/C() TAOTI 9 80 80 80 11 14 11 1 1 AFGOR 12	E AVEN AVEN AVEN AVEN AVEN AVEN AVEN AVE	HILLIA LANCE PRETE PERIO FEMAL TARES - BO ALIFE BO	IIIII 1855) · yı
	ULTI INDIA MINI SI KACATARATI NIBO KO KO KA 121 MI 15 ANSAK 122 Ultikarati mini si kacatarati nibo ko ko ko ki 10 71 minisa (h	BI BASEN BASEN BASEN BASEN BASEN BASEN BASEN HARM KROM KROM HARM UTERL CEPAS HELD POOTTI REGAT BI To press basen basen basen basen basen basen krom krom krom uter (epas Held Regat Besat Bi	HIND LANCE TECH FREN PENN TENAL 12 7 1 NO ALPYE NO HIND LANCE TECH FREN HALE 12 7 1 NO ALPYE NO	HIII (892) - 44 HIII (892) - 44
	ULTIMINI MINI SECONTATI SEN EN 10 10 II 13 II 1600A 16 Regend mini secontati sen en 10 II 14 II 1600A 13			IIII 1920 - ya IIII 1920 - ya
BE DECIM SHEES - 25 12705 APTER BERSE AVOID WHOSE UNDER EMERIC EMERGENCE OF 2 PR	RIPOGRAPIO INIUNI SI KACO TARTI ERO RO RO NO 11 19 71 1 ANGGRE 156	IR ARECH ARECH ARECH ARECH ARECH ARECH HARM HARM WITCH CEPAS 1.1 MEGAT MEGAT 18 NEEC -	HIND BORN TERM FEMAL 25 7 5 80 ALVE BO	IIIII IBSI - Ar
	ULTREAMBRIUM SEXCOTABT SEO NO NO TO ES ON HANCER CA Rencembrium sexcotabt en no no no es en to tancer es	ES ARSEN ARGEN ARGEN ARGEN ARGEN ARGEN HARM HORM HORM UTER CEPAS HELD RECORD RECORD ES 10.00 SERU TO 1. PAREN ARGEN ARGEN ARGEN ARGEN ARGEN HARM HORM HORM UTERL CEPAS HELD RECORD RECORD ES 1.00 SERU TO 1.00 SERU T		HIII (892)
IN SECTI MIZES ST. RESE SHOW BEING MOST MAST MELL BEEL BEEN WING I HIS	ULTI IIIIII IIIIII 31 X2C(0 TAOZ)   6 NO NO 71 121 71 14 AFCOR 127	SI ANGEN ANGEN ANGEN ANGEN ANGEN HAREN HAREN HAREN TECHNI CENNA (E.S. HEGAN HEGAN) (S	· · · · · · · · · · · · · · · · · · ·	IIIII IHRR
	RHIGERAND IIIIII	THAT AT USES . BY TRADITIONAL WAYS STUDMEN MORN MORN ESPECIALISM ASSESSED ESPECIAL LAST USES COLV. B TRADITIONAL WAYS STUDMEN MORN MORN MERCHANICA ASSESSED ESPECIAL LAST USES COLV.		180 80 MILLIONSO- UD (17
DE SECUN NACON - 22 FIRES SECUN DESAN AVOID MAN IN UNITED BETTE BACKS - 4 PR	RMICRAFO IIIII - SIXXIO TAATI - SIXO IXO IXO III - III - III - III AACAR - ISI RMI-IIIIII IIIII - III XXXIO TAATI - IXO IXO IXO IXO IXO IXI - IXI - IXI - IXII - IXIII - IXII - I	B 4450 4450 4450 4450 4450 4450 MAR MAR MAR MAR MAR UTTE CENS (IL MESA MESA) B	HIND BORN TERM FEMAL 25 7 1 80 ALVE BO	IIII 1990 - 171 IIII 1990 - 171
DE SEET BANK IS HESTE UPPAL DESAY WORD WORD UNCIT DECIT DECIT BRENT BING I HU	INTEGRAND INNIN SERVICIO TARTE DE RO DO DO 15 ESE IL ELANÇOR HIS	III HIA AASEN AASEN AASEN AASEN AASEN KARN KARN KARN UTER CEDAS HIA NEGAT NEGAT III 5 · · 15 ·	HILL CONSTITUTE PRESS BRIZE 15 7 1 80 ALTRE BO	IIIII IMR) · · · · · · · · · · · · · · · · · · ·
	ULTICONTO INITIA 31 K/C/O TAOTI IN BO KO KO IN IN 131 71 HIAPEDA (SE Ultinimi mini 31 k/C/O Taoti In Bo ko yes in 131 in 14 apeda 144	AN ANSON AND RANCE AND THE AND THE AND THE MEAN MEAN AND THE CLEVE ALL RECALL RECALL BY.  IN AND RANCE AND THE		11111 1924 ·
DE SECRETARIA SE RESENTANTEMENTANTEMENTALISMENT PRESENTANTO E HA	ULTI IIII II IIII II II II II II II II II	S ANSCH ANSCH ANSCH ANSCH ANSCH ANSCH HARM HARM HARM HARM THE 1 CEPAS - 1 MEGAT MEGAT - S - 12 MEGAT HARM	HIND BORN TERM FENGL 55 7 1 NO ALPIE NO	IIIII IBN - V
UP 2022 SALIA 24 SEMIN FLAM LEGAR MOST MOST UNCTE UNCTE ENCYC HONO 2 MIL	RHOIMMINNIN SEXZOTADT 180 KO KO IS 19 71 SAKSAR 127 Watininininin sexzont. New Yes Yes Is 19 11 diamer (s	SE ANDER ANDER ANDER ANDER ANDER ANDER MARCH MARCH MARCH DITTE CEPAS HILL REGAL MEGAL HI		
	ULTICAND IIIII SECONTATI NIN NO NO II 19 71 NINCAL 100 Ulticonto IIIII Nicontaga (no no no ii 18 71 nincal (s	DI ANCON ANCON ANCON ANCON ANCON ANCON ANON AN		WIII 1924 - yr
III 3027 BASAA 27 SIEM AMARE UBSAR POZO POZO UMERE UMERE UNEVE MONO HU	ILLTICRANIO INI III 15 KYCOV TAOTI III 10 YES 100 III 151 III 16 ANEDR 155	IZ AMEZH AMEH AMEH AMEH AMEH AMEH KARH KARH KARH UTER CEPAK 18 KEGAT KEGAT 1824	HIND LANCE TERM COO MALE ( ? 1 MES PUEM ? ALIVE NO	IIIII IMSI - ya
	ULTI IIIIII IIIII SI X2CO TAATI   180 KO KO KO KO KI 151 71 15 AVESA 151 Ulti IIIIII IIIII   SI X2CO TAATI   180 KO KO KO KI 150 KI 11 11 AVESA 151			
NO DECAM SUDAR ON ESSENS SHORE BURSH, WHOSH WHOSH UNCON UNCON ENERTH WHICH	ULTI IIIIII IIIIII 31 K2C(OTAATI 180 NO NO II 191 SI 11 ANSAR (S	SE ANDER ANDER ANDER ANDER ANDER HARDE HARDE HARDE HARDE HARDE STEEL CERNS HILL RECALL RECALL. H	HIND LONES TERM ELECT HOLE 2.5 7 1 NO ALPIE NO	IIII 1939 · V
	ULTI IIIIII IIIII 91 K/C/O TAOTI   180   100   100   101   131   131   141   152   153   1	ES ARECH ARGEN ARGEN ARGEN ARGEN HAREN HAREN WORM HAREN DIESE CEPAS ELS MEGAT MEGAT 103 . TERTE- Es argen argen argen argen argen haren haren haren haren diese cepas 11.1 megat megat 15 . terte-		11111 1934 ·
	ULTIMINI MINI SERCENTATI (100 NO NO 16 NI 71 NEGRE (S Ulticandinini sercentati (no no no ni ni se negre (2	23 ANSZEM ANGZEM ANGZEM ANGZEM ANGZEM ANGZEM KNOWN KNOWN WORTH CITED ANGZEM ANG	HILL LONG FEELH FRENCH HALE 17 7 1 NO ALIFE NO ALIFE NO ALIFE NO ALIFE NO ALIFE NO	11111 1924 ·
III 2027 UNIX. 20 2750 FUNT BUSIL WOOD WOOD UNCTURED UNCTURED ENCYCHING	INTERNATIONAL ACCORDANT 180 NO NO IS 121 II 40 ARCOR 121	IR AMERI AMERI AMERI AMERI AMERI AMERI AMERI MOMI MOMI MOMI ISSA-IN CEPAS HILI MEGAT MEGAT MEGAT. III - TSA 11	HILLI BORN TECH PENNL SS 7 S NO AUPE NO	IIIII IMSE
	ULTI IIII III III III II KO KO KO K 15 71 (5 AFEN 12 Ulti IIII III III III 5 K/CO TANTI   180 KO KO KO K 15 71 (1 AFEN 15	SI ALLAI AGCEN AGGEN AGGEN AGGEN AGGEN AGGEN HORRN HORRN UTER CEPAG - MEN MEGGN MEGGN - ME - TSIA M -		HIIII H984 - 1/4
MI SEEM SHELT IS SSEE FLOWN BEING MOST WOST LINETE LINETE LINETE KING I HU	ULTI IIII II III II II II II II II II II I	III AASCH AASCH AASCH AASCH AASCH HASCH HARM HARM HARM UTCH CEPAS 15.0 POSITI HEGAT III - TSA 11 -		IIII 1924 - VI
AND DECEMBER OF THE STATE OF TH	ULTININI NINI ALEKKATATI 180 80 80 E ES II GARGAR ES Ultinini nini sekkatati 180 80 80 II 19 71 aleksa es	S ANSON ANSON AND TH AND TH AND TH AND THOSEN MORE MORE MORE MORE OF THE STATE OF T	IIIIII BARKITEH PENAL 21 7 1 80 AUPE 80 IIIII LAKETEEH ELECTYENAL 27 1 1 80 AUPE 80	HIII 1940 - Au
	UTHINININI ARKATAT 10 00 00 6 3 0 100 00 63 UTHINININI SRKATAT 10 00 00 11 13 7 100 00 43	ES ANSON ANGEN ANGEN ANDEN ANGEN ANGEN MORPH MORPH MORPH MOTER CEPAS 19. MEGAT MEGAT 18. TSAT	MINI BORH TECH HOLE SZ 7 1 NO AUTE NO	HIII 1924 - 94
IN 2021 ASSA - SS 1919 YUAYI DESAY AVOSY AVOSY UNCYC DECYC DECYC RANCO - 7 MU	ILLTI IIII II III III II S KACO TARTI   1 BO BO BO II 19 II 10 ACER 15	ES ALLINI ARSER ARSER ARSER ARSER ARSER HARM HARM WARM WITCH CEPAS - 18.1 NEGAT MEGAT - 122	HIND LONGS TERM ELECT FEMAL 5.17 7 1 80 ALPIC 80	IIIII IMRI
	ULTI IIIIII IIIII SI KACAO TAASTI 1 SA 160 160 167 163 161 16 AGESE 163 ULTI IIIIII IIIII SI KACAO TAASTI 1 SA 160 160 160 161 163 164 16 AGESE 163		IIIIII MARKITEH HALE 22 7 1 NO ALIFE NO IIIII LANES TEHN ENERGY ENAL 3 7 1 NO ALIFE NO	IIIII IASSI - Aa
INC. SECON SHARK - SK HAMES SHOWN BROKE MANDS WANDS MEETER RECKE BACK - I HAN	ILLTI IIIIII IIIIII SI KACO TARTI   1 BO BO BO IS 150 SI 11 AFER 157	IN ANSEN ANSEN ANSEN ANSEN ANSEN ANSEN HAREN HAREN HAREN LITER CEDAG (12.4 MEGA) MEGA)   M · · · · · · · · · · · · · · · · · ·	· · · · IIIII LANCETCEM CLECT MALE 15   1 M ALPIC M	MIII 1994 - pr
BILL DECAM LECTH. SE HESTE YUNYI BERSE MOSS MOSS UNCHE EMETE EMETE EMETE MONO. IS HEL	ILLTI IIIIII IIIIII 31 K/C(O TAOTI 180 KO KO II 191 91 11 AFGOR 192	SE ANSON ANDER ANDER ANDER ANDER ANDER MARCH MARCH MARCH MITTER CEPAS 18.1 MEGAT MEGAT 15	IIIIII LONES TECH PREM HALE 27 7 1 NO AUTE NO	IIIII IBSSI - fa
	ULTICARNO ININI 21 KACO TARTI IN NO NO NO IZ 120 71 11 ANCRE 121 Reformini mini 21 kaco tarticaco no no no no 14 71 14 Ancre 121	DI BASEN BASEN BASEN BASEN BASEN BASEN BASEN HARM KROWN KROWN DITTE. CEPAS 10.1 NEGAT NEGAT ING. TH BASEN BASEN BASEN BASEN BASEN BASEN BASEN KROWN KROWN KROWN DITTE. CEPAS 10.2 NEGAT NEGAT ING. TS BLI		IIIII 1924 ·
BE SELVE LACKE - SE KENY CHINC BEING MOST WOST UNCOLLECTE ENCYCLERACY - CHIL	ILLTI IIIIII IIIIII III II XXCO TARTI SERO RO RO II 121 71 11 AFERE 155	EP ANSEN ANSEN ANSEN ANSEN ANSEN ANSEN KNOWN KNOWN WIRTH LITER CEDNIK 1917 HEGAT MEGAT 155 · · · PREE -	HILL BORN TEEN HALE 5 7 5 NO ALTYE NO	IIIII IMRI
DIE SECH LACHE ZU SEIS NACH BEGG FATTE DATTE UND EUTST EINEN MICH AU HU Die Sech Lache zu siche fram deser wahr war die under einem ziehen zech zich zu hu	ULTOCKRONIUM SEKKOTOOTTOOTTO NO NO HE HE HE HEAKER ES Ultimuulimuu sekkotoottokko no no ni is il 1 aaker es	EL ANSON ANSON ANDER ANDER ANDER ANTEN FROM MINOR MINOR MITTER CEPAS HELL PECAN RECALL IN. SERVE SONT PREED IN ANDER AND		11111 1924 ·
	ULTIMINI MINI CORROTTATAMAN NO NO 11 (2 11 CARRA (2 Regimini mini darrottataman no no 11 (2 11 Carra (2	NA ANCON ANCON ANCON ANCON ANCON ANCON MORN MORN WORTH LITTLE COURS 1 MCCAL MCCAL SI S 2001 ALCAL MCCC. NA ANCON ANCON ANCON ANCON ANCON MORN MORN WORTH LITTLE COURS 11 MCCAL MCCAL SI S 11 MAN SATEL .		HIII 1924 - 44
301 SECON TEXAS — 25 SISSIC YUARY BEAR PRICE PRICE UNERS BRENE BECOME — 6 PRI	RIFIGRAFIO III III 31 KZCIO TAOTI   1 BO BO BO BI 191 71 41 AFEDR 155	ST ARSON ARGON ARGON ARGON ARGON ARGON HARM WARM WHICH LITTLE COPIES IN MICHAEL PARTITION IN	· · · · · · · · · · · · · · · · · · ·	IIIII IBN - V
20 SECH LACH 23 SES TWAN BEAR PAST, PAST, DECREDENT BETT BETT BING I HILL 20 SECH TURN 25 STEE KAND BEAR PAST, PAST, DECREDENT BETT BETT BING I HILL		23 ANSEM ANGEM ANGEM ANGEM ANGEM ANGEM MAKAM MAKAM UTER CEPAS I ELI MEGAT MEGAT 162 . TENTJ- Es angem angem angem angem angem angem angem makam makam uter cepas i eli megat megat 18 . Tentj-	IIIIII BORNITERH PENAL 25 1 180 AUPE 80	11111 1924 ·
30 SEETH DIFFE 25 12455 FOATH BEBSE WORD WORD WEST ENERT ETERT KING ( HU	NATI HINNI HINNI SI KACO TAOTI 6 NO NO NO 16 122 N 11 ANTON 152	III ANGEN ANGEN ANGEN ANGEN ANGEN HANGEN HANGEN HANGEN LITTER CEDING 18.1 HEGGAI HEGGAI III - 14.00 ERSUM TERM	HIND HIGH TERM HALE IS 6 1 MES LOVAL CALIFE NO	IIIII MXI.
26 2003 KNAR S. MEL KOAN ERRY PLAN DATE MELL FREJE FREJE KNAO E HEI 28 2003 KNAR SE ZELEK ZOOM FERN FREJE FREJE MELL FREJE FREJE KNAO E HEI	NATI HINNI HINNI SI KACO TAOTI 1 NO NO NO 11 NI 191 II 11 AVESTA 152	SEASON ASSOCIATION OF THE MARCH MARCH MICH MICH MICH CERE 11.1 MICH MICH 115.1 13. TIGHT.  SEALON ASSOCIATION OF THE MARCH MARCH MICH MICH MICH 11.1 MICH MICH MICH 115. TIGHT.	HILLI BORH TECH PENGL 2.17 7 1 MO AUTE NO	HIII H984 - VI
DE STEAM ASSAM SE SIESE CARRELEDIAN AVOIT HAVE DECENTRATE DECENTRACE COMMISSION AVOIT HAVE DECENTRALED AVOIT DECENTRALED		SEASON AND AND AND AND AND AND AND AND AND AN		(8) 95 (IIIII 1924). (7)
32 SECUT MEETA 25 SINEM SHOW BEING WOOD WOOD UNETE ENERY BINNO 5 PR	RHO-IIIIII IIIII - 31 K/C(O TAOT)   1 BO   BO   BO   TS   15   71   11 AFEDR   12	SS ARREM ARCEN ARCEN ARCEN ARCEN ARCEN HARM HARM LITCH CEPAS FILL REGALMEGAT FILE	HIND LONGS TEIM CHED FEMAL 23 7 1 NO ALVE NO	IIIII IHREE
	RHIGRAND HINN 39 K/C/O INTIN 10 NO 1925 1925 HI 100 HI 10 NOSOR 155	EI ANSEN ANSEN ANSEN ANDEN ANDEN ANSEN MORRH MORRH MORRH MOTER CEPAS HELP CONTINECTAT III MARH, SERA ETSA MI- III ANSEN ANSEN ANSEN ANDEN ANDEN ANSEN MORRH MORRH MOTER CEPAS HELS MEGAT POUTTE HEL 1/2 ALON SERA ETAIL II	· · · · · · · · · · · · · · · · · · ·	
	BLET HANNE HANNE SE KYCCO TAGETE 1 MO NO NO DE 120 DE 11 ANGESE 112	SE ANGEN ANGEN ANGEN ANGEN ANGEN HARM HARM LITTER CERNIC HEL HEGGI HEGGE HEL - TSALD-	HINTE BORN TERM HALE 23 ? 1 NO AUTE NO     HINTE BORN TERM HALE 23 ? 1 NO AUTE NO	MIII 1924 - VI
222 SEEVE CEETS - 28 ESSES TELES BEISH WOLL WOLL MELL CHIEF THEM WHO - 38 HIN	BLETKRANNO HININ 28 KYCKI INTIN 1 YES YES II 191 II 11 MEGAR 182	THE PRESENCE AND	HILLI BORH PRETERN HALE LZ NO DEAD BO	IIIII 1890 - IIV ya
201 SECH SANG - SE SIM AFTALLERI, RV SERVE SEURE BETTEREN KON OF HILL 201 SECH SANG - SE SIM AFTALLERI, RV SERVE SEUR BETER BETTEREN KON OF HILL 201 SECH SANG - SE SIM AFTALLERI, RV SERVE SEUR SEUR BETER BETTEREN KON OF HILL		B ANSON ANSON ANDER ANDER ANDER ANDER MARCH MARCH MARCH DITTE (CIVAL S.) MEGAT MEGAT AND B 6.1 SERB		11111 1924 ·
201 2027 SWATE 23 12925 AP AG BERSE WIRTH WIRTH UNCIT ENCIT ENCYCHING 5 HU	ILLTICARNO ININI 19 KACAO TARRE 1.80 KAO KAO KI 19 H 19 ARTOR 127	III ANSEN ANSEN ANSEN ANSEN ANSEN ANSEN HARM HARM UTER CEPAS HELI REGALIREGAL HII 12	HIND LONGSTEIN CLECT FENGL SJ. 7 S YES TRANS SALIFE NO	HIHI HPRI - PI
230 SEEZH SAAM - 31 HESSE SSEEZ BEGGE KOOTE WOTE UNDER UNDER CAME MAKO - 45 HU 230 SEEZH HAART - 35 HORSE AT DAS BEGGE KOOTE WOOT UNDER UNDER CAME MAKO - 6 HU	BLETKRAND HILL SEKZEN HOT O HEMEN HE YES YES. HE KRE 71. HEMEN KRE	THE ANIZON ANGER ANDER ANDER ANDER MERCH MENCH MENCH WITCH WIELDS. (M. A. MICCAN MICCAN) 158 1,5 14(4) 12524 - IN ANIZON ANGER ANDER ANDER MERCE MENCH MENCH MENCH WITCH CERES (M. MICCAN MICCAN) 159 127	HIND HORM TERM FEMAL SE NO DEAD NO	11111 1934 - 110 yr 11111 1934 - 110 yr
230 SECON ERRORS - 18 HEREN GRUSS ENERG KROET WORD WEST BOKEN ERREN KROE - 7 MU 230 SECON Errors - 19 1998 Flown (Nerg Kroet) word wast boken erren kroe - 41 mu		A ANDA ANDA ANDER ANDER ANDER ANDER ANDA MARIA MARIA MARIA METER (CINAS 11.1 MESA) MESA) HE 12.4 (A) TORIL. IN ANDREASON ANDER ANDER ANDER ANDRE MARIA MARIA MARIA METER (CINAS 11.1 MESA) MESA) HE 17.4 (A) TORIL.	HILLI LANCE METELIKKAN PERMU. 2 7 1995 RESMI. 1 MUYE NO     HILLI MARIN TELH. PERMU. 3 7 180 MUYE NO	IIII 1924 - 171
220 2027 SARRA - SK 705'S KERUF RURAL MADER MADER UNCTRUMETRUMETRUSECKI - E PRI	RHIGRAND HINN SEXZON HUNS SEND YES YES IS ASI SI ALAMEDR AG	THE ANGEN ANGEN ANGEN ANDER ANGEN ANGEN MAGEN HARPH LITTER CEPAGE 19.1 MEGAT MEGAT 198 7.3 CIDEN TOTA	HILL LANGE PLETE COMPLETAL DAY 7 1 80 KLIPE BO	IIIII IHXI
DE SECON ARRISON DE CANDO CERSO MODE MODE UNCON ENERT ENERGE MARIO ( PRO	RHI-IIIIII IIIII 31 RECEZ TROD-REVELTO NO NO IE 124 71 41 ANCOR 156	23 ANSEN ANGEN ANDER ANDER ANDER ANDER MOMEN MOMEN MOMEN MOTER CEPAG 5.5 MEGAT MEGAT 25 5.2 5.2 5.2 5.4 5.4 MEGAT MEGAT ANGEN ANDER ANGEN ANDER ANGEN MOMEN MOMEN MOMEN MOTER CEPAG 51.1 MEGAT MEGAT 3.5 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5.4 5	IIIII HORMITEEM PENNI 25 I 190 ALPRE BO	
222 DECEM REBRY - 15 - SESIS KARREL REBRE MARY HARVY LUNCTH EMELLE EMELLE ROMO - 1 PRO	REPORTED THE RESERVE TWO PERSONS TO BE USED TO SERVER SEE	II 492H 4924 M. ARTE ARTE ARTE ARTE MACH MICH MICH HITCH CENG (I. MICH MICH III II I	MINI BORH TECH HALE 23 7 1 MV AUTE NO	IIII IBM
20 SESTA NAVET - SE HESE CHARCEBOOK WORD WAS FUNCTE ONCE CHIEF KING - HU	ULTERANTO III II III III ON ZZY OKONOMOTOKIOTOKIO IIII III III KAROK KII	S ANDER MACEN MACEN MACEN MACEN MACEN MACEN MACEN MACEN WITCH CERW HEAR PACHT MEGAT HE	MINI BORH TECH HALE 11 7 180 AUTE BO	IIIII KTC - (4
THE SECON SHAPE OF THE PRESENCE FROM AND PROCEEDINGS COME, BRICK C	RHANDON DI BERTARATA IN NA NA TANTA DI GANZA CA Ultrandonini gerdarata na nes na di Ganza ca	G ANSON ANSON ANSON ANDON ANDON ANDON MINON MINON MINON DITCH (CITAL S) OF CHATTAGEAR S	IIIIII BARHITEH PENAL 23 7 180 AUPE 80 IIIII BARHITEH HALE 23 7 1925 DELAY CAUPE 80	HIII HEEL VI
221 SECUL RISAU - 25 COM PLANT DESAN WORD WORD DETECUTED FRANCE COM-	RIPHININI NINN SERVOPEARTE EN NO NO 12 121 IS 15 AFGRE 122	IZ ANGEN ANGEN ANGEN ANGEN ANGEN HAREN HAREN HAREN UTERL CENK HILA POSITI NEGAT 91	HILLI LANCE TECH MANSI PENAL 24 7 1 MO ALPIC M	IIIII IBRI
AN ERSON DAMAGE OF HARM FROM MACH WASHINGTH DATA DATA DAMAGE THE ANNO THE COMPANY OF THE COMPANY DATA DATA DATA DATA DATA DATA DATA DAT	RH-IIIII IIIII (1895-1871) N 60 (1754-1974) IIIII IIIII IIIII IIII	OFFICE GREEN RASED RASED RASED RASED RASED ROSEN ROSEN ROSEN ROSED LECEN S. S. S. SOSTINESKAT P. 1. TSA-1- DI ARESEN RASED RASED RASED RASED RASED ROSEN ROSEN ROSEN ROSEN DITEL CEPAS 11.1 REGALF POSITI 181 5.3	HINTE LOVER TECH INDO-MALE 23 5 10 NO AUTE NO	
		II 44509 44509 44509 44509 44509 44509 46609 46609 4660 4650 4650 46509 465000 46509 46509 46509 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 465000 46		HIII 1924 - 91 HIII 1924 - 17
HE SECRETARISM SEE HER FLOATS REESE AND EN AND EN LINCOLD ENGLISH ENGLISH HOME	ULTI MINI MINI SERVO PARTI DENO NO NO SE 111 SE 11 ANCOR 135	III ANSEN ANSEN ANSEN ANSEN ANSEN ANSEN ANSEN HORPH HORPH LITERL CEPAN HELP POSITI REGAT III E.E.	HILLIANTE TECH ENDANCHAL 24 7 LYES LAV 2 AUTE IN	IIIII IMRI
HE SECTIONS TO STATE CHARLES BERN MADE WAS DIRECT BELLE BREAD BREAD OF THE	ILTI IIII IIII III II 1005 NOTO NEVANDO PES NO 16 NO 16 NO 16 NOSER 18	II 4450 4650 4650 4650 4650 4650 4650 4650		
SHE SHEEM SURES. 27 HEMS AT PHY BURSH WHICH WHICH UNERS UNERS CAME WHICH I PRI	RINGERMAN BELLEVILLE BY TYPRICTARD METALLER OF MY NO HO BELLEVILLE BY NEW AND	A 44CO 44CO 45CO 45CO 45CO 45CO 45CO 46CO 46CO 46CO 46CO 46CO 46CO 46CO 46	· · · · · · · · · · · · · · · · · · ·	HIII 1931 - 97
MI MAN AND A SECURE OF A SECUR	THE RESERVE OF THE RESERVE OF THE RESERVE OF	A MAN TON MAN WAS THAT ONCE OWN DRIVEN AND THE REAL PROPERTY IN 12	INDER STATE OF THE STATE OF	min ora Vi